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ABSTRACT
GEORGE DANIEL GRASS. The role of CD147 in Breast Cancer Progression
(Under the direction of BRYAN P. TOOLE)

In the U.S., approximately 40,000 women will die from breast cancer this year,
while an additional 230,500 women will be newly diagnosed with invasive breast disease.
Despite tremendous advancement leading to earlier detection and novel therapeutic
approaches, recurrent metastatic breast cancer remains a major cause of mortality.
Invasive breast cancer cells employ specialized actin-rich protrusions called invadopodia,
which are enriched in proteases, to degrade the extracellular matrix and these structures
correlate with metastasis in vivo. The multifunctional immunoglobulin superfamily
protein emmprin (CD 147) is highly enriched'on tht! surface of malignant breast cancer
cells and is associated with matrix metalloproteinase (MMP) induction and invasion. In
this dissertation we found that CD147 regulates the activity of invadopodia in non1

transformed breast epithelial cells and invasive breast cancer cells by regulating the
expression and localization of membrane type-l MMP (MTI-MMP). Furthermore, we
discovered that up-regulation of CD 147 regulates invasiveness by facilitating the
assembly of multi-protein signaling complexes containing CD 147, CD44 and EGFR.
Assembly of these complexes leads to the activation of EGFR-Ras-MEK-ERK signaling
cascades. We further found that Ras regulates CD 147 expression and may participate in
a complex feedback loop involving hyaluronan-CD44 interactions and ERK signaling.
Lastly, we observed that sub-populations of cells with differential CD147 surface
expression correlate with distinct functional phenotypes. Our work has begun to unravel

xii

the complexity of CD 147 function in breast cancer invasion and provides strong evidence
that CD 147 should be a therapeutic target in future studies.

xiii

Chapter 1: An Overview of CD147 Biology
Introduction
CD147 is a type I integral membrane protein belonging to the Ig superfamily that
is variably glycosylated and expressed across several tissue types. The expression of
CD 147 is elevated on the surfaces of various cancer types, whereas the expression in
most normal tissues is at much lower levels. CD147 was originally identified as a tumorassociated protein that stimulates matrix metalloproteinase (MMP) production in
'",

:'.

r

fibroblasts, but over the years it has become cle.9-r1}hat CD147 is a molecule with
pleiotropic biology. In addition to MMP induction, the role of CD 147 in cancer
progression has been associated with multi -therapy resistance, angiogenesis, migration,
invasion and chaperoning of metabolic transporters to the c~ll surface.
\

CD147 Nomenclature and Gene and Protein Structure
Nomenclature

CD147 was identified and characterized independently under numerous names in
various species and tissues using different experimental protocols: RET-PE2 (Finnemann
et a!., 1997), CE9 (Nehme et aI., 1993) and OX-47 (Fossum et aI., 1991) in rats, gp42
(Altruda et aI., 1989) and basigin (Miyauchi et aI., 1990) in mice, HT7 (Seulberger et aI.,
1990), neurothelin (Schlosshauer et a!., 1995), and 5All (Fadool and Linser, 1993) in
1

chickens, the human leukocyte-activation associated antigen M6 (Kasinrerk et ai., 1992),
the blood group Oka antigen (Spring et ai., 1997), the hepatoma-associated antigen
HAb18G (Jiang et aI., 2001) and matrix-metalloproteinase (MMP)-inducing factor,
emmprin (Biswas et ai., 1995) in humans. CD147 was first functionally characterized by
Biswas and colleagues (Biswas, 1984; Ellis et ai., 1989) using a co-culture system with
lung carcinoma cells and fibroblasts, in which they identified a Tumor cell-derived
Collagenase-Stimulatory Factor (TCSF) that was present on the cell surface and in
conditioned media. In later years, in addition to collagenase (matrix metalloproteinase-1;
MMP-1), TCSF was found to stimulate increases in both message and protein levels of
MMP-2 and MMP-3 and was renamed to Extracellular Matrix Metalloilloteinase Inducer
(emmprin) (Biswas et ai., 1995; Kataoka et aI., t993) . It is now clear that all of the above
~-

'.
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designated proteins are in fact the same and are now commonly termed CD147
(Kanekura et aI., 1991; Kasinrerk et aI., 1992; Yan et ai., 2005).
Gene Structure
\

The gene locus for CD147 is located at chromosome 19p13.3 in human (Kaname
et ai., 1993) and was originally thought to contain eight exons spanning over 10.8
kilobases (Guo et al., 1998), but new evidence suggests that the CD147 gene contains 10
exons that span 15,000 nucleotides (Belton et ai., 2008; Liao et ai., 2011). Interestingly,
the CD147 gene displays many unique features including: a multi-exon 3' -untranslated
region (3' -UTR), immunoglobulin (Ig)-like domains encoded by paired exons, and a
junctional exon of the second Ig-like domain encoding the transmembrane domain and
part of the cytoplasmic domain (Guo et ai., 1998). The CD147 gene is flanked on the 5'
end with a CpG island (CGI)-rich sequence in the promoter region, which was previously
2

described to lack CAAT or TAT A boxes, but subsequent evidence suggests this promoter
region may contain a TATA box (Liang et aI., 2002). The mouse CD147 gene is located
on chromosome 10 and is smaller in size compared to the human gene due to shorter
intronic sequences interspersed between size-conserved exonic sequences (Cheng et aI.,
1994; Guo et aI., 1998; Miyauchi et aI., 1995).
Message and Protein Organization

Based on data in the Entrez Gene database, the CD 147 gene is encoded into 4
variant transcripts, designated as CD 147 -1,2,3 and 4 (Figure 1-1). Recent findings have
demonstrated that alternative splice variants of CD147 are formed: a tissue specific
variant resulting in three Ig-like domains (CD147-1) was identified in the retina (Hanna
,.
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et aI., 2003; Ochrietor et aI., 2003) as well as tw%ther variants lacking the N-terminal
Ig-like domain (CD147-3 and CD147-4) (Belton et aI., 2008; Liao et aI., 2011).

,

However, CD147-2 is the most abundant, widely distributed and best characterized
isoform and will be designated as CD147 hereafter. Sequence analysis of CD147 by
\

several groups revealed that it is a single-chain type I transmembrane molecule and
member of the Ig superfamily (IgSF). The mRNA transcript for CD147 encodes a 269
amino acid protein that is composed of a 21 amino acid signal sequence, a 186 residuelong extracellular portion consisting of two Ig -like domains at the N-terminus, a 21
amino acid transmembrane domain, and a 41 residue cytoplasmic domain at the Cterminus (Weidle et aI., 2010).

3

Extracellular Ig-like
domains

IgC2 domain
Igl domain

Transmembrane
Cytoplasmic domain

C0147-1

C0147-2

(retina)

(Most abundant)

C0147-3

C0147-4

Figure 1-1. CD147 isoforms. CD147 alternative splice variant protein structures.
CD 147 -2 is the most abundant and best characterized isoform and will be designated
as CD 147 hereafter.

Due to the presence of certain sequence motifs, CD 147 has been described to
have homology to both the major histocompatibility complex class II (MHC II) betachains and Ig variable domain (V); this has

led , sam~' investigators

'; ";;-Il '

to propose that CD147

may be an evolutionary intermediate between a primordial Ig form and MHC II-beta
chain-like and V domain-containing molecules (Altruda et ai., 1989; Fossum et ai., 1991;
Kanekura et ai., 1991; Miyauchi et aI., 1990; Miyauchi et at, 1991). In line with this,
high resolution crystallography has revealed that CD147 contains aN-terminal IgC2
\

domain and a membrane proximal IgI domain that are organized in a unique manner, thus
distinguishing CD147 from other IgSF proteins (Yu et aI., 2008). The protein sequence
shows varying conservation across several species, especially in the extracellular
domains, but the linker sequence between the Ig-like domains, the cysteine residues,
asparagine glycosylation sites, transmembrane domain, and cytoplasmic domain
demonstrate strong homology (Fossum et aI., 1991; Miyauchi et ai., 1995; Schuster et ai.,
1996; Seulberger et ai., 1990; Yu et ai., 2008). Interestingly, the highly conserved
regions of CD147 contain unique structural characteristics. The flexible 5-residue linker

4

domain has been shown to provide CD147 a great deal of domain mobility, possibly
allowing the first IgC2 domain to alter its orientation to interact with ligands or adjacent
binding partners (Yu et aI., 2008). The transmembrane domain contains a uniquelyembedded charged glutamic acid residue in the hydrophobic-rich sequence as well as a
leucine zipper motif (Yan et aI., 2005). Proteins with these characteristics have been
shown to oligomerize into multi-protein complexes and are often involved in cell
signaling events: this is especially recognized in immune cell receptor complexes
(Humphrey et aI., 2005). Support for this homo- or hetero- oligomerization is found in a
study identifying that polyleucine rich transmembrane domains with an embedded
glutamate residue confer strong interactions between a-helices, possibly via hydrogen
bonding (Zhou et aI., 2001).

...

.-',

The predicted molecular weight from the sequence of CD147 is 27-29 kDa, yet
many investigators discovered that CD147 migrates on sodium dodecyl-sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) between 31-65 kDa. Originally,
discovered as a protein that carries a developmentally-regulated\carbohydrate moiety, in
conjunction with three conserved N-glycosylation sites, CD147 is classified as a
glycoprotein. Studies with glycosylation inhibitors and specific lectins revealed that
approximately 50% of the mass of CD147 is due to carbohydrate side groups bearing
~1,6-branched,

polylactosamine-type sugars, fucosylations, Lewis x glycan epitopes, and

sialylations (Kamada et aI., 1987; Riethdorf et aI., 2006; Tang et aI., 2004a; Yang et aI.,
2011). CD147 glycoforms were previously characterized as low-glycosylated (LG) and
high-glycosylated (RG) forms, representing -32 kDa and -45-65 kDa, respectively (Tang
et ai., 2004a). The LG-CD147 was found to contain a high-mannose carbohydrate,
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whereas the HG-CD147 was enriched for branched polylactosamine chains. It is clear
that CD147 is heterogeneously glycosylated across many tissue and cell types (Nakai et
aI., 2006) and even shows variations in glycosylation in cell lines derived from the same
tissue of origin (Riethdorf et aI., 2006). Currently, it is unclear whether different CD147
glycoforms have different biological functions.
Very little data exists on how CD147 glycosylation status is regulated. Currently
the only published mechanistic data describes a role for caveolin-1 in regulating CD147
glycosylation. It was recognized that CD147 associates with caveolin-1 mostly on the
cell surface via its membrane proximal IgI domain and that this association attenuates
CD 147 self-aggregation (Tang and Hemler, 2004). Further evaluation of this interaction,
revealed that LG-CD147 preferentially associat~~;With caveolin-1 and that the caveolin1-CD147 interaction inhibited CD 147-induced MMP induction (Tang et aI., 2004a). The
authors of these studies proposed that caveolin-l associates with CD 147 during its transit
through the golgi and two divergent pathways regulate CD1147 glycosylation status: 1)
CD 147 associates with caveolin-1 and is escorted to the cell surface forming caveolin-lCD147 complexes possibly in membrane compartments adjacent to lipid rafts; 2) Nacetylglucosaminyltransferase V initiates the addition of ~ 1,6-branched polylactosaminetype sugars on CD147, forming HG-CD147, which does not bind caveolin-1 and is
thought to be the major active form of CD147 in relation to MMP induction. However,
other studies have found that up-regUlation of caveolin-1 increases MMP synthesis (Jia et
aI., 2006). Further clarification of this mechanism is needed as these authors previously
published apparently contradictory data suggesting that HG-CD147 associated with
caveolin-1and that the majority of the identified CD147-caveolin-1 complex was isolated

6

after cell surface biotinylation (Tang and Hemler, 2004). However, there may be a small
sub-population of caveolin-l in the golgi that regulates CD 147 glycosylation distinct
from caveolin-l pools present on the cell surface. Alternatively, a less clarified
mechanism has also suggested that hypoxia increases the HG-CDI47 glycoform, which is
independent of an increase in transcription (Floch et aI., 2011).

Regulation of CD147 Expression
Transcriptional Regulation

As mentioned previously, prior characterization of the promoter region ofCD147,
t.

,J,

consisting of 950 base pairs (bp) upstream oftQe- ~nscription start site, revealed that it is
enriched in a CGI and contained consensus binding sites for the transcription factor (TF)
specificity protein 1 (Spl) and activator protein 2 (AP-2) (Guo et aI., 1998). Subsequent
promoter analysis demonstrated that a fragment 471 bp upstream of the previously
identified coding region was necessary to mediate CD147 trans<!ription: deletion analysis
of this fragment revealed that a 30 bp element from -142 to -112 bp, containing
overlapping binding sites for Sp 1, AP-l, early growth response protein 2 (EGR2), and
transcription factor II (TFII), was sufficient to initiate CD 147 transcription. Of these
potential regulatory TFs, only Spl demonstrated binding to the 30 bp region and
cooperated with Sp3 to augment CD147 transcription. Interestingly, this study also
identified a negative regulatory element in the 5' -flanking segment consisting of the 1413 to -1024 bp region, though this regulatory region needs further evaluation (Liang et
ai.,2002). Further studies, demonstrated that a 66 bp region (-108 to -42) containing the
7

third Sp 1 binding site, was the minimal essential element needed to regulate constitutive
CD147 expression (Kong et aI., 2011b). Though Spl appears to be the main
transcriptional regulator of CD147, other studies also support a role for EGR2 (Dai et aI.,
2012). In addition to this first recognized promoter, a new study found that an alternative
promoter located in the -656 to -473 bp region upstream of exon 1 regulated CD 147 -3/4
expression, which was distinct from the promoter regulating CDI47-1/2 (Liao et aI.,
2011).
Due to the fact that Sp 1 binds to CpG motifs present in CGIs, which can be
epigenetically modified by methylation, Sp I-mediated transcriptional initiation can be
regulated by altered binding affinity to methylated CpG motifs present in promoters
t·

(Deaton and Bird, 2011). In support of this,

:"J
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promoter was found to be

hypomethylated in cancer tissue compared to normal tissue, resulting in increased Sp 1
binding and subsequently increased CDI47 expression (Kong et aI., 2011a). This
evidence clearly supports the idea that CDI47 expression iJ regulated via Spi-mediated
events. Although previous studies demonstrated that Sp 1 is a ubiquitous TF that is a
constitutive activator of housekeeping genes, accumulating evidence now suggests it is
also involved in the regulation of inducible genes (Wierstra, 2008).
In addition to SpI, CD147 has been shown to be regulated by Snail-l (Snail)

(Kuphal et aI., 2005) and Snail-2 (Slug) (Wu et aI., 2011a), TFs that orchestrate the
epithelial-mesenchymal transition (EMT). The latter study by Wu et. al determined that
Slug, but not Snail, binds to an E-box 2 domain located in a 306 bp region of the CD 147
promoter (-644 to -338), which results in CDI47 transcription. Interestingly,
transforming growth factor-beta

(TGF-~)-induced

8

CDI47 expression was attenuated by

knockdown of other EMT-related TFs, such as ZEB-l and ZEB-2; this down-regulation
of CD147 may be due to upstream regulation of factors that directly bind to the CD147
promoter rather than direct promoter activation. A possible association between the Etwenty six (ETS) TF family member PEA3 and CD147 may exist, but this study only
demonstrated a co-staining pattern in tumor tissues (Davidson et ai., 2003b). Treatment
of ovarian cancer cells with signal transducers and activators of transcription 3 (STAT3)
decoy oligodeoxynucleotides resulted in decreased CD147 expression, suggesting that
STAT3 may have a role in regulating CD147 transcription (Zhang et aI., 2010). In
addition, a transcriptionally active fragment of Sterol-Carrier Protein 2 (SCP-2), which
regulates cycling of endogenous cholesterol between membrane compartments, thus
altering cholesterol metabolism, was found to

incr~'ase
1--

,- "' '0,,1

CD 147 transcription (Ko and

I,

'1','

; /r
Puglielli,2007). This study identified a high affinity binding site in the -245 to -95 bp

region and a low affinity binding site between the -392 to -242 bp region in the CD147
promoter. A recent study employing a 1 kb fragment

upstr~am

of the mouse CD147

coding sequence found an E2F binding site that mediated nitric oxide (NO)-induced
\

repression of CD 147 in cardiomyocytes, which was dependent on a cyclic guanosine
monophosphate (cGMP)-dependent protein kinase G (PKG) pathway (Tarin et aI., 2011).
Thus, it is clear that many transcriptional regulators influence CD 147 expression in
various cellular contexts.
Control of CD147 expression by cis-regulatory elements and sequence
variations/polymorphisms has also been described. Recently, the seed regions of let-7, a
tumor-suppressive non-protein coding microRNA (miRNA) family, was shown to have
complementary sequence to the 3' -UTR of CD 147, with let -7b being the most

9

complementary (Fu et aI., 2011a; Fu et aI., 2011b). In addition, miRNA-492 was found
to interact with the CD 147 3' -UTR; interestingly, the efficiency to suppress CD147
expression was dependent on a single nucleotide polymorphism (SNP) located at the 4th
nucleotide complementary to the miRNA-492 seed region (Wu et aI., 2011 b). It is
thought that --2-6 contiguous base pairs in the seed region of miRN As are needed for
effective miRNA-mRNA duplex formation and target suppression (Brodersen and
Voinnet, 2009), hence the SNP in the miRNA-492 binding site may alter affinity to the
CD 147 3' -UTR resulting in differential suppression of CD 147. Other SNPs located in
the membrane-proximal IgI domain and 3'-UTR have been shown to alter CD147
expression in the equine genus (Koho et aI., 2012), though the relevance in humans is
currently unknown.
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Regulators o(CD147 Upstream of Transcription Factors
Many studies have identified factors upstream of the CD 147 transcription
1

initiators and repressors mentioned above. Some of the earliest studies identified an
\

increase in CD147 expression after activation of lymphocytes with granulocyte
macrophage colony-stimulating factor (GM-CSF), concanavalin-A or
phytohemagglutinin (Kasinrerk et aI., 1992; Paterson et aI., 1987). Additionally,
endothelial cells that invaded co-cultured brain tissue demonstrated increased CD 147
expression (Risau et aI., 1986). These earlier studies set the premise that CD147 may be
an inducible molecule in both physiological and pathological contexts.
Over the years many soluble factors such as growth factors, cytokines and
hormones have been shown to regulate CD147 expression (see Table 1-1). In breast

10

cancer cells, epidermal growth factor (EGF) and amphiregulin induced the expression of
CD147 via a EGF receptor (EGFR) kinase activation pathway (Menashi et aI., 2003; Xu
et aI., 2011). In addition,

TGF~

induced CD147 expression via a phosphatidylinositol-3-

kinase (PI3K) -Akt pathway in hepatocytes (Wu et aI., 20lla).
Since CD147 most likely has a role in inflammation, ischemic injury,
atherosclerosis, rheumatoid arthritis and tissue repair (Gabison et aI., 2009; Yan et aI.,
2005), it is no surprise that it is regulated by inflammatory mediators. A coculture model
between macrophages and breast or ovarian cancer cells demonstrated that cancerassociated CD147 is induced via a tumor necrosis factor alpha (TNFu)-c-Jun-N-terminal
kinase 2 (JNKII)-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KP)
pathway (Hagemann et aI., 2005). CD147 is;reglijftted by hydrogen peroxide (Siwik et
aI., 2008) and the cytokine interleukin-18 (IL-18) in both cardiomyocytes (Reddy et aI.,
2010) and smooth muscle cells (Venkatesan et aI., 2009). Preliminary evidence suggests
that IL-l may also regulate CD 147 expression in corneal fi~roblasts, though in other cell
types this does not seem to be the case (Braundmeier et aI., 2006; Gabison et aI., 2009).
Another cytokine that regulates CD147 expression is receptor activator of NF-K~ ligand
(RANKL), an osteoclastogenic mediator involved in bone remodeling in physiologic and
pathologic states (Rucci et aI., 2010; Si et aI., 2003). Furthermore, in support of CD147
involvement in inflammation, treatment of cells with C-reactive protein (CRP) induced
CD147 transcription (Abe et aI., 2006) and iron deficiency upregulated CD147 via a p38NFK~

related pathway (Fan et aI., 20llb). NO treatment negatively regulated CD147

expression in cardiomyocytes, but had no regulatory role in macrophages, indicating celltype specific regulation (Tarin et aI., 2011). A recent finding also suggested a role for
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prostaglandin E2 in regulating CD147 expression and this may involve an interaction
with the non-tyrosine kinase c-Src (Lee et aI., 2011).
Regulation of CD147 by sex hormones has been suggested by studies involving
analysis of the menstrual cycle, pregnancy, and peri-implantation events. These studies
found that CD147 expression was induced by both estrogen and progesterone, with the
latter possibly regulating post-transcriptional glycosylations of the core protein
(Braundmeier et aI., 2006; Noguchi et aI., 2003; Xiao et aI., 2002). Analysis of estrogen
receptor (ER)-a or -~ null mice demonstrated that CD 147 is regulated by ERa in select
tissues, whereas in others it is independent of estrogen signaling. Furthermore, the
regulation of CD 147 expression seemed to be at the translational level rather than

...

',

transcriptional (Chen et aI., 2010). Other horm9~-that have been shown to regulate
CD147 expression include the peptides Thyroid-stimulating hormone (TSH) (Fanelli et
aI., 2003; Nehme et aI., 1995) and Angiotensin II (Pons et aI., 2011; Yang et aI., 2010a).
Also, somatostatin was shown to increase CD 147 cell surfate levels in intestinal
epithelial cells (Saksena et aI., 2009). Interestingly, these hormones signal through G
protein-coupled receptors (GPCRs), suggesting CD 147 can be modulated via this
pathway_
Other pathways that have been shown to regulate CD147 expression include: the
Protein Kinase C delta (PKC8)-ERK pathway in activated macrophages (Wang et aI.,
2011 b) and

~6

integrin-Fyn kinase signaling in oral squamous cell carcinoma (Ramos

and Dang, 2011). Elevated expression of the scaffold protein receptor for activated
protein kinase C 1 (RACK 1) was shown to increase CD 147 expression in breast cancer
(Cao et aI., 2010). Also, Notch1 signaling has been shown to regulate CD147 expression
12

in breast cancer, though the exact mechanism of regulation is currently unknown (Wang
et aI., 2011a). An additional mechanism regulating CD147 expression is a positive
feedback mechanism. This was demonstrated by treating fibroblasts with a recombinant
soluble form of the extracellular domain of CD 147 (rbCD 147), which in turn, increased
CD147 transcription (Tang et aI., 2004b).
Interestingly, CD147 also appears to be regulated by several molecules involved
in cell metabolism. As mentioned above, CD147 is regulated by a transcriptionallyactive fragment of SCP-2, a protein involved in cholesterol metabolism (Ko and Puglielli,
2007) as well as TSH, a hormone that regulates global metabolism (Fanelli et aI., 2003;
Nehme et aI., 1995). In this latter case, TSH induced CD147 expression in thyroid cells
t·

,",

via a cyclic adenosine monophosphate (cAMP}~~~}tited pathway, but interestingly this
regulation was at the post-transcriptional level. Also, peroxisome proliferator-activated
receptor alpha and gamma (PPARa/y) TFs have been shown to regulate CD147
expression, with the latter suppressing CD147 translation irl activated macrophages (Ge
et aI., 2007; Konig et aI., 2010). In relation to this aforementioned regulatory network,
up-regulation of PPARy-coactivator 1 alpha (PGC-1a) resulted in elevated CD147
expression in skeletal muscle cells (Benton et aI., 2008). Additionally, the adipocytokine,
nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme involved in generating
nicotinamide adenine dinucleotide (NAD), has been shown to increase CD147 expression
via an ERK-p38-NF-K~ pathway (Fan et aI., 2011a). In a recent study, it was
demonstrated that elevated glucose concentration induces CD 147 transcription (Bao et
aI.,2010). This compilation of data strongly suggests that CD147 may be a protein
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related to the cellular response of metabolic stress or aids in the general metabolism of
the cell.
In addition to being regulated by soluble factors that activate various signaling
pathways, CD147 expression and cellular localization is determined by protein binding
partners. One of the most studied and best characterized binding partners of CDl47 are
the family of MonoCarboxylate Transporters (MCTs). MCTs are proton-coupled
transporters that mediate transit of L-Iactate, pyruvate, and ketone bodies across the
plasma membrane (Halestrap, 201Ia). Earlier studies indicated that CDl47 is tightly
associated with MCT1 and MCT4 via a transmembrane/cytoplasmic domain interaction
(Kirk et aI., 2000), which was later determined to be mediated mainly by hydrophobic
"

:',

interactions in the c-terminal aspect of the tran8;Ul~fobrane domain rather than ionic
interactions with the glutamate residue (Finch et aI., 2009; Wilson et aI., 2009). This was
later followed up with a fluorescence resonance energy transfer (FRET) study
demonstrating that CD147 and MCTs interact and form a hJterotetramer complex
consisting of two central oligomerized CD147 molecules associated with peripherally
localized MCTs (Wilson et aI., 2002).
As it is clear that CD147 and the MCT isoforms 1,3, and 4 associate (Halestrap,
201Ia), other studies evaluated whether either interacting member regulated expression
or localization of the other. Knockdown of MCT I expression resulted in an alteration of
the CDl47 glycoforms expressed, with a proclivity to accumulate the high-mannose form
of CD147 relative to the highly-complex branched glycoform (Deora et aI., 2005);
interestingly no changes in mRNA were found with MCTI knockdown, indicating
regulation at the post-transcriptional level. In addition to regulation of CD 147 protein,
14

specific membrane localization to the basolateral (BL) membrane was determined by
dominant BL signals in MCT3 and MCT4, whereas CD147 contains a dominant BL
signal at leucine 252 (Deora et a!., 2004) that directs MCTllocalization. MCT3
knockout mice supported this conclusion as well, as they demonstrated reduced CD 147
trafficking to the basolateral membrane (Daniele et aI., 2008). A similar study found that
depletion of MCT4 in metastatic breast cancer cells resulted in an enrichment of the high
mannose glycoform of CD147, which did not traffic to the cell surface and remained
confined to the endoplasmic reticulum; this study also found that there was no difference
in mRNA levels of CD147 (Gallagher et a!., 2007). Also, knockdown of CD147 resulted
in decreased MCT4 protein, but not message, and caused an enrichment of MCT4 in
endolysosomes, possibly leading to increased MCT4 degradation. Other studies also
"~~I ~i/~

found that a dual knockdown ofMCTI and MCT4 resulted in decreased CD147
expression and surface localization (Floch et aI., 2011).
Additional studies have suggested that CD147 exprJssion is necessary for MCT
membrane localization and this seems to be independent of the G;harged glutamate residue
imbedded in the CDI47 transmembrane domain (Deora et aI., 2005; Kirk et aI., 2000;
Manoharan et a!., 2006). This is further supported by studies demonstrating that CD147null mice were found to have decreased surface expression of MCT 1/3/4, even when
MCT transcription was still present (Philp et aI., 2003). A recent study demonstrated that
the affinity of interaction between CD 147 and MCT 1 is moderate ( --1

~M),

approximately the same as for an antibody-antigen complex (Howard et aI., 2010). This
compilation of data strongly suggests that CD147 and MCTs regulate each other posttranscriptionally and act as co-chaperones.
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Another protein class that regulates CD 147 cell surface expression is the
cyclosporine A-sensitive (CspA) cyclophilin protein family. Cyclophilins contain
peptidyl-prolyl cis-trans isomerase (PPlase) activity, are known to regulate protein
trafficking, and act as intercellular mediators in inflammatory events (Yurchenko et aI.,
2010). Earlier studies found that CD147 cell surface expression was decreased by
treatment with the immunosuppressive drug CspA (Yurchenko et aI., 2005) and that the
proline 211 residue located near the CD147 transmembrane domain facilitates interaction
with Cyclophilin 60 (Pushkarsky et aI., 2005), which may be involved in escorting
CD147 to the cell surface.
Membrane-type 1 MMP (MT1-MMP; MMP-14) has been shown to associate with
CD 147 at the cell surface and decreases cell sur:£a~>CD 147 by cleaving it in the linker
'j

region between the Ig-like domains (Egawa et aI., 2006). Further analysis demonstrated
that CD147 associated with both the pro and active forms ofMT1-MMP (Niiya et aI.,
2009). Surface expression ofMTI-MMP is tightly regulatetl by protease-mediate
cleavage of the propeptide during transport from the golgi to the. plasma membrane
(Zucker et aI., 2002). Thus, association ofCD147 with the pro and active form ofMTlMMP may indicate a role in regulating cell surface expression of one another.
Studies evaluating the turnover of CD147 are scant. One study suggests that
CD147 is ubiquitinated and degraded in the proteasome. They further suggested that this
is regulated by the enzyme ubiquitin carboxyl-terminal esterase L1 (UCH-L1) and Nglycosylation (Wang et aI., 2008), where decreased glycosylation increases CD147
ubiquitination and subsequent degradation. Furthermore, another study suggested that
CD147 does not appreciably localize in lysosomal compartments following
16

internalization (Eyster et aI., 2011). An opposing study suggests that CD147 is
downregulated via a p53-mediated lysosomal pathway instead of a proteasomal
degradation mechanism (Zhu et aI., 2009). Thus, it remains unclear as to which pathway
CD147 is primarily degraded.
It is apparent that CD 147 is regulated by complex signaling networks in different

physiological, pathological and tissue-specific contexts. The regulation of CD147
expression by various transcription factors, soluble mediators and binding partners
underscores the complexity of CD 147 function.
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Table 1-1. Regulators of CD147 Expression and Localization.
Regulator
GM-CSF
EGF/Amphiregulin
TGF~

Pathway

Message/Protein/Both

-

-

Surface/Soluble
l ' Surface levels

EGFR
PI3K/Akt

l'Both
l'Both

-

-

-

l ' Surface levels

VEGF-O
TNFa

NF-K~

-JNKII

l'Message

-

Il-18
RANKl
C-reactive protein
Iron deficiency
Nitric oxide
PGE 2 (decreased)

PI3K/Akt-ERK;
JNK/Sp1

l'Both

-

l'Both
l'Message
l' Both
-J., Message
-J., Protei n

p38- NF-K~
cGMP
c-Src

Estrogen
ERa

-

Progesterone
TSH
Angiotensin II

-

Somatostatin
SCP-2
PPARy
PPARa
PGC-1a
RACK1
STAT3 (decreased)
NOTCH
(decreased)
Glucose (high)
C0147

NAMPT
MCT1 (decreased)
Cyclophilin 60
MT1-MMP

-

-

-

l'Message
l'Message
(tissue specific)
Post-transcription .....
Post -transcr+ption;.fi~:

-

Cell Type
lymphocyte
Breast cancer
Hepatocyte
Endothelial
Co-culture
Breast/Ovarian
cancer w/
macrophage
Smooth muscle;
cardiac muscle
Breast Cancer
Macrophage
Macrophages
Cardiac muscle
Endometrial and
Stromal
Reproductive
Reproductive

l' Both; message

-

-

-

l ' Su rface levels

Reproductive
Thyroid cells
Macrophages;
RPE
Intestinal

-

l'Message
-J., Protein

-

-

-

Macrophage
Hepatocytes
Skeletal muscle
Breast cancer
Ovarian cancer
Breast cancer

cAMP
COX-2-PGE 2;
p38-ERK

NF-K~

-

-

-

p38- NF-K~

-

0

l'Message
l' Protein
l' Protein
-J., Protein
-J., Protein
l' Both
l' Both

l ' Both
Post-transcription

-

See text for references.
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l

-

-

\

-

l'Soluble
C0147
-

-J., Surface levels
l' Surface levels
l'Soluble
C0147

Monocytes
Co-culture breast
cancer w/
fibroblast
Macrophages
Various cells
Various cells
Various cancers

CD147 Expression Patterns and Subcellular Localization
Expression in Normal and Cancer Tissue
Numerous investigators have indicated that CD 147 is expressed in various tissues.
Earlier studies identified that CD 147 was expressed in many epithelia, neuronal,
lymphoid and myeloid cell types (Arjonen et aI., 2011; Fossum et aI., 1991; Kanekura et
aI., 1991; Kasinrerk et aI., 1992; Nakai et aI., 2006), though with various glycoforms. A
tissue array analysis of CD147 expression in various normal and cancer tissues
demonstrated that a limited number of normal cells express CD 147, whereas elevated
expression of CD 147 was recognized in the majority of malignant cancers compared to
their benign counterparts (Riethdorf et aI., 2006); squamous cell carcinoma (SCC),
,.

.
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pancreatic, chromophobic kidney, hepatocellular ,Ifnedullary breast adenocarcinoma and
glioblastoma multiforme demonstrated the highest incidence of expression.
Expression of CD147 was found to have negative prpgnostic value for patients
with serous ovarian carcinoma (Davidson et aI., 2003a), breast cancer (Liu et aI., 2010;
\

Reimers et aI., 2004), acute lymphoblastic leukemia (Beesley et aI., 2005), clear cell renal
cell carcinoma (Jin et aI., 2006), hepatocellular carcinoma (Zhang et aI., 2006), gastric
carcinoma (Zheng et aI., 2006), endometrial carcinoma (Ueda et aI., 2007) lung
adenocarcinoma (Sienel et aI., 2008), differentiated thyroid carcinoma (Tan et aI., 2008),
colorectal cancer (Buergy et aI., 2009), prostate cancer (Han et aI., 2009), adenoid cystic
carcinoma of salivary glands (Yang et aI., 2010b) and pediatric medulloblastoma (Chu et
aI., 2011). In addition to relative expression levels in tumor tissue samples, specific
localization of CD147 to plasma membrane was a strong prognosticator for survival in
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lung adenocarcinoma in the absence of increased CD147 expression (Sienel et aI., 2008).
Similarly, a borderline relationship between overall survival and surface CD147 staining
was identified in laryngeal SCC (Rosenthal et aI., 2003).
Characterization of Cytoplasmic CD147

In support of the histological studies above, CD 147 localization was originally
identified on the cell surface with a proclivity to localize at cell-cell interfaces (Ellis et
aI., 1989; Hubbard et aI., 1985; Schlosshauer et aI., 1995). As imaging techniques have
improved, it is becoming clearer that CD 147 is also localized in the cytoplasm of various
cells. The characterization of these cytoplasmic CD147-positive signals is just
beginning. A novel study by Eyster et al. found that an Arf6-GTPase mutant expressed
t.
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of,'

•

,... /" .
.~

'fl"

in HeLa cells led to enlarged vacuolar-type stru;ctJres enriched with clathrin-independent
endocytic (CIE) cargo; in this study, they found that CD147, CD44, CD98 and GLUT 1
were novel cargo internalized via CIE (Eyster et aI., 2009). Interestingly, they found that
l

CD147, CD44 and CD98 rapidly joined the recycling tubular endosomes via the
\

juxtanuclear endocytic recycling compartment; this rapid transit, in contrast to other CIE
cargo, may be due to the dynamic processes each of these proteins take part in, such as
nutrient uptake and ECM remodeling. Additional studies found that CD 147 did not sort
to late endosomes and therefore did not appear to be degraded by I ysosomes; cell surface
expression of CD 147 was minimally affected by up-regulation of membrane-associated
RING-CH E3 ubiquitin ligases, which reduced surface expression of other CIE cargo
members (Eyster et ai., 2011). Other studies have recognized that CD147 requires
clathrin-dependent sorting to localize to the basolateral membrane, but is independent of
the adaptor protein AP1B (Castorino et aI., 2011; Deborde et aI., 2008). Thus, it appears
20

that CD 147 may recycle from the cell surface rapidly and in some cells this mayor may
not rely on clathrin.

Characterization of Extracellular Vesicle-associated CD147
In addition to cytoplasmic vesicular localization, CD 147 has also been identified
in extracellular vesicles. In the initial characterization of CD147 in cancer, it was
recognized that it was also present in tumor-conditioned media (Ellis et aI., 1989).
Subsequent studies suggested that CD147 was released from the cell surface in a full
length soluble form (Taylor et aI., 2002) or a 22-kDa proteolytic cleavage product
(Egawa et aI., 2006) not associated with vesicles; whereas another study demonstrated
that CD 147 was associated with an ERK-dependent ~eleased microvesicle, but the vesicle
,..

degraded releasing CD147 into the media

:",

(sidh~~al., 2004).

Microvesicle-associated

CD147 was shown to be released from ovarian cancer cells and this elicited an
angiogenic phenotype in endothelial cells (Millimaggi et aI., 2007). Since lipid rafts may
1

be a point of origin for microvesicles (Muralidharan-Chari et aI., 2010), preceding
\

CD 147 accumulation in lipid rafts may lead to enrichment of CD 147 in microvesicles.
Other studies have found that CD 147 localizes in exosomes, which arise from
inward budding of endosomal membranes forming a late-endosome-associated
multivesicular body (MVB). Those MVBs that do not fuse with lysosomes, may act as a
temporary storage compartment that can later fuse with the plasma membrane releasing
exosomes (Stoorvogel et aI., 2002). CD147 has been found in exosomes derived from
the malignant ascites of ovarian cancer patients (Keller et aI., 2009) and in bladder cancer
(Welton et aI., 2010). In addition, CD147 is enriched in exosomes released by

21

cardiomyocyte progenitor cells, which stimulated endothelial cell migration (Vrijsen et
aI.,2010). Currently, the exact mechanism regulating the release of CD147 from the cell
surface or how vesicle-associated CD 147 functions in various aspects of cell biology is
unknown.

The Multi-functional Nature of CD147 Biology
CD147 Function Identified in Knockout Models
It is clear that CD147 is a ubiquitously expressed molecule attributed with many
biological functions in physiologic and pathologic contexts. Two of the earliest credited
,.

..

~',

functions of CD147 include a MMP-inducer ori~t~or cells (Ellis et aI., 1989) and a cell
recognition molecule involved in neuronal-glial patterning and aggregation (Fadool and
Linser, 1993). Subsequently, more understanding of the role of CD147 in cell biology
came from knock-out mice and mutant Drosophila strains.

1

Mice lacking the CD147 gene display a variety of adverse phenotypes.
Experiments revealed that the majority of CD 147 -null embryos died around the time of
initial blastocyst implantation, though different unknown modifier regions surrounding
the CD147 gene may attenuate this death rate (Chen et aI., 2004), and the few that
implanted subsequently died at post-implantation (Igakura et aI., 1998). In the rare event
that an embryo successfully implanted, the offspring were small in size and usually died
before one month due to difficulty of breathing attributed to interstitial pneumonia. It
was also noted that the surviving male CD 147-null mice were sterile due to
spermatogenesis arresting in meiosis I and female null mice have problems with
22

fertilization (Igakura et aI., 1998; Kuno et aI., 1998). Further studies revealed that
CDl47-null mice have abnormalities in spatial learning, memory, and sensory perception
to painful stimuli and noxious odors (Igakura et aI., 1996; Naruhashi et aI., 1997).
Additionally, CDl47-null animals displayed an exacerbated mixed lymphocyte reaction,
an assay that measures susceptibility to graft rejection via incompatibilities in major
histocompatibility complex antigens (Igakura et aI., 1996) and when challenged with
ligation of the ureter they demonstrated less fibrosis, matrix remodeling, and infiltration
of macrophages (Kato et aI., 2011).
Other studies with CD 147 -null mice found delayed entrance into dark
compartments, which led to subsequent studies describing retinal dysfunction as early as
.'

:I f

five weeks leading to blindness (Hori et aI., ~~Ochrietor et aI., 2001; Ochrietor et aI.,
2002). In light of this identified vision impairment, earlier studies demonstrating
neurological deficits may be due to preceding vision abnormalities, since the mice used in
the behavioral studies were 3-5 months old (Naruhashi et ai., 1997), whereas functional
retinal abnormalities were identified as early as eye opening (Ochrietor et aI., 2002). One
of the main mechanisms suggested to contribute to retinal pathology in CD 147 -null mice
is a disturbed metabolic interface between cellular constituents regulating retinal
physiology; this is attributed to reduced MCT surface expression (Ochrietor and Linser,
2004; Philp et aI., 2003). As mentioned previously, CD147 participates in a cochaperone relationship with MCT1, MCT3, and MCT4 and this was further confirmed in
vivo with a studying identifying a similar relationship across a diverse set of specific

tissue and cell types (Nakai et aI., 2006). These results in conjunction with the various in
vitro studies strongly support a role of CD147 in regulating MCT surface expression.

23

Evaluation of CD147 function in other model systems revealed additional
biological roles. Up-regulation of CD147 in High five insect cells causes a drastic
change in cytoskeletal organization characterized by an induced elaborate microfilament
and microtubule network, which seemed to be independent of cell contact or conditioned
media from CD 147-upregulated cells (Curtin et aI., 2005). Depletion of CD147 in
Drosophila has also revealed several other interesting phenotypes. For instance, CD147null fruit flies are embryonic lethal and flies manipulated to lack CD147 only in the eye
demonstrate that CD 147 regulates cell architecture. These studies found that the absence
of CD 147 in photoreceptors leads to misplacement of nuclei, rough endoplasmic
reticulum and mitochondria, possibly due to perturbed interactions with integrins;
interestingly these phenotypes could be rescued-with the mouse CD147 gene. Additional
,. ..
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phenotypes identified in CD 147-depleted flies include misplaced epithelial glia cells
surrounding photoreceptors, altered synaptic vesicle release, and a greatly reduced
presence of glial capitate projections induced by CDI47-as~ociated photoreceptors
(Curtin et aI., 2007). Other studies further identified that CD147 may act in a cell-cell
interaction module in the neuromuscular junction by regulating synaptic cytoskeletal
architecture and vesicle dynamics (Besse et aI., 2007). A study screening mutations in
CD 147 identified that specific residues in the extracellular domains and transmembrane
domain are vital for proper function (Munro et aI., 2010), yet other studies also suggest a
prominent role for the conserved YEKRRK sequence in the cytoplasmic tail of CD 147
for function (Besse et aI., 2007). These studies suggest that CD147 has a role in
regulating the cytoskeleton, cell-cell interaction modules, and vesicle distribution,

24

implying that CD147 may have an essential role in linking organization on the plasma
membrane with cytoplasmic vesicular networks.

The Role of CD147 in Cancer Progression
Tumor cells co-opt many physiological processes and use them to their advantage
as they attempt to survive, expand, and spread to other tissue compartments. CD147 is
highly enriched on the surfaces of many cancer types and plays a role in many aspects of
cancer progression. The following section will review the pleiotropic roles of CD 147 in
relation to the various mechanisms of tumor evolution and maintenance.

Cancer Migration and Invasion
Cellular migration and invasion defined as cell motility and migration through or
within a barrier, respectively, constitutes an essential biological mechanism used in many
1

diverse physiological and pathological situations by various cell types. In epithelial
cancer, cells depart from the primary tumor bulk by utilizing diverse migratory and
invasive mechanisms (Yilmaz and Christofori, 2009). In order for cancer cells to
successfull y metastasize and colonize distant sites, several obstacles must be surmounted:
they must detach from neighboring cells, break down the local basement membrane,
activate programs to resist anoikis, migrate and invade through surrounding tissue, gain
entry into the circulation via lymphatic or endothelial channels, survive mechanical or
immune-mediated destruction in transit through the circulation, extravasate into a new
tissue microenvironment, adapt their metabolic phenotype to different surrounding
nutrient gradients, and recruit supportive stromal cells to the new microenvironment to
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generate a macroscopic tumor (Chaffer and Weinberg, 2011). Many of the initial steps of
the metastatic cascade are believed to involve transitions in cellular programs that support
an increased migratory capacity. Cancer cells have been shown to utilize diverse modes
of movement, including mesenchymal, amoeboid and collective migration (Sahai, 2005).

Mesenchymal Movement

Single cell mesenchymal movement in epithelial cells is believed to be initiated
during the epithelial-mesenchymal transition (EMT). Established hallmarks of EMT
include: 1) down-regulation of characteristic cell junctional proteins, 2) increased
expression and nuclear translocation of several EMT -promoting transcription factors,
including

~-catenin

and the T cell factor/l ymph0Cyte enhancer factor 1 (TCF/LEF 1)
""~I ~i>

complex, Snail, and Twist, 3) alterations in cytoskeletal arrangements and protein
expression, 4) loss of cell polarity, 5) and up-regulation of proteases (Teng et aI., 2007).
Recently, EMT programs were classified into 3 distinct gropps: 1) EMT involved in
embryonic implantation and development, 2) EMT involved in wound repair/tissue
regeneration, and 3) EMT involved in cancer invasion and metastasis; though, these are
separate biological processes, they most likely have many interrelated signaling networks
(Kalluri and Weinberg, 2009). Recent evidence also suggests that the EMT program may
endow cells with a stem-like quality, which has been demonstrated to promote increased
tumorigenicity, invasiveness and therapy resistance (Dave et aI., 2012).
Interestingly, CD147 has been shown to regulate biological processes in each of
these EMT classifications (Gabison et ai., 2009; Igakura et aI., 1998; Zucker et aI., 2001).
CD147 has been shown to be regulated by the EMT-promoting TF Snail in melanoma
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cells (Kuphal et aI., 2005) and may be involved in an EMT-like process during
embryonic stem cell differentiation (Ullmann et aI., 2008). A role for CD147 in EMT
was recently identified in hepatocytes where up-regulation of CD147 initiated a TGF-~
signaling cascade resulting in Slug up-regulation, cadherin switching and morphological
changes (Wu et aI., 2011a). Whether CD147 is involved in EMT in other cell types is
unknown. A direct link has also been suggested between EMT and resistance to anoikis,
a cell death process initiated upon detachment from a supportive ECM potentiating
survival signals (Onder et aI., 2008). Up-regulation of CD147 in breast cancer cells
confers resistance to anoikis (Yang et aI., 2006) facilitating survival during matrix
detachment in invasion.
t.
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Amoeboid Movement
Amoeboid cellular movement acts as another mechanism of single cell motility.
This migratory mechanism is characterized by a plastic rouJtded morphology and
intermittent actomyosin-regulated blebbing with little dependence on protease activity
(Sanz-Moreno and Marshall, 2009). It is clear that cell migratory phenotypes exist as a
fluxing continuum between different forms of membrane protrusion and contraction
states, which are regulated by diverse signaling and physical matrix cues (Friedl and
Wolf, 2009). Recently, it was demonstrated that the interplay between mesenchymal and
amoeboid movement is regulated by the signaling activity differences in the Rho protein
family members. Guanine nucleotide phosphate (GTP)-bound proteins are regulated by
GTP exchange factors (GEFs) and GTPase activating proteins (GAPs), which promote
activation and inactivation, respectively (Vigil et aI., 2010). Inasmuch, amoeboid

27

movement is promoted when Rho-kinase (ROCK) signaling activates a Rac GAP and
mesenchymal movement is stimulated with increased Rac activity, which in turn
suppresses amoeboid motility; this study strongly supports the notion that cancer cells
interconvert their migratory phenotypes (Sanz-Moreno et aI., 2008).
A new mechanistic study provides evidence that CD 147 can inhibit
phosphorylation of Annexin II (AnxA2), which leads to attenuation of ROCK-mediated
suppression of mesenchymal motility. Furthermore, they also found that up-regulation of
CD147 increased Rae activity and Wiskott-Aldrich syndrome protein family member 2
(WA VE2) expression and membrane localization, which led to actin polymerization,
lamellipodia formation and a mesenchymal morphology (Zhao et aI., 2011). In a separate
study in cardiomyocytes, CD147-induced functi()n~, w'ere also shown to be dependent on
"'J~J ~i;'

Racl activity (Venkatesan et aI., 2010). These studies suggest that CD147 may playa
role in modulating the interconversion of individual cell migratory phenotypes via
regulation of Rac signaling events.

Cellular Protrusions Involved In Cell Migration/Invasion

Filopodia
It has been suggested that concomitant with the mesenchymal transition and

migratory phenotype, cells also utilize finger-like projections called filopodia to probe
and explore the surrounding microenvironment (Yilmaz and Christofori, 2009).
Filopodia are protrusions extending from the plasma membrane, usually originating from
lamellipodia, that are composed of parallel actin filaments bundled by cross-linking
proteins (Arjonen et aI., 2011). Filopodia formation may serve as a precursor for cell-
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ECM adhesion, thus promoting cell migration (Faix et aI., 2009). Increased presence of
filopodia formation promotes migration (Zhang et aI., 2004) and increased filopodia have
been seen at the invasive front of colorectal cancer cells, indicating that filopodia may
facilitate the invasion process (Vignjevic et aI., 2007). In support of this, a subset of
filopodia have been found to have invasive characteristics in 3D culture and may have a
role in invadopodia (see below) and mesenchymal invasion (Li et aI., 2010). Knockdown
of CD147 in prostate cancer cells resulted in a --.J50% decrease in filopodia formation
(Zhu et aI., 2011) and up-regulation of CD147 in insect cells resulted in similar protrusive
structures (Curtin et aI., 2005). Fascin, the major actin-bundling protein in filopodia may
interact with CD147 in promoting aggressive cancer types (Tsai et aI., 2007), though
further research is needed to elucidate possible molecular interactions between the two.
"'~'~I ~i:-

Invadopodia
In the early 80's investigators identified that Rous

s~rcoma

virus (v-src)-

transformed cells cultured on 2D substrata form ventral protrusions located at points of
cell-ECM contact, which are enriched in actin and tyrosine phosphorylated proteins.
Subsequently, these protrusions were found to degrade the ECM at cell contact points and
thus were termed invadopodia (Chen et aI., 1985). Other investigators found that similar
protrusions could be formed in osteoclasts, macrophages, dendritic cells, endothelial
cells, and vascular smooth muscle cells, yet these structures are termed podosomes.
Recently, it has been suggested that the term 'invadopodia' be reserved for cells with
transformed properties and the term 'podosome' for normal cells (Murphy and
Courtneidge, 2011). Due to the presence of these degradative protrusions in both normal
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and tumorigenic cells, much effort is focused on their potential roles in regulating
physiological and pathological invasive processes.
Over the past couple of decades, it has become clear that invadopodia contain an
actin-rich core inundated with modulators of actin polymerization (Albiges-Rizo et aI.,
2009). Many proteins orchestrate the dynamic reconstruction of the actin cytoskeleton,
but recent findings have identified key players in invadopodia formation. Invadopodia
construction has been characterized into initiation, assembly and maturation stages.
Briefl y, in the initiating stage the cancer cell attaches to the ECM and tyrosine kinase
substrate with 5 SH3 domains (Tsk5) is recruited to phosphatidylinositol-3,4bisphosphate (PIP 2 )-enriched membranes via a Src-dependent mechanism (Oikawa et aI.,
2008), which leads to subsequent interaction Wi:tli?brtactin. Also, PIP3 may serve as an
initiating site of invadopoda formation by activating Akt signaling (Yamaguchi et aI.,
2011). In the assembly stage, this protein complex then recruits N-WASP, Arp2/3 and
cofilin to initiate actin polymerization (Oser et aI., 2009), which is regulated by various
kinases, soluble mediators and actin polymerization modulators~\ In the maturation stage,
proteases, including soluble and membrane-type MMPs, become enriched at the
invadopodial tips and microtubules and vimentin filaments cooperate in the elongation of
invadopodia (Schoumacher et aI., 2010). MTI-MMP appears to be a vital component of
invadopodia degradation machinery, as several investigators have demonstrated
decreased invadopodia activity following attenuation of MTI-MMP activity (Hu et aI.,
2011 ; Nakahara et al., 1997; Sakurai -Yageta et al., 2008). MT 1-MMP trafficking to
invadopodia has been attributed to a diverse group of proteins, including caveolin-l
(Yamaguchi et aI., 2009), cortactin (Clark et aI., 2007) and the conserved octameric
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exocyst complex (Liu et aI., 2009; Sakurai-Yageta et aI., 2008). Delivery of these
proteases to invadopodia facilitates ECM degradation and promotes the invasion process.
Active trafficking in invadopodia is also supported by electron micrographs
demonstrating vesicles within invadopodia (Schoumacher et aI., 2010) and a proclivity
for the golgi to localize in close proximity to invadopodia (Baldassarre et aI., 2003). See
a recent article by Murphy et al. for a complete review on invadopodia dynamics
(Murphy and Courtneidge, 2011).
Coupled with the dynamic stages described above, invadopodia may be regulated
by various growth factors (e.g EGF) and signaling inputs (e.g. ERK) (Ayala et aI., 2007;
DesMarais et aI., 2009; Eckert and Yang, 2011; Mader et aI., 2011), reactive oxygen
species (Weaver, 2009), pH gradients (Busco ettaL", 2010; Magalhaes et aI., 2011), matrix
·-"'·~I ~i;'

composition and orientation (Alexander et aI., 2008) and lipid raft integrity (Caldieri et
aI., 2009; Yamaguchi et aI., 2009). Thus, it is clear that myriad factors seem to converge
and dictate the tendency of invadopodia to form and activeo/ degrade the underlying
ECM barrier. Evidence for EMT involvement in invadopodia was identified when nontransformed breast epithelial cells stably-expressing Twist or Snail, EMT-promoting TFs,
formed invadopodia and may be involved in metastasis in vivo (Eckert et aI., 2011). Very
strong evidence supporting a role of invadopodia in metastasis in vivo was recently
demonstrated using intravital multiphoton imaging; in this study N-WASP deficient cells
demonstrated defects in migration, invasion, intravasation and dissemination, which
seemed to be MMP-mediated (Gligorijevic et aI., 2012). Additionally, knockdown of
Tsk5 in zebrafish neural crest cells resulted in attenuated EMT -like migration, suggesting
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that regulators of invadopodia may also be involved in development processes (Murphy
et aI., 20 11 ).
As imaging techniques have advanced, high resolution characterization of
invadopodia dynamics is now possible in 2D and 3D models. Total internal reflection
fluorescence (TIRF) microscopy, a technique that permits high resolution evaluation of
events occurring directly at the cell membrane with little cytosolic noise, revealed that an
invadopodial core attaches to the ECM, which then projects out multiple filament -like
processes (Artym et ai., 2010); culture of cells in a 3D dermis-based matrix demonstrated
a similar invasive superstructure (Tolde et aI., 2010). Culture of invasive cancer cells on
a native basement membrane isolated from rat peritoneum demonstrated that invasive
cells initially form invadopodia that degrade the. un,derlying ECM, these invadopodia
"
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further elongate to 1-7flm in length and after a period of 5-7 days the whole cell has
infiltrated through the basement membrane defect (Schoumacher et aI., 2010). A new
linear invadopodia configuration was identified when cells rere cultured in a collagen I
model; these invadiopodial structures formed along the collagen fibrils and demonstrated
proteolytic activity in 3D (Juin et aI., 2012).
It is evident that many physical and biological inputs are integrated
spatiotemporall y to determine the configuration( s) of protrusions that a motile cell will
employ. As it is clear that distinct protrusions are formed in various cells, many studies
have recognized that similar protein constituents are involved in the dynamics of each of
these protrusions (Linder et aI., 2011). For instance, invadopodia rely on filopodiaassociated proteins for function and vice versa (Li et aI., 2010; Schoumacher et aI., 2010).
Hence these protrusive structures may represent a hybrid structure that has different
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functional capacities in various biological/physical contexts (Ridley, 2011; Yilmaz and
Christofori, 2009).

Protease Induction
In the mid to late 80' s, Chitra Biswas' laboratory attempted to characterize a
factor present on lung carcinoma cell membranes that stimulated collagenase production
from co-cultured fibroblasts (Biswas, 1984; Biswas and Nugent, 1987). Later studies
found that this cell surface factor was CD 147, which was identified as a protein with
diverse molecular weights both in the membrane fractions and conditioned media (Ellis et
aI., 1989). Additional studies revealed that MMP-inducing activity via CD147 could be
;.

,"'.

achieved by cell-cell contact or via shedding fr~~jhe cell surface. Subsequent studies
found that CD147 could induce the synthesis ofMMP-1, MMP-2, MMP-3, MMP-9,
MMP-14, and MMP-15 (Yan et aI., 2005). In addition to induction in fibroblasts, CD147
has been shown to increase MMP production in endothelial 1cells, macrophages, tumor
cells, and non-immortalized epithelial cells (Weidle et aI., 2010). Supplemental to MMP
induction, CD147 also participates in the activation of the urokinase-type plasminogen
activator (uPA) system; in this study, up-regulation of CD147 or treatment with CD147enriched membranes were able to stimulate the uPA system in breast cancer, oral
squamous and endothelial cells (Lescaille et aI., 2012; Quemener et aI., 2007).
Several mechanisms have been proposed to explain how CD147 induces MMPs,
yet the exact mechanism on how this occurs is currently unknown. Current variables that
have been described to influence the ability of CD 147 to induce MMPs include:
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glycosylation status, dimerization/oligomerization, and association with various protein
binding partners leading to activation of cell signaling pathways.
Glycosvlation

Earlier experiments demonstrated that CD147 cDNA expressed in bacteria
resulted in a non-glycosylated form around 29 kDa, which had no MMP-inducing activity
when added to fibroblasts. These studies also suggested that lower glycosylated forms of
rbCD147 (30-45 kDa) were unable to induce MMP synthesis (Guo et ai., 1997).
Following studies further demonstrated that deglycosylated endogenous CD147 had no
MMP-inducing activity and was able to attenuate the ability of HG-CDI47 to induce
MMPs (Sun and Hemler, 2001). Conversely, others

~ave

demonstrated that non-

t • • ',

glycosyJated CD147 (Attia et al., 2011;

Belto~~(i, 2008) or a peptide corresponding to

the IgC2 domain with a single N-acetylglucosamine (GlcNac) or chitobiose unit
(Kawakami et ai., 2011) was capable of stimulating MMP production. Studies in
1

atherosclerosis and muscle differentiation proposed that different CD 147 glycoforms
\

induce a differing MMP repertoire (Attia et ai., 2010; Sluijter et ai., 2005), though further
exploration of this phenomenon is needed. A recent study found that multiple colorectal
cancer cell lines contained synonymous mutations in codons that correspond to
glycosylation sites in the extracellular domain of CD147, though the significance of these
alterations is unknown (Zheng et ai., 2011). Clearly, the relationship between CD147
glycoforms and MMP induction warrants further intense investigation.
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Homo-DimerizationlOligomerization
CD 147 was first found to homo-oligomerize in several avian tissues, in which the
authors proposed that CD 147 can potentially interact both in cis and trans fashion
forming a macromolecular complex (Fadool and Linser, 1996). Subsequent studies
found that CD147 forms homo-oligomers only in a cis-like manner and that the IgC2
domain was sufficient for this dimerization while N-glycosylation appeared to play no
role (Yoshida et aI., 2000). Since tumor-associated CD147 and soluble CD147 can
induce MMP synthesis in neighboring cells, this implies that a counter-receptor may
participate in trans-interactions between these cells (Yan et aI., 2005). Studies using
immobilized CD 147 fusion protein determined that CD 147 may be a receptor for itself,
t,

:',

similar to other IgSF members, and that this ass99,jtion was dependent on the IgC2
domain. Additionally, treatment of cells with a monoclonal antibody demonstrated to
specifically bind multimerized CD147 inhibited MMP induction, implying oligomerized
CD147 may facilitate MMP induction (Sun and Hemler, 2061). Subsequent cross-linking
studies between the Ig-like domains of rbCD147 and fibroblasts Jollowed by MALDIMS/MS sequencing identified CD147 as a receptor for rbCD147 (Belton et aI., 2008).

Other studies using crystallographic approaches have found that Ig-like domains in
CD147 dimerize in both cis and trans fashion (Yu et ai., 2008) possibly through

~-strand

domain swapping (Luo et ai., 2009). A systematic mutational analysis of the ectodomain
of CD147 revealed that multiple mutations in the Ig-like domains inhibited
dimerization/oligomerization and subsequently MMP induction (Cui et aI., 2012).
Though the above studies demonstrate that the CD 147 N-terminus can interact
homophilicaBy between homo/hetero-typic cell types, surface plasmon resonance (Hanna
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et aI., 2003) and FRET analysis (Wilson et aI., 2002) suggest otherwise. In contrast, a
new study also suggests that CD147-3 binding to the IgI domain of CD147-2 attenuates
induction of MMP synthesis and invasion, though this relevance is questionable as
CD147-3 has been identified as a nonsense-mediated decay gene, thus additional studies
are needed for further clarification (Liao et aI., 2011). The above studies suggest that
CD147 may self-associate in a cis or trans orientation on the cell surface, which results in
MMP induction.

Heterophilic Protein Interactions
The protein structure and binding characteristics of CD 147 suggest a role in being
a component of protein-protein interactions. As described previously, CD147 contains an
t·

•

unusual glutamate residue as well as a leucinezf;(er motif in its transmembrane domain
(Jian-Li and Juan, 2007); both of these characteristics have been associated with multiprotein complex assembly (Humphrey et aI., 2005; Zhou et aI., 2001). Other single span
transmembrane proteins, such as discoidin domain receptors (Noordeen et aI., 2006),
erythropoietin receptors (Ruan et aI., 2004) and E-cadherin (Huber et aI., 1999) utilize
leucine zipper motifs in dimerization. Additionally, further studies indicate that the IgC2
domain may also interact with Igl/V -like domains on other IgSF proteins (Yu et aI.,
2008) and CD147 may associate with proteins with attached oligomannose moieties
(Heller et aI., 2003). In addition to these mentioned characteristics, differential
glycoforms of CD147 provide prodigious advantages to participate in diverse proteinprotein interactions.
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The most characterized binding partner of CD 147 that regulates MMP induction
is caveolin-l. As mentioned previously, caveolin-1 is thought to decrease CD147induced MMP production by decreasing cell-surface clustering and further complex
glycosylations, though these appear to be independent of each other (Tang et aI., 2004a;
Tang and Hemler, 2004). Conversely, studies evaluating MMP synthesis in a lung injury
model and hepatocellular carcinoma progression suggest that an inverse relationship
exists between caveolin-1 and CD147 (Barth et aI., 2006; Jia et aI., 2006), though this
could be due to different cell models and experimental evaluation.
Another protein that has been shown to interact with CD147 and regulate MMP
induction is Annexin II (AnxA2). AnxA2 is a multifunctional protein that regulates
t·

:",

cytoskeleton organization, lipid raft dynamics.,..·~~;endo/exo-cytic trafficking events
(Gerke et aI., 2005). A recent study found that CD147 and AnxA2 might cooperate in
hepatocellular carcinoma migration and invasion by regulating MMP production (Zhao et
aI., 2010).
,

Earlier studies found that CD147 interacted with

a3~1

and a6~1 integrins at cell-

cell contacts, but not at focal adhesions sites; interestingly, it appears that LG-CD 147 was
the glycoform primarily associated with integrins (Berditchevski et aI., 1997). Later
studies found that these CD147-integrin interactions contributed to cancer invasiveness
by inducing MMP synthesis in hepatoma cells via a PI3K signaling pathway (Dai et aI.,
2009). A recent study identified that ASp179 in the IgI domain of CD147 interacts with
the metal ion-dependent adhesion site in the

~A

domain of the integrin

~1

subunit, this

interaction was shown to lead to focal adhesion kinase (FAK) signaling events, which
regulated in vivo tumor growth. This CD14737

~l

interaction was facilitated by manganese

and was attenuated by competing RGD containing ligands (Li et ai., 2012). Interestingly,
CD147 also interacts with caveolin-1 via this IgI domain (Tang and Hemler, 2004),
though whether competing interactions between integrins, caveolin-1 or RGD-containing
ligands influences CD 147 function is unknown.

Angiogenesis
As the primary tumor bulk expands, nutrient availability becomes a limiting
variable governing the success of further tumor growth. Nutrient, oxygen and metabolic
waste transport through endothelial cell channels recruited by tumor cells is a major
mechanism that can supply adequate nutrient s,~p'p~to a primary or newly colonized
tumor bed. CD147 has been shown to promote increased angiogenesis by upregulating
soluble vascular endothelial growth factor (VEGF) protein and secretion in breast tumor
cells and cancer cell-fibroblast cocultures; this induction of ~EGF was also seen in vivo
(Tang et ai., 2005). Further characterization of this effect revealed
that CD147
,
specifically increased the soluble VEGF 121 and VEGF 165 splice variants along with
VEGF receptor 2 (VEGFR-2) via induction of hypoxia-inducible factor 2a (HIF-2a) in
normoxic conditions (Bougatef et ai., 2009). Similar findings were also observed in
melanoma cells, where CD147 may be involved in a VEGF autocrine signaling
mechanism promoting migration, invasion and proliferation (Bougatef et ai., 2010).
CD147 also appears to be involved in VEGF secretion during Kaposi sarcoma-associated
herpesvirus' induction of a tumor-associated fibroblast phenotype (Dai et ai., 2012). The
exact mechanism of how CD147 induces VEGF production is not known, but analysis of
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tumor-endothelial cross-talk revealed that tumor-derived CD 147-associated microvesicles
induce invasiveness, MMP production, and tubule formation in endothelial cells
(Millimaggi et aI., 2007). Thus, CD147 may mediate VEGF signaling and angiogenic
events either by cell-cell contact, soluble or vesicle-associated CD147 mechanisms.
To date, a relationship between CD147 and VEGF has been demonstrated in
breast cancer (Tang et aI., 2005; Tang et aI., 2006), liver cancer (Jia et aI., 2007), renal
cancer (Liang et aI., 2009), osteosarcoma (Zhou et aI., 2011), bladder cancer (Xue et aI.,
2011), colorectal cancer (Zheng et aI., 2011), pancreatic cancer (Zhang et aI., 2007),
glioblastoma (Liang et aI., 2005), gastric cancer (Zheng et aI., 2006), melanoma
(Bougatef et aI., 2010; Chen et aI., 2006a; Voigt et aI., 2009) and head and neck SCC
,.

.-',

(HNSCC) (Newman et aI., 2008a). AdditionaU,,; !'lfrecent study suggested a potential use
of CD147 expression to stratify patients and their response to anti-VEGF therapies such
as bevacizumab (Newman et aI., 2009). CD147 takes part in tumor angiogenesis in
several cancer types and induces VEGF production autonorhously in tumor cells and in a
paracrine fashion between tumor cells and fibroblasts and endothelial cells. In addition,
to angiogenesis, CD 147 also contributes to vasculogenic mimicry, a process in which
malignant tumor cells form non-endothelial-lined channels and behave like blood vessels
(Millimaggi et al., 2009).

Multi-therapy Resistance

Broad, combined and targeted chemotherapy regimens are limited in their
efficacy by the development of tumor drug resistance. Tumor drug resistance can be
39

achieved in numerous ways. Cancer cell autonomous mechanisms include: alteration of
metabolic and morphologic phenotype, amplification of the target, acquired mutation in
the target via positive selection during drug exposure, bypassing signaling pathway(s)
being targeted, increased repair and detoxification mechanisms, augmented capability to
efflux drugs via cell membrane transporters and enhanced activation of cell survivallantiapoptotic signaling pathways. Additionally, many of these drug-resistant characteristics
can be modulated in the tumor tissue by stromal, endothelial and immune cell influences
as well as the physical matrix/tissue barriers surrounding the vicinity of the growing
tumor (Garraway and Janne, 2012).
CD147 expression has been correlated with a multidrug resistance (MDR)
phenotype in several cancer types (Kuang et .al~;~8; Yang et aI., 2003) possibly by
regulating expression of the MDRI gene product, P-glycoprotein (P-gp) drug efflux
pump (Li et aI., 2007a). Subsequent studies revealed that reduction of CD147 expression
led to increased accumulation of chemotherapy drugs in cahcer cells (Yang et aI., 2007).
A growing amount of evidence also indicates that CD147 is increased upon
chemotherapy exposure (Li et aI., 2007b; Qin et aI., 2011) and may associate with P-gp
during this event (Wang et aI., 2008). In the previously mentioned studies, CD147 has
been associated with resistance to doxorubicin, paclitaxel, cisplatin, 5-fluorouracil,
vincristine, and all-trans retinoic acid; therefore CD 147-mediated drug resistance cannot
be due solely to Pgp regulation. In support of this, a recent study found that CD147
regulates breast cancer resistance protein (BCRP) expression and plasma membrane
presence (Qin et aI., 2011), a protein that has a differing substrate profile than Pgp
(Lemos et aI., 2008). Additionally, CD147 has been shown to regulate the expression of
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X-linked inhibitor of apoptosis, a protein related to chemotherapy resistance. Recently, a
study employing laser capture microdissection identified CD 147 expression as the most
discriminatory protein in stratifying tamoxifen therapy resistance in breast cancer tumor
samples (Umar et aI., 2009) and CD147 expression in bladder cancer is associated with
poor survival following cisplatin-based therapy (Als et aI., 2007).
In addition to the regulation of drug efflux pumps, CD 147 has also been shown to
potentiate drug resistance by inducing the synthesis of hyaluronan (HA) (Toole and
Slomiany, 2008). HA is a large non-sulfated extracellular sugar composed of repeating
N-acetylglucosamine and glucuronic acid units, which can act as a scaffold for other
ECM constituents in the construction of the interstitial milieu. HA engages cell surface
receptors, including its main receptor CD44, aR~ Ifbelieved to promote the formation of
multi-protein cell surface complexes by creating a stabilizing pericellular scaffold
(Ghatak et aI., 2005; Toole, 2004). Disruption of HA-CD44 interactions leads to
internalization of CD44 and respective binding partners, indluding metabolic and drug
transporters (Slomiany et aI., 2009a; Slomiany et aI., 2009b).
The involvement of CD147 in resistance to radiation therapy is just beginning to
emerge. A relationship between CD 147 expression following brachytherapy for cervical
carcinoma was identified, where patients with elevated CD147 tissue staining posttherapy demonstrated poorer survival (Iu et aI., 2008). The exact mechanisms underlying
this putative association of CD 147 and radio-resistance are currently unknown, but may
depend on altered control of reactive oxygen species (Xie et aI., 2011).
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CD147-induced Cell Signaling Pathways
It is clear that CD 147 has various roles in diverse cell types in physiological and

pathological contexts, though the signaling pathways activated in each setting are not
completely clear. The first activated signaling pathway identified by exogenous CD 147
treatment was the mitogen activated protein kinase (MAPK) p38-associated pathway,
which led to MMP-1 synthesis in fibroblasts (Lim et aI., 1998). Following studies found
that full length soluble CD147 released from breast cancer cells induces a phospholipase
A 2/5-lipoxygenase pathway resulting in arachidonic acid metabolism in fibroblasts
(Taylor et aI., 2002). Other studies have indicated that CD147 also regulates MAPK
signaling pathways, including ERK and JNK (Qian et aI., 2008; Xu et aI., 2007). CD 147
associates with the heparan

sulfate-containingfr~in

syndecan-l, resulting in CypB-

mediated ERK activation (Pakula et aI., 2007) and can also interact with a osteopontin
peptide-CypC complex to elicit Akt 1/2 signaling (Mi et aI., 2007). Other studies have
1

demonstrated that CD 147-integrin interactions lead to focal adhesion kinase (FAK)-PI3K
related pathways (Dai et aI., 2009; Tang et aI., 2008). A recent study found that CD147
was a regulator of the canonical Wnt/~-catenin pathway in lung cancer. Specifically, upregulation of CD147 led to an EMT-like phenotype, nuclear accumulation of ~-catenin
and additional tumorigenic characteristics (Sidhu et aI., 2010). Co-culture of tumor cells
and fibroblasts revealed a novel mechanism involving fibroblast growth factor (FGF)
signaling and CD147 (Liu et aI., 2011). In this study it was proposed that early in tumor
progression CD 147 expression may be low and tumor growth is dependent on fibroblasts
and FGF signaling, whereas later stages of tumor growth have elevated CD 147
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expression with a concomitant reduction in FGFR signaling allowing the tumor to
become independent of fibroblasts for further progression.
In inflammatory scenarios, CD147 can stimulate ERK and NF-K~ signaling (Kim
et aI., 2009; Schmidt et aI., 2008) and inflammatory cytokines/chemokines IL-l, IL-6 and
IL-8, CCL3, CCL20, CXCL2 and CXCL5 (Chen et aI., 2009; Dean et aI., 2009).
As mentioned above, CD147 can also interact with CD44 (Slomiany et aI.,
2009b), though no activated pathways have been ascribed to this interaction. Since
CD147 has been shown to regulate HA synthesis (Edward et aI., 2011; Ghatak et aI.,
2005; Kato et aI., 2011; Marieb et aI., 2004; Qin et aI., 2011), it is possible that CD147induced HA-CD44 interactions may activate similar pathways that HA alone induces. In
t·
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this manner, CD 147-mediated HA-CD44

/-

inte'~~~tig~s have led to activation of PI3K and

ERK signaling pathways (Marieb et aI., 2004). Whether the other aforementioned
CD 147-induced signaling pathways are intertwined with HA-CD44 signaling complexes
1

is unknown.
In conjunction with inducing activation of 'linear' signaling pathways, CD147
also appears to be involved in autocrine signaling loops. For instance,

TGF~

has been

shown to increase CD 147 expression and in turn CD 147 increased TGF~ signaling
leading to an EMT phenotype (Wu et aI., 20l1a). In melanoma, CD147 may stimulate an
autocrine VEGF-VEGFR2 signaling loop (Bougatef et aI., 2010) and VEGF-D may
potentiate this by increasing CD 147 expression at the plasma membrane (PapiewskaPajak et aI., 2010). During inflammatory or wound healing processes CD147 may also
participate in an autocrine loop consisting of interleukin signaling (Gabison et aI., 2009;
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Venkatesan et aI., 2009). A positive feedback loop for CD147 itself has also been
identified (Tang et aI., 2004b). Finally, the influence of CD147 in regulating HA
synthesis also raises the question of whether CD 147-induced HA-CD44 interactions also
mediate autocrine signaling events, seen with up-regulation of HA alone (Misra et aI.,
2005).
Though no kinase motif has been identified in CD 147, other studies have emphasized
that interactions in the extracellular Ig-like domains activate downstream signaling
pathways. CD147 dimerization/oligomerization has been shown to be a major factor in
regulating ERK phosphorylation (Cui et aI., 2012) and association with integrin B1 is
associated with FAK signaling (Li et al., 2012). The short cytoplasmic tail contains
partially conserved serine residues (Weidle et"a~,:f010) and our own preliminary analysis
"f

suggests that Serine 246 may be a putative Casein Kinase 1 phosphorylation site, though
this needs further clarification. Whether the cytoplasmic domain has a role in signaling is
not known, currently one study suggests that this may not bb the case in CypA-CD147induced signaling (Pushkarsky et aI., 2007). Another study in activated T cell suggests
that a membrane-localized CD147 cytoplasmic tail was sufficient to mediate the
signaling effect mediated by CD147 (Ruiz et aI., 2008).
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The Role of CD147 in Metabolic Processes of the Cell

As described previously, CD147 is an inducible molecule governed by many
diverse stimuli. CD147 has been demonstrated to be regulated by TSH, an active
fragment of SCP-2, PPAR proteins, PGCl-a and NAMPT, which are all direct regulators
of cell metabolic processes. In addition, exposure of cells to glucose, butyrate or pectin
increases CD147 expression (Kirat et aI., 2009). CD 147-depleted oral SCC cells
demonstrated a differential gene expression pattern with most of these genes being
related to cellular metabolism (Kuang et aI., 2008).
The strongest evidence, thus far, for CD 147 being involved in cellular energetics
is the observed associations between CD 147 and mo~ocarboxylate transporter (MCT)
t·
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family members MCT1/2/3/4, which are proton'-lifiked transporters that facilitate the
movement of pyruvate, lactate, and ketone bodies across cell membranes (Halestrap,
2011b). CD147 has been shown to be an essential chaperone needed for surface
t

expression of these MCTs, since overexpressed MCTs don't traffic to the plasma
\

membrane unless CD147 is co-expressed (Gallagher et aI., 2007; Kirk et aI., 2000; Philp
et aI., 2003). The role of MCTs in lactic acid flux has been exploited by cancer cells as
they utilize these transporters to maintain metabolic homeostasis.
Otto Warburg observed that cancer cells exhibited increased glycolysis to
generate adenosine triphosphate (ATP), even in the presence of abundant oxygen supply;
this process has now been coined the 'Warburg effect' (Warburg, 1956). A number of
studies have gone on to demonstrate that accumulation of lactate is associated with poor
prognosis in several cancer types and is strongly associated with highly invasive
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phenotypes (Kennedy and Dewhirst, 2010). In addition to genetic/epigenetic
heterogeneity in the tumor, metabolic heterogeneity is also present. For example, tumors
contain cell populations localized in oxygenated and hypoxic regions and evidence of
metabolic symbiosis between lactate-producing and lactate-utilizing cells has been
demonstrated in vivo with MCT inhibitors (Sonveaux et aI., 2008). Thus it appears that
many cancers rely on glycolysis to generate ATP to synthesize the biomass needed for
various anabolic reactions during proliferation (Vander et aI., 2009).
Multiple studies have identified that inhibition of CD 147 expression in various
cancer types results in perturbed MCT -mediated lactic acid flux across the plasma
membrane (Baba et aI., 2008; Floch et aI., 2011; Schneiderhan et aI., 2009; Slomiany et
aI., 2009b; Su et aI., 2009); in some studies thi~;l#to highly decreased ATP levels and
cell death. A recent study has provided very strong evidence that one of the main
functions of CD147 in tumorigenesis is the escorting of MCTs to the cell surface, which
is vital for highly glycolytic and aggressive cancers (Floch ~t aI., 2011). An elegant study
employing cell surface crosslinking in the midst of different detergent conditions
followed by mass spectrometry analysis identified that CD 147 associates in a super
metabolic complex on the cell surface. Specifically, CD147 was found to complex with
the following: MCTs (lactate and pyruvate transporters), CD98hc (a multifunctional
chaperone for nutrient transporters), L-type amino acid transporter 1 (LAT 1), ASCT2
(neutral amino acid transporter) and epithelial cell adhesion molecule (EpCAM). The
organization of the complex is proposed to consist of a CD 147-MCT complex with direct
linkage of CD147-to CD98, which associates with the other amino acid transporters and
EpCAM (Xu and Hemler, 2005). Finally, this study identified that CD147 and CD98
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regulated the surface expression of one another and that depletion of either one resulted
in increased activation of the cellular energy sensor AMP kinase.
In addition to association with MCTs on the cell surface, CD147 has also been
shown to associate in the inner mitochondrial membrane with MCT 1, lactate
dehydrogenase and cytochrome oxidase in a lactate oxidation complex (Hashimoto et aI.,
2006). This mitochondrial complex may aid in the utilization of lactate transferred
between glycolytic and respiring cancer cell populations or aid in the consumption of cell
autonomous lactate produced in the cytosol, thus maintaining redox balance (Hussien and
Brooks, 2011).
CD147 has also been proposed to regulate
G,rp75 (mortalin) expression (Kuang et
,.
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aI., 2008), a 70 kDa heat shock protein (Hsp70) f{mily member involved in the cellular
response to glucose deprivation, mitochondrial import, vesicular trafficking and
regulation of p53 activity (Wadhwa et aI., 2002).
Clearly, CD147 appears to be involved in multiple

aspe~ts

of cellular metabolism.

This is supported by elevated expression of CD147 on many metabolically active cell
types, such as lymphoblasts (Spring et aI., 1997), brown adipocytes ((Nehme et aI.,
1995), inflammatory and malignant cancer cells (Muramatsu and Miyauchi, 2003). It
may be inferred from the studies above that diminished CD 147 expression may result in
impaired lactate, pyruvate and amino acid transport across cell membranes, thus leading
to an altered metabolic phenotype and may explain how CD 147 inhibits starvationinduced autophagy (Gou et al., 2009).
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Hypothesis and Experimental Rationale

Hypothesis
It is hypothesized that CD147 induces breast cancer invasion by regulating
invadopodial dynamics via the assembly of multi-protein signaling complexes.
Rationale
CD147 expression is associated with an invasive phenotype in a wide array of
cancer types, including breast cancer. CD147 is a predominant marker in breast cancer
micrometastases (Klein et aI., 2002; Reimers et aI., 2004) and is enriched in malignant
pleural effusions and circulating tumor cells (Davidson et aI., 2004; Pituch-Noworolska
et aI., 2007), suggesting a prominent role for CD147 in tumor progression. The role of
CD147 in invasion has been demonstrated in§xY~fi model systems, including a study in

vivo in which CD 147-transfected breast cancer cells injected into mammary fat pads of
nude mice were found to be more locally invasive than control transfected cells and in
several animals metastasized to the liver, spleen, mediastinum, lymph nodes, and
mesentery (Zucker et aI., 2001). The mechanism mostly attJributed to CDl47-induced
invasion is the induction of proteases, including soluble and membrane-type MMPs,
though the mechanism regulating this process have not been fully elucidated.
Cancer cells employ multiple mechanisms to migrate, degrade and invade through the
ECM. Invadopodia, actin-based proteolytic superstructures, have gained much attention
for their role as vital organelles in cellular invasion (Murphy and Courtneidge, 2011) both

in vitro and in vivo. The purpose of this project was to further characterize the
mechanism(s) by which CD147 facilitates breast cancer invasion by evaluating the role of
CD147 in invadopodia activity and potential related signaling pathways.
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Chapter 2: Regulation of Invadopodia Formation and Activity by CD147

Abstract
A defining feature of malignant tumor progression is cellular penetration through the
basement membrane and interstitial matrices that separate various cellular compartments.
Accumulating evidence supports the notion that invasive cells employ specialized
structures termed invadopodia to breach these structural barriers. Invadopodia are actinbased, lipid raft-enriched membrane protrusions. c01)taining membrane-type-l matrix
'f'~'~/' ~j;'

metalloproteinase (MTI-MMP) and several signaling proteins. CD147 (emmprin;
basigin), an immunoglobulin superfamily protein that is associated with tumor invasion
and metastasis, induces the synthesis of various matrix met,lloproteinases in multiple
systems. In this study we show that up-regulation of CD147 is sufficient to induce MT1MMP expression, invasiveness, and formation of invadopodia-like structures in nontransformed, non-invasive, breast epithelial cells. We also demonstrate that CD147 and
MTI-MMP are in close proximity within these invadopodia-like structures and cofractionate in membrane compartments with the properties of lipid rafts. Moreover,
manipulation of CD 147 levels in invasive breast carcinoma cells causes corresponding
changes in MTI-MMP expression, invasiveness, and invadopodia formation and activity.
These findings indicate that CD147 regulates invadopodia formation and activity, most
likely via assembly ofMTI-MMP-containing complexes within lipid raft domains of the
invadopodia.
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Introduction
Focal penetration through the basement membrane is a defining event in the transition
from a dysplastic carcinoma in situ to an invasive and malignant cancer. Invasive cancers
most likely utilize various mechanisms to breach the surrounding extracellular matrix
(ECM) scaffolds that segregate different tissue compartments (Friedl and Wolf, 2003).
Cellular protrusions directly abutting and penetrating the ECM have been observed in
multiple cancers as invasion progresses (Rowe and Weiss, 2008) and very similar,
ventrally-localized, membrane superstructures called invadopodia are seen when invasive
cells are cultured on 2D substrata (Artym et aI., 2006). A recent study demonstrated a
direct role for invadopodia in promotion of metastasis (Eckert et aI., 2011). Invadopodia
...

;'[

are composed of actin filaments and modulatot~/(jfRctin polymerization, including
cortactin (Artym et aI., 2006; Clark et aI., 2007), and are enriched in kinases, celladhesion molecules, and matrix metalloproteinases (MMPs), notably membrane-type 1
MMP (MTl-MMP), a crucial enzyme for basement membr!ne and interstitial matrix
degradation (Frittoli et aI., 2010; Poincloux et aI., 2009). A coordinated step-wise model
for invadopodia formation has been described, in which cortactin-actin puncta form
initially at sites of matrix attachment, followed by delivery and accumulation of MT 1MMP at the invadopodia-ECM interface (Artym et aI., 2006; Oser et aI., 2009;
Schoumacher et aI., 2010). Importantly, multiple studies have demonstrated that cancer
cells primarily employ MTl-MMP targeted to invadopodia to degrade underlying ECM,
which is orchestrated by a number of diverse proteins that integrate various signals to
induce focalized MTl-MMP localization and matrix degradation (Artym et aI., 2006;
Clark et aI., 2007; Frittoli et aI., 2010; Liu et aI., 2009; Murphy and Courtneidge, 2011).
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Interestingly, a recent study found that MT1-MMP and other major invadopodia
constituents localize in detergent-resistant membrane fractions characteristic of lipid raft
domains (Yamaguchi et aI., 2009). Thus, an emerging model describes invadopodia as
dynamic cellular depots where diverse cell signaling inputs, vesicular trafficking, and
protease activity converge in spatially-defined membrane compartments at the leading
edge of an invasive cancer cell.
Emmprin/basiginlCD 147 is a single pass integral membrane protein, belonging to the
Ig superfamily, that is variably glycosylated across different tissue types. It is usually
expressed at low levels in most normal tissues, but is highly up-regulated during dynamic
cellular events, such as tissue remodeling and cancer progression (Gabison et aI., 2009;
t ......

Nabeshima et aI., 2006; Yan et aI., 2005). EmrpPrJn was originally identified as a cell
surface factor that induces MMP production in stromal cells (Ellis et aI., 1989; Kataoka et
aI., 1993), but later studies revealed that emmprin is identical to basigin-2 (Biswas et aI.,
1995; Liao et aI., 2011), and is multifunctional; it is now widely known as CD147.
CD147 induces several MMPs at both the message and protein level, including MMP-1,
MMP-2, MMP-3, MMP-9, MT1-MMP, and MT2-MMP, though there is variation in the
particular MMPs induced in different systems (Nabeshima et aI., 2006; Yan et aI., 2005).
Furthermore, CD147 has been shown to induce MMPs in tumor cells themselves as well
as in stromal cells (Caudroy et aI., 2002; Sun and Hemler, 2001). CD147 is a
predominant marker in breast cancer micrometastases (Klein et aI., 2002; Reimers et aI.,
2004) and is enriched in malignant pleural effusions and circulating tumor cells
(Davidson et aI., 2004; Pituch-Noworolska et aI., 2007), suggesting a prominent role for
CD 147 in tumor progression. The role of CD 147 in invasion has been demonstrated in
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several model systems, including a study in vivo in which CD 147 -transfected breast
cancer cells injected into mammary fat pads of nude mice were found to be more locally
invasive than control transfected cells and in several animals metastasized to the liver,
spleen, mediastinum, lymph nodes, and mesentery (Zucker et aI., 2001).
In this study we show that up-regulation of CD 147 is sufficient to induce many
features of invadopodia in non-transformed breast epithelial cells and that manipulation
of CD147 levels in invasive breast carcinoma cells causes corresponding changes in the
formation and activity of invadopodia.

Materials and Methods

Cell culture
The human breast adenocarcinoma cell line MDA-MB-231 was obtained from American
1

Type Culture Collection (ATCC) and was cultured in RPMI 1640 (R-8755) with 2.38 gIL
HEPES, 2 gIL sodium bicarbonate, and 10% FBS (pH 7.4). The spontaneously
immortalized human breast epithelial cell line MCF-I0A was obtained from ATCC. The
immortalized human mammary epithelial cell line HMLE was a generous gift from Dr.
Robert Weinberg (MIT, Cambridge, MA). Low passage MCF-I0A and HMLE cells were
maintained in Mammary Epithelial Cell Growth Medium (MEGM) with BulletKit
supplements (Lonza). All cells were cultured in a humidified 95% air/5% CO 2 incubator
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Antibodies and Reagents
The following primary antibodies were obtained for these studies: CD147 (BD
Pharmingen); Alexa Fluor 488-conjugated CD147 (Biolegend); cortactin (clone 4F11)
and MT1-MMPI hinge-region polyclonal (Millipore); MT1-MMP monoclonal
(Epitomics); caveolin-1 (BD Biosciences); rabbit and mouse EEA1 (AbCam); and

~-actin

(Sigma). Alexa Fluor-488 goat anti-mouse, Alexa Fluor-488 goat anti-rabbit, Alexa
Fluor-647 goat anti-rabbit, Alexa Fluor-555 goat anti-mouse, Alexa Fluor-555 goat antirabbit, and Alexa 647-phalloidin were purchased from Invitrogen. Goat anti-mouse HRP
and goat-anti-rabbit HRP (Chemicon) were used as secondary antibodies for
immunoblotting. Western blotting detection reagent (enhanced chemiluminescence) was
purchased from Pierce. Recombinant TIMP . . J,';a~'-TIMP-2 were purchased from
Chemicon and were used at concentrations indicated in the figure legends. A function
blocking antibody targeting the catalytic domain of MT1-MMP (LEM-2/15.8) and the
IgG control antibody were obtained from Millipore.

Recombinant adenovirus infections
Recombinant human CD147 adenovirus and control

~-galactosidase (~-gal)

adenovirus

were constructed and used as described previously (Li et aI., 2001).

RT-PCR
Total RNA was isolated using the RNeasy Mini kit (Qiagen) and quality control and
quantification was performed with the Agilent 2100 Bioanalyzer (Agilent Technologies,
Inc., Santa Clara, CA) and Agilent RNA 6000 Pico LabChip kits. cDNA was synthesized
from equal total RNA using iScript cDNA synthesis kit (Biorad) according to the
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procedures of the manufacturer. The primers designed for targeting the genes included
the following: CD147 sense, 5' GGAATAGGAATCATGGCGGCTGCG 3'; CD147
antisense, 5'GAGCCTCAGGAAGAGTTCCTCTGGC 3'; MTI-MMP sense, 5'
CCATTGGGCATCCAGAAGAGAGC 3'; MTI-MMP antisense, 5'
GGATACCCAATGCCCATTGGCCA 3'; GAPDH sense, 5'
ATGTTCGTCATGGGTGTGAA 3'; GAPDH antisense, 5'
GGTGCTAAGCAGTTGGTGGT 3'. The PCR was performed in a DNA thermal cycler
(Thermo Hybrid PCR Express Thermo Cycler, ) under conditions of 95°C for 2 minutes;
30 cycles each at 95°C for 30 seconds, 59°C for 30 seconds, and 72°C for 60 seconds;
followed by 72°C for 5 minutes.
RNAi

Control non-silencing siRNA and target-specific pooled CD147 siRNAs (#35298) were
purchased from Santa Cruz Biotechnology and used according to manufacturer's
1

protocol. For all experiments, cells were transfected with siRNA 72 hrs before each
experiment.

Matrigei invasion assay
Matrigel invasion inserts (8 J!m pores) for 24-well tissue culture plates were purchased
from BD Biosciences. Briefly, the matrigel inserts (upper and lower chambers) were rehydrated for 2 hrs at 37°C with serum culture medium (MDA-MB-231) or nonsupplemented MEGM (MCF-IOAlHMLE). 4.0xl05 MDA-MB-231 cells treated with
siRNA (72 hrs) or adenoviruses (24 hrs) were detached and seeded in the upper chamber
of the inserts and cultured for 24 hrs at 37°C. 8.0xl04 MCF-IOA or HMLE cells, non54

treated or treated with adenoviruses, were placed in the upper chamber in nonsupplemented MEGM, while medium in the lower chamber was replaced with complete
growth medium containing 20 nM EGF, and cultured for 36 hrs at 37°C. After incubation,
the cells were fixed in 3.7% paraformaldehyde for 15 minutes at room temperature, the
chambers were rinsed with PBS and stained with 0.2% crystal violet for 10 minutes,
followed by extensive washing. After scraping off the cells at the top of the matrigel
membrane with a Q-tip, the cells that passed through the 8

~m

pores in the membrane

were visualized by imaging with a phase contrast microscope (Leica DFC320). Cells
were counted in 4 separate fields for 3 independent experiments.

Gelatin degradation assay for invadopodia
This assay was perfonned as described

previ~~~i~ith minor modifications (Artym et

aI., 2009). Briefly, gelatin was conjugated with 568 Alexa Fluor dye (Molecular Probes)
using the manufacturer's protocol. Glass coverslips (18 mm) were acid washed with 1 M
1

HCI for 12-16 hours and washed extensively with water. 70% Ethanol-sterilized
coverslips were coated with 50

~g/ml

poly-L-Iysine for 20 minutes at room temperature,

washed with PBS, and fixed with ice cold 0.5% glutaraldehyde for 15 minutes followed
by extensive washing. The covers lips were then inverted on an 80

~L

drop of

fluorescent gelatin matrix (0.2% gelatin and Alexa Fluor-gelatin at an 8: 1 ratio) and
incubated for 15 minutes at room temperature. The coverslips were washed with PBS
and the residual reactive groups in the gelatin matrix were quenched with 5 mg/ml
sodium borohydride in PBS for 10 minutes followed by further washing in PBS. The
coated coverslips were placed in 12-well plates, sterilized in 70% ethanol for 10 minutes,
washed in PBS, and equilibrated in serum free medium and switched to serum medium
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30 minutes before the addition of cells. For invadopodia assays, 5.0x104 cells were plated
on the coated coverslips and incubated at 37°C for 5-6 hrs (MDA-MB-231) or 15 hrs
(MCF-IOA). Cells were fixed-permeabilized with 3.7% paraformaldehyde/O.l % Triton
X-100 for 10 minutes, washed with PBS, blocked in 3% BSA in PBS for 1 hour, and
incubated with appropriate primary and secondary antibodies in 3% BSA in PBS. Actin
filaments were visualized with Alexa 647 -phalloidin.

In Situ Proximity Ligation Assay
Interaction of CD 147 and MT 1-MMP was detected in situ using the Duolink II secondary
antibodies and detection kit (Olink Bioscience, Uppsala, Sweden) according to
manufacturer instructions. Briefly, primary antibodies targeting CD147 (BD Pharmingen)
to

and MTl-MMP (Millipore) were applied

:",

'.

,

uSi~g;~;iudard procedures. Oligonucleotide-

conjugated Duolink secondary antibodies were then added, followed by Duolink Ligation
solution. The oligonucleotides ligate together in a closed circle only when the secondary
1

antibodies are in close proximity «40 nm) (Soderberg et aI., 2006). Finally, polymerase
was added, which amplified any existing closed circles, and detection was achieved with
complementary, fluorescently labeled oligonucleotides. Specificity of the reaction was
determined by treating cells with a single primary antibody followed by Duolink
secondary antibodies, which results in no signal amplification due to absence of a second
oligonucleotide needed for ligation and subsequent closed circle amplification.
Microscopy and image analysis
Images were captured with a Leica Total Confocal System SP5 Acoustic Optical Beam
Splitter Confocal (TCS SP5 AOBS) microscope using a 63X/1.4 N.A. oil objective in the
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Josh Spruill Molecular Morphology & Imaging Center in the Department of Regenerative
Medicine and Cell Biology (MUSC, Charleston, SC). Images were acquired at high
confocality (pinhole

= 1 Airy unit) to achieve the thinnest possible optical slices at the

matrix-cell interface. Potential overlaps in emission spectra were eliminated by
sequential scanning and tuning of the AOBS. Differential interference contrast (DIC)
microscopy was performed using the Leica SPS Confocal System. 3-dimensional (3D)
volumetric reconstruction of invadopodia-producing cells was carried out using the 3D
reconstruction software Amira S.2 (Visage Imaging, San Diego, CA). Image processing
and compilation were performed using Canvas Software (Deneba Systems Inc.) and
Adobe Photoshop.
To assess the ability of cells to form

in~dJbdia and degrade matrix, at least 10
"

randomly chosen fields were imaged per trial and evaluated for foci of degraded matrix,
which appear as dark "holes" in the bright fluorescent matrix field. A cell degrading at
1

least one hole under the cell or near the cell edge was counted as a cell able to degrade
matrix. Invadopodia, defined as actin puncta that colocalize with cortactin, were
manually counted and analyzed for underlying matrix degradation and graphed as
number of invadopodia per cell or percentage of cells with invadopodia over degraded
matrix. Quantification of matrix degradation area per cell was analyzed as described
previously (Liu et aI., 2009) and was reported as normalized degradation, which is total
area of degraded matrix relative to the area of the whole cell. Briefly, the area of
degraded matrix in the cell field was measured using ImageJ 1.43s software. Areas of
degraded matrix in the bright fluorescent field were converted to 8 bit grayscale files,
automatically thresholded into black dots on a white background, followed by automatic
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outlining of the dots. The area of each individual cell was measured by manually
outlining the cell boundary using the p-actin channel. Data was collected in an Excel
spreadsheet and was used to calculate degradation area per cell area.

Detergent-resistant membrane fractionation
Detergent-resistant membrane domains (e.g. lipid rafts) were isolated from MCF-I0A
cells as described previously (Thankamony and Knudson, 2006) with minor
modifications. Briefly, cells cultured on gelatin-coated D150 plates were washed with
ice cold PBS 3 times. Cells were lysed in 500

~llysis

buffer (25 mM Tris-HCI, pH 7.5,

150 mM NaCI, 1 mM DTT, 10% sucrose, 1% Triton X-100, and protease inhibitors) on
ice for 30 minutes. The cells were mechanicall y dis~upted by passaging 20 times through
,

a 3-inch 22-guage needle. The lysates were

.-

'J~

~i~:idirect1y with iodixanol stock solution

(60% solution of Optiprep iodixanol) to yield a 40% (v/v) iodixanol-Iysate solution,
which was placed at the bottom of an ultracentrifuge tube. Equal volumes of 35%,30%,
1

25%,20% and 0% Optiprep in lysis buffer without Triton X-IOO were carefully overlaid
above the iodixanol-Iysate solution. The samples were centrifuged at 160,000 x g for 8
hours at 4°C in a SW41-Ti rotor (Beckman Coulter). Equal fractions were carefully
collected from the top of the tube and equivalent aliquots of each fraction were subjected
to immunoblotting using antibodies recognizing proteins of interest.

Immunoblot analysis
Whole cellI ysates were prepared for immunoblotting using a RIP A buffer modified to
contain I mM PMSF, 10

~g/ml

aprotinin and leupeptin, 2 mM sodium orthovanadate,

and 10 mM sodium fluoride. Protein content was determined by BCA assay (Pierce;
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Rockford, IL), and aliquots were solubilized in SDS sample buffer, resolved on Pierce 420% reducing polyacrylamide gels, transferred to nitrocellulose (Osmonics,
Westborough, MA) with a Pierce apparatus, and stained with antibody.

Results

Up .. regulation of CD147 is sufficient for induction of invasiveness in non ..
transformed breast epithelial cells
We first evaluated endogenous CD147 protein levels expressed by non-transformed
MCF-10A cells, a spontaneously immortalized, phenotypically normal, human breast
epithelial cell line, and the resulting expression'~f~D 147 after treatment of these cells
with recombinant CD147 adenovirus or

~-galactosidase (~-gal)

adenovirus (as control).

We found that an MOl of 2 was effective in expressing CD147 protein expression to a
moderate degree (Fig. 2-1A), within the range observed pre~iously in invasive cancer
cells; an Mal of 2 was used for the following experiments. It should be noted, however,
that the --38kDa form of CD147 was increased to a greater extent than the . . . 52kDa form,
as observed previously when using recombinant CD147 adenovirus (Li et aI., 2001). The
38kDa and 52kDa forms of CD147 have been shown previously to differ in their degrees
of glycosylation of the same . . . 27 kDa protein core (Li et aI., 2001; Tang et aI., 2004a)
We then evaluated the effect of increased CD 147 on invasion of reconstituted
basement membrane, Matrigei. We found that the

~-gal-treated

MCF-10A cells were

non-invasive whereas increased CD147 expression induced their ability to invade (Fig. 21B, C). To ensure that this effect was not restricted to MCF-10A cells, we examined the
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effect of increased CD147 on invasiveness in HMLE cells, another immortalized, nontransformed, human breast epithelial cell line; these cells also express low endogenous
levels of CD147 (not shown). In similar fashion to the MCF-IOA cells, up-regulation of
CD 147 induced invasion by these cells as compared with

~-gal

adenovirus treated cells

(Fig. 2-1B, C). These results suggest that up-regulating CD 147 is sufficient to induce an
invasive cellular phenotype in non-transformed breast epithelia.

Up-regulation of CD147 is sufficient for induction of matrix-degrading invadopodialike structures in non-transformed breast epithelial cells
Parental MCF-lOA cells normally do not fo~W~?opodia (Sung et aI., 2009). Thus we
next investigated whether the CD 147-induced increase in invasion is associated with
invadopodia formation and activity. Initially, we found that untreated and control

~-gal

virus-treated cells cultured on thin fluorescent matrices were unable to degrade the
underlying matrix, whereas CD 147-adenovirus-treated cells degraded the matrix
significantly; moreover the areas of degradation appeared as discrete spots in the matrix
(Fig. 2-2A, left panels). To evaluate whether this matrix degradation is due to
invadopodia activity, we probed the cells for cortactin and actin; we observed that only
cells with increased CD 147 demonstrated significant co-localization of cortactin and
actin in a punctate manner (Fig 2-2A), which is indicative of invadopodia formation.
CD147 up-regulation increased the percentage of cells degrading matrix to approximately
40%, compared to less than 5% in the control groups (Fig. 2-2B, left panel); the areas of
matrix degradation corresponded to areas of actin-cortactin co-localization in --30% of
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cells examined (Fig. 2-2C, left panel), indicating induction of active invadopodia by
CD 147 in these cells. We further evaluated the degradation areas and number of
invadopodia present in each of the cell groups and found that CD 147 up-regulation
resulted in a greater area of matrix degradation per total cell area compared to parental
and

~-gal-treated

cells (Fig. 2-2B, right panel). Moreover, whereas the parental and

~-gal-

treated cells had essentially no invadopodia, cells with increased CD147 expression had
an average of -6 invadopodia per cell (Fig. 2-2C, right panel).
In order to visualize the induction of invadopodia more clearly, we compiled a
volumetric 3D-reconstruction of serial confocal images of MCF-l OA cells treated with
CD147 adenovirus, using Amira 3D image software. In Figure 2-3, panel A depicts the
t,

3D environment for a single cell, where the

(",

fl~.r~ent

matrix appears as red, the actin

cytoskeleton is blue, and cortactin is labeled in green. Approximately six invadopodia
are penetrating through to the bottom of the matrix (Fig. 2-3B) and a cross-section
through the cell-matrix interface demonstrates co-Iocalizati6n of actin and cortactin in
these protrusions (Fig. 2-3C); supplementary videos illustrate protrusion of several of
these invadopodia-like structures through the underlying matrix (supplementary material:
Movies 1 and 2).
These observations indicate that CD 147 plays an important role in the induction of
invadopodia formation and activity.
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CD147-induced, invadopodia-mediated, matrix degradation is dependent on
membrane-type MMPs
Although multiple MMPs effectively degrade components of the ECM and mediate
invasiveness in vitro, several studies show that invadopodia utilize membrane type
MMPs, particularly MTI-MMP, to degrade the ECM (Artym et aI., 2006; Frittoli et aI.,
2010; Liu et aI., 2009; Poincloux et aI., 2009; Rowe and Weiss, 2008). Since CD147
induces both soluble and membrane type MMPs in various systems (Nabeshima et aI.,
2006; Yan et aI., 2005), we employed the MMP inhibitors, TIMP-I and TIMP-2, to
distinguish which class of MMP was responsible for CD 147-induced, invadopodiamediated matrix degradation. TIMP-I selectively inhibits the activity of soluble MMPs
whereas TIMP-2 is an inhibitor of both solublt}';a~;membrane-bound MMPs (Hotaryet
aI., 2006). As expected, TIMP-2 inhibited most CD 147-induced matrix degradation
whereas TIMP-I did not (Fig. 2-4A, B). These results show that cells expressing
increased levels of CD147 utilize MT-MMPs to facilitate in\radopodia-mediated matrix
degradation.
Since the major membrane type-MMP associated with invadopodia formation and
activity is MTI-MMP, we next evaluated whether increased CDl47 in MCF-IOA cells
induces MTI-MMP expression. We found that MCF-IOA cells express low amounts of
MTI-MMP, but treatment with CD147 adenovirus increases MTI-MMP as well as
CDl47 protein levels (Fig 2-4C). CD147 induced expression of both the active form (--50
kDa) and pro-form (-63 kDa) of MTI-MMP when the cells were cultured on gelatin
(Fig. 2-4C), the conditions employed for invadopodia formation. However, when the
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CD 147 -upregulated cells were grown on polystyrene, only the

~63

kDa MT 1-MMP pro-

form was detected (data not shown).
To evaluate further whether the invasive phenotype of CD 147 -upregulated cells was
due to MT1-MMP activity, we treated the cells with a function blocking antibody
targeting the catalytic domain of MTI-MMP. We found that the MTI-MMP blocking
antibody significantly decreased both CD 147-induced matrix degradation and Matrigel
invasion compared to cells treated with a control IgG antibody (Figures 2-4D and E).

CD147 associates with MTI-MMP in CD147-induced invadopodia-Iike structures
and in membrane sub-fractions with the propertles' of lipid rafts
'~'"'~i -.~/~'

Since the data above support regulation of MT 1-MMP expression by CD 147, we
investigated whether CD 147 co-localizes with MT 1-MMP and whether co-localization
occurs within the induced invadopodia-like structures. We found that the two proteins
co-localize over a subset of foci of degraded matrix (Fig 2-SA; yellow arrows), but also
co-localize in foci that do not coincide with matrix degradation (Fig 2-SA; red arrows).
Corresponding staining of ~-gal-infected cells showed relatively weak staining for MT1MMP or CD147 (Fig. 2 Supplemental 1). Previous studies have shown that CD147 and
MTI-MMP are present in endocytic compartments, as well as in the plasma membrane
(Eyster et aI., 2009; Jiang et aI., 2001). Thus, we evaluated whether SUb-populations of
CD147 and MT1-MMP were present in a vesicular compartment within MCF-10A cells
over-expressing CD147, and found that distinct sub-populations ofCD147 and MTlMMP are co-localized in EEA1-positive vesicles (Fig. 2-SB). These results, together with
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those in Fig. 2-5A, indicate that sUb-populations of CD147 and MTI-MMP are present in
vesicular compartments distinct from the populations that are localized in invadopodia.
These findings are consistent with FACS analyses (data not shown), which showed that
up-regulation ofCD147 induced . . . 30% increase in cell surface MTI-MMP compared to a
total increase in MTI-MMP expression of . . . 80% (from Western blots), implying that a
significant fraction of induced MT I-MMP remains inside the cells.
Recent studies have shown that invadopodia are highly enriched in lipid raft domains
and are dependent on these raft domains for invadopodia initiation and degradative
activity (Yamaguchi et ai., 2009). Independent studies have shown that CD147 (Schwab
et ai., 2007; Tang and Hemler, 2004) and MTI-MMP (Annabi et aI., 2001; Yamaguchi et
,

.- J

J~

aI., 2009) are at least in part localized in membra¥'compartments similar to lipid rafts.
Thus, we examined whether CD147 influences MTI-MMP localization into lipid rafts.
Using a detergent-based lipid raft isolation protocol we showed that up-regulation of
CD147 in MCF-IOA cells results in an enrichment of both tD147 and MTI-MMP in the
raft fractions (light fraction) compared to

~-gal-treated

cells (Fig. 2-5C). Notably, most of

the CD147 in the raft fractions was the lower molecular weight form of -38kDa. These
results, in conjunction with earlier findings (Yamaguchi et ai., 2009), imply that upregulation of CD 147 leads to enrichment of MT 1-MMP within specialized regions of the
plasma membrane, most likely within invadopodia. However some of these lipid raft
domains might reside in the membranes of intracellular vesicles, as discussed above.
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CD147 regulates invadopodia function in invasive breast cancer cells
Multiple cell models have been used to study invadopodia dynamics, but the majority of
these studies have utilized the invasive human breast cancer cell line MDA-MB-231
(Artym et aI., 2006; Hu et aI., 2011; Liu et aI., 2009; Yamaguchi et aI., 2009). Thus, we
also evaluated whether CD147 regulates invadopodia dynamics in MDA-MB-231 cells.
Figure 2-6A shows the endogenous level ofCD147 expression in MDA-MB-231 cells
and the resulting expression of CD 147 after treatment of these cells with recombinant
CD147 adenovirus or p-gal adenovirus as control. We found that an MOl of 2 was
effective in up-regulating CD147 protein expression to a moderate degree (Fig 2-6A),
within the range observed in various invasive cells; this MOl was used for the following
,.

experiments. As with the MCF-10A cells,

:",

the~3S;rDa

form of CD147 was increased to a

greater extent than the --52kOa form. The MOA-MB-231 cells express MT1-MMP and
invade Matrigel to a moderate level. However, up-regulation of CD147 in these cells was
accompanied by increased MTI-MMP expression (Fig. 2-6B) and increased Matrigel
invasiveness (Fig. 2-60) as compared to controls. Bands corresponding to pro-form and
active form of MTI-MMP were induced. We also treated MOA-MB-231 cells with
pooled target-specific siRNAs. Dose-dependent down-regulation of CD147 was observed
and was accompanied by corresponding partial decreases in MTI-MMP message and
protein levels (Fig. 2-6C), as well as invasiveness in Matrigel (Fig. 2-60).
We next determined whether changes in CD147 expression in MDA-MB-231 cells
led to corresponding changes in invadopodia formation and activity. Cells treated with pgal adenovirus showed a moderate number of invadopodia and degradation spots in the
fluorescent matrix field, in similar numbers to those reported in earlier studies (Artym et
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aI., 2006). However, when cells were treated with CD147 adenovirus there was an
increase in the percentage of cells degrading the matrix, concomitant with an increase in
the percentage of cells with invadopodia (Fig. 2-7 A-C). Up-regulation of CD147 resulted
in an increase in invadopodia number from ,..,4 per cell to ,..,8 per cell (Fig. 2-7C, right
panel), coincident with large increases in degradation area per cell (Fig 2-7B, right
panel). Partial down-regulation of endogenous CD147, using pooled siRNAs (Fig. 26C), resulted in corresponding partial decreases in the percentage of cells degrading
matrix, cells with invadopodia, number of invadopodia per cell, and area of matrix
degradation per cell, whereas cells treated with control siRNA were comparable to

~-gal-

treated cells (Fig 2-7 A-C).
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Co . . localization of CD147 and MTl . . MMP in invasive breast cancer cells
In similar manner to our experiments with CD 147-treated NICF-IOA cells (Fig. 2-5A),
parental MDA-MB-231 cells displayed CD147 and MTI-MMP that co-localized over
foci of degraded matrix (Fig 2-8A; yellow arrow/asterisk) and non-degraded matrix (Fig.
2-8A; red arrow/asterisk). These results were confirmed with a monoclonal antibody
against MTI-MMP from Epitomics Inc. (Fig. 2 Supplemental 2)
To further evaluate the observed co-localization of CD147 and MTI-MMP, we
performed a proximity ligation assay (PLA), which can detect endogenous proteinprotein interactions that occur within 40 nm (Soderberg et aI., 2006). Probing for CD147
and MTI-MMP in MDA-MB-231 cells using the proximity ligation method revealed that
endogenous CD147 and MTI-MMP associate closely (Figure 2-8B). In a control
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experiment using only CDl47 primary antibody followed by secondary PLA probes and
amplification, no interaction was observed; additional field images demonstrated that
CD147-MTl-MMP interactions occur throughout the cell population (Fig. 2
Supplemental 3). Furthermore, we confirmed the specificity of the reaction by
performing DIC microscopy, which demonstrated that the interactions occurred only in
association with cells and did not represent non-specific staining of the culture
substratum (Figure 2-SB, right panels; Fig. 2 Supplemental 3). We found approximately
12-15 CD 147 -MT 1-MMP interactions per cell and, when the proximity ligation method
was combined with the gelatin degradation assay, these CDI47-MTl-MMP interactions
were found over areas of both degraded and non-degraded matrix (Fig. 2-SC), similar to
the results in Fig. 2-SA. These data strongly suppoxt close interactions of sub"

t~~;'

'~~~III'

populations ofCD147 and MTI-MMP in actively degrading invadopodia, as well as in
other areas of the cell such as EEAl-positive vesicles (Fig. 2-5B).

Discussion
Cancer cells employ various strategies to compromise the ECM scaffolds that inhibit
their spreading through different tissue compartments. A major mechanism used by
many cancer cell types to degrade the surrounding ECM is the formation of specialized
actin-enriched membrane protrusions called invadopodia. The proteolytic activity of
invadopodia has been mainly attributed to the localization of MTl-MMP at the cell
surface in specialized membrane domains with the properties of lipid rafts, a process that
is orchestrated by a diverse group of interacting molecules (Frittoli et aI., 2010; Murphy
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and Courtneidge, 20 11; Poincloux et aI., 2009). Here we have made several novel
findings indicating that CD 147 has a major mechanistic role in invadopodia formation
and activity, and consequently in invasion.
CDI47 expression is associated with many malignant phenotypes, including chemoand radio-therapy resistance, aerobic glycolysis, anchorage-independent growth,
angiogenesis, invasion and increased metastatic potential. Among the best characterized
functions of CDI47 is induction of MMPs, including MTI-MMP (Nabeshima et aI.,
2006; Yan et al., 2005). The exact mechanisms by which CD147 induces MMPs is not
known, but current evidence indicates that h~mophilic CD 147 interactions mediate this
induction (Sun and Hemler, 2001; Tang et aI., 2004b) and result in various downstream
signaling events that promote MMP synthesi8'~n~fother activities (Ghatak et aI., 2005;
Lim et aI., 1998; Tang et aI., 2008; Venkatesan et aI., 2010; Yang et aI., 2006). In
agreement with earlier studies, we demonstrated that up-regulation or down-regulation of
CDI47 increases or decreases, respectively, the levels of Mrl-MMP and invasiveness.
In addition, we have demonstrated that modulation of CD147 expression correspondingly
alters invadopodia function.
Most strikingly, we found that up-regulating CD147 expression in non-transformed
breast epithelia was sufficient to induce an invasion program similar to that seen in
already invasive cancer cells, which was characterized by Matrigel invasion and
formation of MT -MMP-dependent, actively degradative invadopodia. This suggests that
up-regulation of CDI47 enriches the cell surface with active pools of MTI-MMP that
subsequently degrade the matrix, as depicted in the gelatin degradation assays (Fig. 22A). Though the mechanisms are not fully understood, earlier reports have demonstrated
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that CD147 interacts with actin (Schlosshauer et aI., 1995) and that manipulation of
CD147 expression results in reorganization of the actin cytoskeleton (Qian et a!., 2008)
and formation of actin-rich lamellipodia in Drosophila cells (Curtin et a!., 2005); whether
these findings are related to the mechanism of invadopodia formation is not known. In
addition to its interactions with the actin cytoskeleton, CD 147 interacts with several other
invadopodia-enriched molecules, such as integrins (Berditchevski et a!., 1997) and CD44
(Slomiany et a!., 2009), that mediate attachment of ECM components to the cell surface
and influence cytoskeleton remodeling. Recent evidence also suggests that CD147 can
up-regulate various transcription factors leading to multiple downstream signaling events
associated with ECM remodeling and invasion (Venkatesan et a!., 2010). Thus, CD147regulated invadopodia formation may be due in tpartto interactions with other ancillary
'f'~~/' ~;;

invadopodia-associated proteins.
Another established function of CD 147 is in lactate transporter trafficking to the cell
surface, where CD 147 is an essential chaperone needed to display sub-classes of lactate
transporters on the cell surface (Halestrap and Meredith, 2004) .. Though it is currently
unknown whether CD147 is also involved in trafficking of MMPs to the cell surface, our
data demonstrate that endogenous CD147 and MT1-MMP are in close proximity and that
sub-populations of this complex occur in actively degrading invadopodia whereas other
sub-populations are present in EEA1-positive endocytic vesicles. These results suggest
the possibility that CD 147 -MT 1-MMP complexes may cycle between these two
compartments. Other investigators have shown that CD147 associates with both the pro
and active forms of MT1-MMP (Egawa et a!., 2006; Niiya et a!., 2009). In addition, we
found that up-regulation of CD147 in non-transformed MCF-IOA epithelial cells results

69

in enrichment of both CD147 and MT1-MMP in membrane compartments with
characteristics similar to lipid raft domains, supporting previous observations that
invadopodia formation and activity are dependent on these domains (Yamaguchi et aI.,
2009). These results are compatible with the idea that CD147 may playa role in
subcellular trafficking or surface presentation of MT 1-MMP. However, further work is
required to determine whether CD147 is involved at multiple steps during initiation and
maturation of invadopodia or whether it aids solely during the degradation process.
Of interest also is our observation that a relatively low-glycosylated form of CD147
was induced by treatment with recombinant CD147 adenovirus and that this form was the
major form targeted to the lipid raft domains (Figure 2-5C). The results of some previous
,.

:",

studies suggest strongly that high levels of gly¢o~fation are necessary for induction of
MMP production (Guo et aI., 1997; Tang and Hemler, 2004), whereas others have
demonstrated robust MMP production after treatment with non-glycosylated CD147
(Belton et aI., 2008) or CD147 substituted only with the diiaccharide, chitobiose
(Kawakami et aI., 2011). Clearly, further investigation is required to elucidate the role of
glycosylation in CD147 activities within different contexts.
Mechanisms of regulation of endogenous CD 147 expression are not well established,
although several growth factors and cytokines have been shown to increase CD 147 levels
in a variety of contexts (Hagemann et aI., 2005; Menashi et aI., 2003; Reddy et aI., 2010;
Rucci et aI., 2010). Previous studies have shown that Src is a critical regulator of
invadopodia formation (Murphy and Courtneidge, 2011), and a recent study showed that
the Src family kinase, Fyn kinase, induces emmprin expression (Ramos and Dang, 2011).
We have also found that CD147 is elevated in cells over-expressing wild-type or
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constitutively active Src (O.D.G, unpublished data), suggesting that Src may act at least
in part via induction of CD 147.
In the present study, we provide evidence that increased CD147 alone is sufficient
to induce the formation of actively degradative invadopodia-like structures in nontransformed epithelial cells and that CD147 may regulate localization of MT1-MMP in
lipid raft domains. Furthermore, we have demonstrated that CD147 and MT1-MMP are
in close proximity to each other and these interacting pools are present in part within
active invadopodia. Since CD 147 is enriched on the surface of numerous malignant
cancer cell types, it represents a plausible molecular target to evaluate for future cancer
therapies, especially with respect to invasion and metastasis.
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Figure 2-1. Up-regulation of CD147 in non-transformed breast epithelial
cells increases invasion. (A) Western blot showing endogenous CD147
protein expression in MCF-lOA cells and increased CD147 expression after
up-regulation with increasing MOl of CD147 adenovirus. An MOl of 2 was
used in all subsequent experiments. (B) MCF-lOA or HMLE cells that were
untreated or infected with

~-gal

or CD147 adenovirus were plated on Matrigel-

coated invasion chambers and analyzed for invasion. (C) Quantitation of
invasion; columns represent means +/- SEM of numbers of cells invaded per
field in 3 independent experiments.

** P < 0.01.
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Figure 2-2. CD147 induces the formation of matrix-degrading invadopodialike structures in non-transformed breast epithelial cells. MCF-I0A cells, noninfected or infected with ~-gal or CD147 adenovirus, were cultured on a
fluorescent gelatin matrix for 15 hours. (A) Representative micrographs of noninfected, ~-gal, and CD147 adenovirus-infected cells cultured on fluorescent
matrix. After fixation, cells were immunolabeled for cortactin (primary 4Fll
antibody followed by secondary Alex Fluor-488 antibody) and Alexa Fluor 647phalloidin. Actin and the gelatin matrix were pseudo-colored to red and blue,
respectively; this allows easier visualization of colocalization (yellow) of actin
(red) and cortactin (green). Invadopodia-mediated matrix degradation appears as
dark black foci in the bright fluorescent matrix field. Boxed insets, higher
magnifications of examples of invadopodia (arrowheads), identified by
colocalization of cortactin and actin punctae over areas of degraded matrix. Scale
bar, 10 ~m. Each experiment was repeated at least three times.
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Figure 2-2 (continued). CD147 induces the formation of matrix-degrading
invadopodia-Iike structures in non-transformed breast epithelial cells. (B-C)
Quantification of invadopodia characteristics: (B) Left panel: Percentage of cells
degrading matrix. Right panel: Normalized degradation, calculated as area of
degradation/total cell area defined by actin channel. (C) Left panel: Percentage of
cells with active invadopodia, defined as cortactin-actin aggregates over degraded
matrix. Right panel: Number of invadopodia/cell. Each parameter was calculated
by evaluating 10 random fields containing at least 15 cells/field over 3 independent
experiments. Columns, mean; Bars, SEM. *** (p-value <0.001).
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Figure 2-3. Three-dimensional volumetric reconstruction of CD147-induced
invadopodia-like structures penetrating the underlying matrix. CD147
adenovirus-infected MCF-IOA cells cultured on a fluorescent-gelatin matrix were
analyzed with confocal microscopy. Leica SP5 confocal softw,are was employed to
obtain an optimal image stack from single cell images and was further processed with
Amira software to reconstruct a 3D volumetric image of a cell producing invadopodialike protrusions that are penetrating the underlying fluorescent matrix. Cells were
stained with Alexa-phalloidin (blue) to image actin filaments and cortactin (green) to
identify invadopodia; fluorescent matrix is depicted in red. A) Overhead view of a
single cell cultured on fluorescent matrix; B) View underneath the fluorescent matrix
showing -6 invadopodia (arrows) penetrating the matrix; C) Magnified cross-section
through cell demonstrating one of the invadopodia-like protrusions (actin and cortactin
positive; arrowhead) penetrating the fluorescent matrix.
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Figure 2-4. CD147-induced, invadopodia-mediated, matrix degradation is
dependent on membrane-type MMPs. (A-B) MCF-10A cells infected with CD147
adenovirus were pre-treated with the protease inhibitors, TIMP-1 (0.5 ~g/ml) and TIMP2 (0.5 ~g/ml) for 30 minutes and then plated on fluorescenr matrices for 12 hours in the
presence of these inhibitors. A) Representative micrographs of matrix degradation in
control and CD147 up-regulated cells in the presence of proteas,e inhibitors. Scale bar,
10 ~m. B) Quantitation of normalized degradation area, expressed as means +/- SEe **
p < 0.01. Experiment was repeated 3 times. C) Western blot of CD147 and MT1-MMP
in aliquots of lysates obtained from MCF-10A cells that were cultured on gelatin and
untreated or treated with control (~-gal) or CD 147 adenovirus. Actin was used as a
loading control; n=3. (D-E) MCF-10A cells infected with CD147 adenovirus were pretreated with function-blocking antibody against MT1-MMP (LEM-2/1S.8; 12 J.lg/ml) or
control IgG and then plated on fluorescent matrices for 12 hours in the presence of the
blocking antibody or IgG. D) Representative micrographs of matrix degradation in
control and CD147 up-regulated cells in the presence of blocking antibody or IgG. Scale
bar, 10 ~m. E) Left panel: Quantitation of normalized degradation area. Right panel:
Quantitation of invasion through Matrigel. Expressed as means +/- SEe **p < 0.01;
***p<O.OOl; experiments were repeated 3 times.
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Figure 2-5. CD147 associates with MTI-MMP in invadopodia-Iike
structures and in membrane sub-fractions with the properties of lipid
rafts. A) Representative micrographs of CD147 and MTI-MMP colocalizing
over degraded matrix in CD 147-overexpressing MCF-I0A cells. Yellow arrows
indicate colocalization of CD147 (green) and MTI-MMP (red) over foci of
degraded matrix; red arrows indicate colocalization of CD147 and MTI-MMP
over areas not showing degraded matrix. Scale bar, 10 ~m. B) Representative
micrographs showing co-localization of CD147 (top panels) or MTI-MMP
(bottom panels) with EEA I-positive vesicles. Yellow arrows indicate colocalization of proteins; green arrows indicate lack of co-localization. Scale, 10
Jlm C) MCF-I0A cells infected with ~-gal or CD147 adenovirus were plated on
gelatin-coated plates overnight and were subjected to detergent-resistant
membrane isolation. Light fraction represents the gradient interface (0-20%)
where detergent-resistant membrane domains such as lipid rafts localize. n=2
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Figure 2-6. CD147 regulates MTI-MMP expression and Matrigel invasion in
invasive breast cancer celIs. (A) Western blot showing endogenous CD147 protein
expression, CD147 expression following treatment with control adenovirus (~-gal),
and CD 147 expression following treatment with increasing amounts of recombinant
CD147 adenovirus in MDA-MB-231 cells; n=2. An MOl of 2 was chosen for upregulating CD 147 in subsequent experiments. ~-actin was used as the loading control.
(B) Representative western blot of increased MTI-MMP levels following CD147 upregulation in MDA-MB-231 cells; n=3. f3-gal treatment was used as the control; 13actin demonstrates equal loading. C) Left panel: Western blot demonstrating that
knockdown of CD 147 with increasing concentrations (3 and 611,1) of pooled targetspecific siRNA results in decreased MTI-MMP protein expression. Non-specific
siRNA was used as a control and ~-actin was used to demonstrate equal loading; n=3.
Right panel: RT-PCR analysis of CD147 and MTI-MMP mRNA after treatment with
control or CD147 siRNAs. D) Left panel: Representative images of Matrigel invasion
assay with MDA-MB-231 cells treated with ~-gal or CD147 adenovirus or with
control or CD 147-specific siRNA. Right panel: Quantification of invaded cells per
field by evaluating four separate fields in 3 independent experiments. Columns
represent means and bars are SEM. * p-value <0.05.
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Figure 2-7. CD147 regulates invadopodia dynamics in invasive breast cancer
cells. (A) Representative micrographs demonstrating MDA-MB-231 cells treated
with ~-gal or CD147 adenovirus or with control or CD 147-targeted siRNA. Cells
were cultured on Alexa Fluor 568-conjugated gelatin for 5 hours, fixed, and
probed for actin (Alexa 647 phalloidin) and cortactin (primary 4Fl1 antibody
followed by secondary Alex Fluor-488 antibody). Actin and the gelatin matrix
were pseudo-colored to red and blue, respectively; this allows for easier
visualization of colocalization (yellow) of actin (red) and cortactin (green). The
left panels demonstrate invadopodia-mediated matrix degradation (dark holes).
Boxed insets, higher magnifications of invadopodia. Bars, 10 ~m. n=3.
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Figure 2-7 (continued). CD147 regulates invadopodia dynamics in invasive breast
cancer cells. (B-C) Quantification of invadopodia characteristics for MDA-MB-231
cells: (B) Left panel: Percentage of cells degrading matrix; calculated as cells with at
least one area of degradation underneath the cell or near cell border. Right panel:
Normalized degradation, calculated as area of degradation/total cell area defined by
actin channel. (C) Left panel: Percentage of cells with invadopodia, defined as actincortactin aggregates localized over degraded matrix. Right panel: Number of
invadopodia/cell in cells exhibiting at least one invadopodium. Each parameter was
calculated by evaluating 10 random fields containing at least 20 cells/field over 3
independent experiments. Columns, mean; Bars, SEM. * (p-value <0.05), ** (p-value
<0.01).
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Figure 2-8. Co-localization of CD147 and MTI-MMP iQ. invasive breast cancer cells.
(A) Representative image demonstrating CD147 and MTI-MMP co-localization in
MDA-MB-231 cells. Cells were cultured on Alexa Fluor 568-conjugated gelatin for 5
hours and probed with CD147-488 and MTI-MMP followed by an Alexa Fluor-647
secondary antibody. Polyclonal antibody against MTI-MMP (Millipore) was used for
these images; monoclonal antibody against MTI-MMP (Epitomics) gave similar results
(Supplemental Figure 2). MTI-MMP and the gelatin matrix were pseudo-colored to red
and blue, respectively; this allows easier visualization of colocalization (yellow) of
CD147 (green) and MTI-MMP (red). Yellow arrow depicts CD147-MTI-MMP colocalization over foci of degraded matrix; red arrow indicates colocalization of CD147
and MTI-MMP over an area not showing degraded matrix. XZ section: Yellow asterisk,
CD147-MTI-MMP over a region of degraded matrix; red asterisk, CD147-MTI-MMP
over an area not showing matrix degradation. n=3. (B-C) A proximity ligation assay
(PLA) was employed to detect close protein-protein interactions «40nm) of CD147 and
MTI-MMP in MDA-MB-231 cells (see Materials and Methods for details). B) Left
panel: interactions of CD147 and MTI-MMP (small green dots at arrowheads); cells
were also stained with DAPI (blue). Right panel: DIC images of a single cell; arrowheads
indicate sites of CD147-MTI-MMP interactions, which are restricted to areas over the
cell. C) PLA combined with gelatin degradation assay, showing that CD147- MTI-MMP
interactions occurred over areas of degradation (arrowheads), as well as over areas
lacking degradation. Bars, 10 ~m.
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Figure 2. Supplementall. CDl47 and MTl-MMP expression in MCF-lOA
cells treated with p-gal adenovirus. MCF-IOA cells were treated with ~-gal
adenovirus, fixed and stained for CD147 and MTI-MMP. Images demonstrated
that staining is relatively weak for both proteins.
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Figure 2. Supplemental 2. CD147 and MTI-MMP co-localize in MDAMB-231 cells (alternative MTI-MMP antibody). Representative micrograph
depicting MDA-MB-231 cells probed with CD147-488 conjugated antibody
(Biolegend) and a monoclonal MTI-MMP antibody (Epitomics) followed by an
Alexa Fluor-647 secondary antibody.
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Figure 2. Supplemental 3. Proximity ligation assay demonstrates that
endogenous CD147 and MTI-MMP are in close proximity in MDA-MB-231
cells. A) Cells were probed with CD147 (BD Pharmingen) and MT1-MMP
(Millipore) primary antibodies using standard labeling ~ethods. They were then
probed with Duolink II secondary antibodies and detectIon kit reagents
according manufacturers protocol. Protein-protein interactions appear as green
dots. Red arrows depict examples of CD 147 -MT 1-MMP interactions
throughout the cell population. B) Using similar techniques as stated in A), DIC
microscopy demonstrates that CD 147-MT1-MMP interactions are specific to
cells and do not represent non-specific staining. Red arrows depict multiple
interactions throughout the cell population. C) Control PLA experiment
demonstrating specificity of Duolink reaction. Cells were initially probed with
only CD147 (BD Pharmingen) primary antibody. This was then followed by
reagents of the Duolink II kit. No signal (e.g. protein-protein interaction) was
detected due to the lack of rolling circle amplification, which is dependent on
the 2 primary antibodies localizing in close proximity.
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Chapter 3: CD147 and the Ras-ERK signaling pathway co-regulate breast
epithelial cell invasiveness

Abstract
Breast cancer is a heterogeneous disease, and similar to other cancers, metastases
to distant vital organs is the main cause of mortality. It has become evident that invasive
breast cancer cells employ various mechanisms to spread from their tissue of origin. One
of the main mechanisms utilized is the formation of actin-rich membrane protrusions
called invadopodia. Invadopodia are enriched:<vtth various signaling proteins, adhesion
molecules and proteolytic enzymes and are thought to be a major superstructure at the
leading edge of an invasive cell.
The IgSF protein, CD 147 is associated with an invasive phenotype in various
cancer types, including malignant breast cancer. CD 147 was first identified as a major
matrix metalloproteinase (MMP) inducer localized to the tumor cell surface. It has
become clear, in addition to stimulation of soluble and membrane-type MMP synthesis,
that CD 147 has pleiotropic functions in various aspects of cancer progression, including
cytoskeleton remodeling. Recent evidence suggested that up-regulation of CD147 alone
in non-transformed and non-invasive breast epithelial cells induced an invasive
phenotype characterized by MT1-MMP (MMP-14)-dependent invadopodia activity.
Earlier evidence suggests that CD 147 cooperates with various binding partners, including
CD44 the main hyaluronan (HA) receptor, to promote a tumorigenic phenotype.
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In this study we found that up-regulation of CD147 activates an EGFR-Ras-ERK
signaling cascade that mediates invasiveness, and that these effects are partially
dependent on HA-CD44 interactions. We also discovered that oncogenic Ras regulates
CD147 expression and may elicit a positive feedback loop involving ERK signaling. We
further found that enrichment of cells with differential CD 147 surface levels afforded us
the ability to isolate sub-populations of breast cancer cells with distinct phenotypes.

Introduction
CD147 (emmprin; basigin) is a highly and variably glycosylated transmembrane protein
that is involved in both physiological and patholqgl¢al cellular processes (Nabeshima et
·'·"·~/·{f·

aI., 2006; Yan et aI., 2005; Yurchenko et aI., 2010). CD147 expression is elevated in a
wide range of cancer types, including breast cancer (Li et aI., 2009; Riethdorf et aI.,
2006). Earlier studies employing in situ hybridization and \mmunohistochemistry
techniques found that CD147 was expressed at pre-invasive and invasive areas, as well as
proliferative regions in breast lesions; though CD 147 was identified in normal breast
tissue, it was expressed at much lower levels (Caudroy et aI., 1999; Polette et aI., 1997).
CD147 expression gradually increases during progression from atypical ductal
hyperplasia to invasive breast cancer and is correlated with hormone receptor negative
and Erbb2 over-expressing breast cancers (Liu et aI., 2010). Originally identified as a
tumor-associated factor that induces stromal fibroblasts to synthesize and secrete matrix
metalloproteinases (MMPs) (Biswas, 1984; Biswas et aI., 1995; Ellis et aI., 1989; Guo et
aI., 1997), CD147 has since been shown to have pleiotropic functions. In addition to
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inducing MMP synthesis in stromal, tumor, and endothelial cells, CD 147 contributes to
therapy-resistance, angiogenesis, inflammatory signaling, cytoskeletal remodeling, and
migration/invasion programs (Weidle et aI., 2010). CD147 also participates in regulating
the synthesis of the large extracellular polysaccharide, hyaluronan (HA), the main ligand
for the cell surface receptor CD44 (Edward et aI., 2011; Ghatak et aI., 2005; Kato et aI.,
2011; Marieb et aI., 2004; Qin et aI., 2011). CD 147-induced HA-CD44 interactions
modulate various signaling pathways and potentiate tumorigenic properties in various cell
types (Toole and Slomiany, 2008). CD147 also cooperates with cyclophilins to induce
intracellular signaling pathways (Yurchenko et aI., 2010), and with MCTs to influence
tumor cell metabolism (Kennedy and Dewhirst, 2010), although in each case the exact
mechanisms by which CD147 activates signaling cascades are not fully understood.
'"·~·~/.~jr

Dysregulated expression of Ras genes has been identified in many cancer types
(Karnoub and Weinberg, 2008) and oncogenic Ras expression is associated with
aggressive cancer phenotypes, such as proliferation, invasidnlmetastasis and therapy
resistance (Pylayeva-Gupta et aI., 2011). Though the common point mutations identified
in oncogenic forms of Ras are a very rare occurrence in breast cancer, chronic Ras
activity has been documented in breast cancer cell lines and patient tumor tissue in the
absence of Ras mutations (Eckert et aI., 2004; Lintig et aI., 2000; Rochlitz et aI., 1989).
In the absence of oncogenic Ras signaling, up-regulation of normal Ras activity can
facilitate similar transformed phenotypes (Zhang et aI., 2009). Aberrant Ras signaling
may be due to amplified expression and activation of cell surface receptor tyrosine
kinases (RTKs), such as epidermal growth factor receptor (EGFR) family members,
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mutations in modulators of the Ras activation state or effectors downstream of Ras
(Campbell and Der, 2004; Stamatakos et aI., 2010).
In this study we have identified novel signaling associations between CD 147,
HA-CD44 interactions, and EGFR, Ras and ERK signaling that regulate the invasive
properties of breast epithelial cells.

Materials and Methods

Cell Culture
The human breast adenocarcinoma cell lines MQA~,MB-231 and MCF-7 were obtained
",.,'", jj"
from American Type Culture Collection (ATCC}/and were cultured in RPMI 1640 (R8755) with 2.38 gIL HEPES, 2 gIL sodium bicarbonate, and 10% FBS (pH 7.4). The
spontaneously immortalized human breast epithelial cell line MCF-10A was obtained
l

from ATCC. MCF-IOA cells stably expressing a lentivirus construct containing KRas V12 (lOA-K-Ras V12) or empty vector (10A-EV) were generously provided by Dr. Ben
Ho Park (Konishi et aI., 2007). Low passage MCF-IOA cells and MCF-IOA derivatives
were maintained in Mammary Epithelial Cell Growth Medium (MEGM) with BulletKit
supplements (Lonza) unless noted otherwise in legends. All cells were cultured in a
humidified 95% air/5% CO 2 incubator at 37°C.

Antibodies and Reagents
The following primary antibodies were employed for these studies: CD 147,
CD 147-FITC, IgG-FITC and caveolin-l (BD Biosciences); Alexa-Fluor 647-conjugated
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CD147, Alexa-Fluor 488-conjugated CD147 and PE-conjugated EGFR (Biolegend);
cortactin (clone 4Fll) and MTI-MMPI hinge-region polyclonal (Millipore); phosphoERK1/2 (Thr202/Tyr204), pan-ERKI/2, phospho-EGFR (TyrI173), phospho-EGFR

(Tyrl068), and EGFR (Cell Signaling Technology, Inc); CD44IHCAM (mouse) and
Alexa-Fluor 647-conjugated CD44 (Santa Cruz Biotechnology, Santa Cruz, CA); PEconjugated CD44 (Cedarlane Laboratories); CD44 (rabbit) (Epitomics);

~-actin

and

~-

tubulin (Sigma). Goat anti-mouse-HRP and Goat anti-rabbit-HRP (Chemicon) were used
as secondary antibodies for immunoblotting. The inhibitors Tyrphostin (Calbiochem),
U0126 and PD98059 (Cell Signaling Technology, Inc) were used at concentrations
indicated in figure legends.
.

Recombinant adenovirus infections

"",

"'~'~" ~;..

Recombinant human CD 147 adenovirus and control

~-galactosidase (~-gal)

adenovirus

were constructed and used as described previously (Grass et aI., 2012; Li et aI., 2001).
\

Surface Biotinyiation '
Cell surface biotinylation was performed using a Cell Surface Protein Isolation Kit
according to manufacturer's protocol (Pierce). Briefly, cells were treated with EZ-Link
Sulfo-NHS-SS-Biotin for 45 minutes at 4°C, followed by quenching and harvesting of
celllysates. Equivalent amounts of protein from each experimental group was added to
spin columns containing NeutrA vidin resin, incubated for several hours with rocking at
4°C, washed, eluted and followed by immunoblotting.
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Ras Activity Assay
Ras activation status was evaluated by employing the Active Ras Pull-Down and
Detection Kit according to manufacturer's protocol (Pierce). This assay is based on the
observation that Ras-GTP (active), but not Ras-GDP (inactive), binds Raf-l with high
affinity. Briefly, fresh lysates from MCF-10A cells non-treated or treated with
adenovirus were collected using standard procedures. GTPyS (0.1 mM) or GDP (1 mM)
was added to controllysates for a positive and negative control, respectively. GST -Raf1Ras-binding domain (GST-Raf1-RBD) fusion protein was added to the spin column
containing a glutathione resin, followed by addition of 400-500
positive/negative controls and

~-gal

~g

of protein from

or CD147 treated cells. Lysates were incubated for 1

hour at 4°C with rocking, followed by elutiofi~d;ilbsequent immunoblotting with a
pan-Ras antibody.

Hyaluronan ELISA
Hyaluronan concentrations in the media were determined using an enzyme-linked
immunosorbent-like assay described previously (Gordon et aI., 2003).

Preparation of Hyaluronan Oligosaccharides
Hyaluronan oligosaccharides (oHAs) were prepared as described previously (Zeng et aI.,
1998). Briefly, oHAs used in this study were derived from degradation products of
hyaluronan purified from rooster combs (Sigma). Hyaluronan was dissolved in sodium
acetate buffer at a pH of 5.0 and treated with testicular hyaluronidase (Type I-S, Sigma)
overnight. The digest was precipitated with TCA on ice, dialyzed for 48 hours using a
1000 dalton molecular weight cutoff (MWCO) and fractionated with 5000 MWCO spin90

dialysis tubes. Fractions mainly composed of 6-12 oligosaccharide units were further
concentrated with lyophilization and concentration was determined using a Carbazole
assay, which detects uronic acid. Oligomer size was assessed with the Morgan-Elson
assay by determining the ratio between N-acetyl-D glucosamine D-glucuronic acid.
Matrigel invasion assay

Matrigel invasion inserts

(8~m

pores) for 24-well tissue culture plates were purchased

from BD Biosciences. Briefly, the Matrigel inserts (upper and lower chambers) were
rehydrated for 2 hours at 37°C with non-supplemented MEGM. 7.0x10 5 MCF-I0A-EV
and MCF-I0A K-Ras V12 or MCFI0A-K-Ras V12 cells treated with siRNA (72 hours) or

.

MEK inhibitors were detached and seeded in the upper chamber of the inserts and
.. J"' I-;jr
cultured for 24 hours at 37°C in non-supplemented MEGM, and medium in the lower
",

chamber was replaced with MEGM containing 20 nM EGF. After incubation, the cells
were fixed in 3.7% paraformaldehyde for 15 minutes at room temperature, rinsed with
1

PBS and stained with 0.2% Crystal Violet for 10 minutes, followed by extensive
washing. Cells were scraped from the top of the Matrigl membrane with a Q-tip and the
cells that invaded through the

8~m

pores in the membrane were imaged using a phase-

contrast microscope (Leica DFC320). Cells were counted in four separate fields in three
independent experiments.
Gelatin degradation assay for invadopodia

This assay was performed as described previously (Grass et aI., 2012). Briefly, gelatin
was conjugated with Alexa-Fluor-568 dye (Molecular Probes) using the manufacturer's
protocol. 18 mm round glass coverslips were acid washed with 1 M HCI overnight
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followed by extensive washing in water. Coverslips were sterilized with 70% ethanol
and then coated with 50

~g/ml

poly-L-lysine for 20 minutes at room temperature, washed

with PBS, and fixed with ice-cold 0.5% glutaraldehyde for 15 minutes followed by
extensive washing. The coverslips were then inverted on an 80

~l

drop of fluorescent

gelatin matrix (0.2% gelatin and Alexa-Fluor-gelatin at an 8: 1 ratio) and incubated for 15
minutes at room temperature. The coverslips were washed with PBS and quenched in 5
mg/ml sodium borohydride in PBS for 10 minutes, followed by further washing in PBS.
The coated coverslips were then placed in 12-well plates, sterilized in 70% ethanol for 10
minutes, washed in PBS and equilibrated in serum-free MEGM and switched to fully
supplemented MEGM 30 minutes before the addition of cells. For invadopodia assays,
5.5

X

104 cells were plated on the coated coverslip&.'"and incubated at 37°C for 15-18

"., . ;. ./1,'-

~

,

hours. Cells were fixed and permeabilized with 3.7% paraformaldehyde and 0.1 % Triton
X-I00 for 10 minutes, washed with PBS, blocked in 3% BSA in PBS for 1 hour, and
incubated with appropriate primary and secondary antibodifs in 3% BSA in PBS. Actin
filaments were visualized with Alexa-Fluor-647-phalloidin.

In situ proximity ligation assay
Protein-protein interactions were detected in situ, as described previously (Grass et aI.,
2012), using Duolink II secondary antibodies and detection kit (Olink Bioscience,
Uppsala, Sweden) according to manufacturer's instructions. Briefly, primary antibodies
targeting CD147 (mouse; BD Pharmingen), EGFR (rabbit; Cell Signaling), CD44
(mouse; Santa Cruz Biotechnology), CD44 (rabbit; Epitomics) were applied using
standard procedures. Oligonucleotide-conjugated Duolink secondary antibodies were
then added, followed by Duolink ligation solution. The oligonucleotides ligate together
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in a closed circle only when the secondary antibodies are in close proximity «40 nm)
(Soderberg et aI., 2006). Polymerase was added, which amplified any existing closed
circles, and detection was achieved with complementary, fluorescently labeled
oligonucleotides. Specificity of the reaction was determined by treating cells with a
single primary antibody followed by Duolink secondary antibodies, which results in
minimal to no signal amplification because of the absence of a second oligonucleotide
needed for ligation and subsequent closed circle amplification.

Microscopy and image analysis
Images were acquired with a Leica Total Confocal System SP5 acoustic optical beam
splitter confocal (TCS SP5 AOBS) microscope using
r

;",

~

63x, 1.4 NA oil objective at the

./ ."",,1-;';,"
Josh Spruill Molecular Morphology & Imaging Center in the Department of Regenerative
Medicine and Cell Biology (MUSC, Charleston, SC). Images were captured at high
confocality (pinhole =1 Airy unit) to achieve the thinnest possible optical slices at the
1

cell-matrix interface. Potential overlaps in emission spectra were eliminated by
sequential scanning and tuning of the AOBS. Differential interference contrast (DIC)
microscopy was performed using the Leica SP5 Confocal System.
Assessment of invadopodia characteristics was performed as described previously (Grass
et ai., 2012). Briefly, at least 10 randomly chosen fields were imaged per experiment and
evaluated for degraded matrix foci, which appear dark 'holes' in the fluorescent matrix
field. A cell with at least one degradation foci underneath or near the cell edge was
counted as a cell able to degrade matrix. Invadopodia, defined as actin puncta that
colocalize with cortactin, were manually counted and analyzed for underlying matrix
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degradation. Results were presented as percentage of cells degrading the matrix, number
of invadopodia per cell or percentage of cells displaying cortactin-actin aggregates with
or without degradation underneath.
qRT.PCR

For qRT-PCR experiments, total RNA was isolated using the RNeasy Mini kit according
to the manufacturer's instructions (QIAGEN, Valencia, CA) and quality control and
quantification was performed with the Agilent 2100 Bioanalyzer (Agilent Technologies,
Inc., Santa Clara, CA) and Agilent RNA 6000 Pico LabChip kits. Complementary DNA
(cDNA) was synthesized from equivalent concentrations of total RNA using the iScript
cDNA Synthesis Kit (Bio-Rad) according to

manufa~turer's
..

instructions. Coding

.'J"

d~'.J ~;--

sequences for CD147 and fJ-actin (internal controf) were amplified from synthesized
cDNA using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA). Custom primer
sequences used for amplification were as follows: CD147 sense 5''1

CAGAGTGAAGGCTGTGAAGTCG -3'; CD147 antisense 5'-TGCGAGGAACTCACGAAGAA3'; fJ-actin sense 5'-GGAAATCGTGCGTGACATT -3'; fJ-actin antisense 5'-

GACTCGTCATACTCCTGCTTG -3'. Amplification was performed using an iCycler IQ

Real-Time PCR Detection System and cycle threshold (Ct) values were determined in
duplicate for CD147 and fJ-actin transcripts for each experiment. 'No template' (water)
and 'no-RT' controls were used to ensure minimal background signal from DNA
contamination. Using mean Ct values tabulated for different experiments and Ct values
for fi-actin as loading controls, fold changes for experimental groups relative to assigned
controls were calculated using automated iQ5 2.0 software (Bio-Rad).
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RNA interference
Control non-silencing siRNA and target-specific pooled siRNAs for CD147 and CD44
were purchased from Santa Cruz Biotechnology and used according to manufacturer's
protocol. For all experiments, cells were transfected with siRNA 72 hours before each
experiment.

Detergent-resistant membrane fractionation
Detergent-resistant membrane domains (e.g. lipid rafts) were isolated as described
previously (Grass et aI., 2012). Briefly, cells cultured in D150 plates were washed with
ice-cold PBS three times. Cells were lysed in

500~L

lysis buffer (25 mM Tris-HCI, pH

7.5, 150 mM NaCI, 1mM dithiothreitol, 10% sucro'$,c,' 1% Triton X-100 and protease
d

~~'1'

inhibitors) on ice for 30 minutes. The cells were scraped and mechanically disrupted by
passaging 20 times through a 3-inch 22-guage needle. The lysates were mixed directly
with iodixanol stock solution (60% solution of Optiprep iodixanol) to yield a 40% (v/v)
iodixanol-Iysate solution, which was placed at the bottom of an ultracentrifuge tube.
Equal volumes of 35%, 30%, 25%, 20% and 0% Optiprep in lysis buffer without Triton
X-100 were carefully overlaid above the iodixanol-Iysate solution. The samples were
centrifuged at 160,000 x g for 8 hours at 4°C in a SW41-Ti rotor (Beckman Coulter).
Equal fractions were collected from the top of the tube and equivalent aliquots of each
fraction were subjected to immunoblotting using antibodies recognizing proteins of
interest.
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Labeling of live cells with Cholera toxin-B (Ctx-B) to identify lipid rafts
Lipid raft labeling was performed using the Vybrant Alexa-Fluor-488 Lipid Raft labeling
kit using the manufacturer's protocol (Invitrogen Molecular Probes). Briefly, live cells
were washed with ice cold PBS, labeled with Alexa-Fluor-488-conjugated Ctx-B, crosslinked with anti-CtxB antibody, followed by standard immunofluorescence staining and
mounting techniques.
Cell surface analysis and fluorescent activated cell sorting of CD147 Lo and CD147 Hi
Sub-populations
For cell surface analysis, 2.0x 105 cells were trypsinized to achieve single cell
suspensions, counted and blocked with 3% BSA' in/PBS, and incubated with primary'/"'~/' .~J'

conjugated antibodies for 30 minutes on ice. Unbound antibody as removed in
subsequent washes and cells were analyzed no longer than 1 hour post-staining. Cell
sorting of CD147 Lo and CD147 Hi sub-populations was achiQved in the following manner:
cells (10A-K-Ras V12, MDA-MB-231, and MCF-7) were trypsinized into single cell
suspensions, counted, blocked with 3% BSA in PBS, and treated with antibodies in
culture medium. Cells were incubated with anti-CDI47-FITC or IgG-FITC (negative
control) for 30 minutes on ice. Unbound antibody was washed off and cells were
resuspended in fresh media with DNase (Promega), filtered and sorted. Cells expressing
the lowest surface levels of CD 147 (bottom 20%) and the highest surface levels of
CD147 (top 20%) were selected as CD147 Lo and CD147 Hi SUb-populations, respectively.
For subsequent invadopodia or immunoblotting analyses, cells were directly seeded on
gelatin or lysed post-sort, respectively. All FACS analysis and cell sorting was
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performed with a Beckman Coulter MoFlo Astrios instrument in the Department of
Regenerative Medicine and Cell Biology Flow Cytometry Facility (MUSC, Charleston,
SC).
Immunoblotting
Whole celllysates were prepared for immunoblotting using a RIP A buffer modified to
contain ImM PMSF, 10

~g/ml

aprotinin and leupeptin, 2 mM sodium orthovanadate and

10 mM sodium fluoride. Protein content was quantified using a BCA assay (Pierce),
aliquots were solubilized in reducing sample buffer, resolved on Pierce 4-20%
polyacrylamide gels, transferred to nitrocellulose (Osmonics, Westborough, MA) with a
Pierce apparatus, and stained with antibody. Densit9metric
analysis of western blots was
..
"",

'

'~'/'I' ~;.

performed using Image J software (version 1.43s)'.

Results
Up-regulation of CD147 induces activation of EGFR-Ras-ERK signaling
In a recent study we showed that up-regulation of CD 147 is sufficient to induce invasion
and formation of active invadopodia in the non-transformed human breast epithelial line,
MCF-I0A (Grass et aI., 2012). Here we have investigated the signaling pathways that
might be involved in mediating the effects ofCD147 on these processes. As shown in
our previous study, an MOl of 2 of our CD147 adenovirus construct gives rise to levels
of CD147 in MCF-10A cells that are commonly found in aggressive human breast cancer
cells. In addition, we have now shown that the level of CD147 at the surface of MCF-
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lOA cells, resulting from treatment with an equivalent MOl of virus, is similar to that
expressed on the surface of the malignant breast carcinoma cell line, MDA-MB-231, but
as shown previously the adenovirus induces mainly the less glycosylated form of CD147
found endogenously in cancer cells (Fig. 3-1A). As in our previous study, we used cells
infected with a p-galactosidase (p-gal) adenovirus construct as a control; this adenovirus
did not cause significant changes in CD 147 expression.
Prior evidence suggests that CD147 can activate ERK signaling (Cui et aI., 2012;
Marieb et aI., 2004; Misra et ai., 2003; Tang et ai., 2006), though the upstream regulators
of this pathway have not been fully characterized. First we evaluated the effect of
increased CD147 on the activation status of Ras in MCF-I0A cells, as Ras is frequently
t.

,.J.,'

.

upstream of ERK activation (Bodart, 2010). W~~t1nd that up-regUlation of CD147 led
to increased Ras activation, measured as an increased proportion of Ras-bound GTP, as
well as a concomitant increase in phosphorylated ERK (Figure 3-1B). Next we
investigated EGFR signaling since it is often dysregulated ih breast cancer and is
commonly upstream of Ras and ERK (Eccles, 2011). We found that subsequent
treatment of CD 147 -upregulated MCF-1 OA cells with increasing concentrations of the
specific EGFR kinase inhibitor, AG 1478, resulted in attenuated p-ERK (Fig. 3-1C),
suggesting that CD147 may be involved in EGFR activation. Since phosphorylation of
tyrosine 1173 or 1068 on the cytoplasmic tail of EGFR has been associated with
regulation of Ras-MAPK signaling (Rojas et aI., 1996; Sakaguchi et aI., 1998), we
determined whether one or both of these tyrosine residues is activated in response to
increased CD 147 expression. We found that there was no difference in phosphorylation
of the Tyr 1173 residue, but increased CD 147 led to increased phosphorylation of the Tyr
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1068 residue. This Tyr 1068 phosphorylation occurred whether or not EGF was present
in the medium (Fig. 3-10).

Hyaluronan-CD44 interaction mediates CD147-induced activation ofEGFR
signaling.
Previously we demonstrated that C0147 stimulates the synthesis of HA in breast
carcinoma cells (Marieb et aI., 2004). Here we found that up-regulation of CO 147 in nontransformed, MCF-I0A breast epithelial cells also leads to ,..,2-fold increase in HA
production compared to control cells (Fig. 3-2A). Several studies have demonstrated that
either endogenous or exogenous HA can elicit the activation of multiple signaling
pathways, including those involving RTKs such, as pGFR and downstream effectors such
'-",

'f''''.J'~''

as Ras and ERK (Toole, 2009), which are frequently dysregulated in breast cancer.
Consequently we determined whether the effects of C0147 on activation of EGFR and
ERK were dependent on HA-receptor interactions. We first employed treatment with
1

oligosaccharides of HA (oHA) that are 6-18 residues in length, which compete with
multivalent, HA-receptor interactions, replacing them with monovalent, oHA-receptor
interactions (Lesley et aI., 2000; Underhill and Toole, 1979) and thus attenuating
endogenous HA-receptor signaling (Ghatak et aI., 2002; Ghatak et aI., 2005). We found
that treatment of CO 147 -upregulated MCF-l OA cells with oHA resulted in attenuated
phosphorylation of EGFR-Tyr 1068 and ERK (Fig. 3-2B). Interestingly, the levels of pERK reached near baseline activation levels before Tyr 1068 phosphorylation returned to
baseline. To determine whether this perturbation of HA-receptor signaling may be
dependent on C044, the main HA receptor in breast cancer cells, we determined the
effects of pooled siRNA-mediated knockdown of C044 in CDl47-upregulated MCF99

lOA cells. This treatment resulted in a partial decrease in p-Tyr l068 and p-ERK levels,
whereas no significant difference was seen in membrane type-l MMP (MTI-MMP;
MMP-14) protein levels (Fig. 3-2C); this suggests that CD 147-induced activation of the
EGFR-ERK pathway was at least partially mediated by HA-CD44 interactions and that
CD 147-induced MTI-MMP expression may be separate from this pathway.
CD44 has been shown to interact with EGFR family members in aHA-dependent
manner (Bourguignon et aI., 2006; Ghatak et aI., 2005; Wang and Bourguignon, 2006)
and our above data suggests that up-regulation of CD147 results in increased HA-CD44mediated activation ofEGFR. To evaluate whether up-regulation of CD147 increases
EGFR-CD44, CD147-CD44, or CD147-EGFR interactions, we employed a proximity
ligation assay technique that detects associations ¢'proteins occurring within 40 nm of
each other (Soderberg et aI., 2006). We found that there were significant differences
between CD 147-upregulated and control MCF-IOA cells in regards to the percentage of
1

the cell population demonstrating close protein-protein associations of EGFR with CD44,
CD147 with CD44 and CD147 with EGFR (Fig. 3-2D, E). We and others have
demonstrated that CD147, CD44, and EGFR partially localize in membrane fractions
with properties of lipid rafts in malignant cancer cells (Ghatak et aI., 2005; Grass et aI.,
2012; Irwin et aI., 2010; Tang and Hemler, 2004; Toole, 2009). To determine whether
this also occurs in MCF-I0A cells with up-regulated CD147, we showed that CD147
colocalizes with cholera toxin-B (CtxB), a lipid raft marker, at the leading edge of cells
and appears to arrange in a single-file fashion along CtxB-enriched filopodial projections
(Fig. 3-3A). We also found that CD147, CD44 and EGFR are enriched in caveolin-rich
raft domains after up-regulation of CD147, as compared to the control cells (Fig. 3-3B).
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To evaluate whether enrichment in lipid rafts may be due to increased trafficking of
CD44 and EGFR to the cell surface in cells with up-regulated CD147, we utilized FACS
analysis to evaluate surface expression levels. We found that the MCF-lOA cells with
up-regulated CD147 demonstrated no significant differences in levels of CD44 or EGFR
at the cell surface (Fig. 3-3C), suggesting that the major effect is on organization of these
proteins into raft-like complexes.

Activated Ras and ERK regulate hyaluronan, CD147 and MTI-MMP expression,
and invasiveness
We previously found that up-regulation of CD147 alone in MCF-I0A cells is
sufficient to induce an invasive program characteriz~d by matrigel invasion and active
..

invadopodia formation, the latter being

..

J~}

depe~d~:1~n MTl-MMP activity (Grass et al.,

2012). Our data here indicate that up-regulation of CD147 increases activation of the
Ras-MEK-ERK pathway via HA-CD44 interactions. However, other evidence indicates
1

that the MEK-ERK pathway may also regulate CD147 expression (Pons et aI., 2011;
Ramos and Dang, 2011; Venkatesan et aI., 2009), suggesting the possibility of a positive
feedback loop. Therefore we evaluated if this was the case in our system. To evaluate
whether the Ras-MEK-ERK signaling pathway influences CD147 expression we
employed a MCF-I0A cell line stably expressing the oncogenic K_Ras V12 mutant (lOAK-Ras V12), since this cell line has been shown to activate ERK signaling to a greater
extent than PI3K (Konishi et aI., 2007). First, we found that the 10A-K-RasVl2 cells
contain significantly higher levels of HA, CD147 and MTl-MMP than empty vector
MCF-lOA (lOA-EV) cells (Fig. 3-4A,B). Interestingly, qPCR demonstrated only a slight
increase in CD147 message compared to 10A-EV cells, suggesting that K_Ras V12 may
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regulate CD147 expression post-transcriptionally (Fig. 3-4C). We also found that the
10A-K-Ras V12 cells invaded matrigel (Fig. 3-4D) and formed active invadopodia (Fig.34E) to a greater extent than 10A-EV cells. In the invadopodia assay, . . . 60% of the cells
degraded underlying fluorescent matrix compared to the 10A-EV (Fig. 3-4F). Of the
10A-K-Ras V12 cells with invadopodia, the majority of the population had a mean of 10-12
invadopodiatcell, with a range of 1-28 invadopodia/cell, whereas 10A-EV cells
demonstrated essentially no invadopodia (Fig. 3-4G). Thus, this data indicates that the
K-Ras V12 oncogene imparts an invasive phenotype in MCF-1 OA cells, similar to that
demonstrated previously in pancreatic cells (Botta et aI., 2011; Campbell and Oer, 2004;
Neel et aI., 2012).
As we and others have shown previotlS'.\y~at CD147 regulates MTI-MMP
expression and HA synthesis (Marieb et aI., 2004; Yan et aI., 2005), we determined
whether the increased expression of MT1-MMP or HA in 10A-K-RasV12 cells was due to
the increase in CD147. Knockdown of CD147 using siRNA demonstrated that MTlMMP expression and HA production were partially dependent on CD147 (Fig. 3-5A,B).
Since CD 147 plays a prominent role in breast cancer cell invasion and invadopodia
formation (Grass et aI., 2012; Zucker et aI., 2001), we also evaluated effects on matrigel
invasion and invadopodia formation and activity. We found that knockdown of CO 147
resulted in a partial, yet significant, decrease in matrigel invasion in the 10A-K-Ras V12
cells (Fig. 3-5C). Likewise, in the invadopodia assay, we found that CD147 knockdown
decreased the percentage of cells degrading matrix (Fig. 3-50,E) and that most of this
inhibition was due to decreased activity of invadopodia rather than formation (Fig. 3-SF).
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Next we determined whether increased CD147 expression in lOA-K-Ras Vl2 cells
was dependent on ERK signaling. Treatment of lOA-K-Ras Vl2 cells with two different
MEK inhibitors resulted in a decrease in CD147 and MTI-MMP protein levels as well pERK (Fig. 3-6A), though this effect did not appear to be at the transcriptional level for
CD147 (Fig. 3-6B). We next evaluated whether ERK signaling mediates the invasive
characteristics that we described above in lOA-K-Ras V12 cells. We found that MEK-ERK
inhibition greatly decreased matrigel invasion (Fig. 3-6C), as well as invadopodia
formation and activity (Fig. 3-6D,E,F). In contrast to CD147 depletion in lOA-K-Ras Vl2
cells, MEK inhibition greatly decreased invadopodia formation as well as activity.
Similar to our approach with CD147-upregulated MCF-IOA cells, we evaluated
endogenous protein-protein associations of CP4f~ith EGFR, CD147 with EGFR, and
CD147 with CD44 in lOA-K-Ras V12 cells, using the PLA. We found that lOA-K-Ras VI2
cells also exhibited these associations (Fig. 3-7 A), but the incidence of these associations
varied in the following manner: CD147-CD44> CD 147-EbFR > CD44-EGFR (Fig. 3-7
A,B). This data suggests a similar relationship to what we identified in CD147upregulated MCF-IOA cells (Fig. 3-2D,E). As with MCF-IOA cells with up-regulated
CD147, we showed that endogenous CD147 co-localizes with Ctx-B (Fig. 3-7C) and that
CD147, CD44 and EGFR are enriched in caveolin-rich raft domains in lOA-K-Ras VI2
cells as compared to the lOA-EV cells (Fig. 3-7D).
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lOA-K-RasVI2 cells with high constitutive levels of CD147 are more invasive than
those with low constitutive levels of CD147
It has been clearly demonstrated that cancer cells exhibit heterogeneity in cell surface
marker expression and contain sub-populations with different functional capacities
(Ricardo et aI., 2011). Therefore we extended our current findings further by evaluating
whether sub-populations of 10A-K-Ras Vl2 cells with different levels of constitutive
CD147 expression could be isolated from the parent cells. Immuno-staining of 10A-KRas Vl2 cells demonstrated a sub-population of cells with greater CD 147 and CD44
staining intensity (Fig. 3-8A). Next, using FACS, we isolated cells with relatively low
surface expression of CD147 (CDI47 Lo ) versus relatively high surface expression of
..

:'1

CD147 (CDI47 Hi ). We separated the bottom'2{'~)[nd top 20% with respect to CD147
cell surface expression and found that these two sUb-populations exhibited distinct
properties as indicated by scatter analysis (Fig. 3-8B). The CD147 Hi population also
1

demonstrated 3-fold more CD44 and 2.5-fold more EGFR on the surface compared to the
CD147 Lo population (Fig. 3-8C; left panel). Similar analysis of highly invasive MDAMB-231 breast cancer cells, which possess an endogenous K_Ras G13D mutation (Kozma
et aI., 1987), demonstrated a 1.8-fold increase in CD44 and 1.9-fold increase in EGFR in
CD147 Hi vs. CD 147 Lo cells (Fig. 3-8C; middle panel) while much less invasive MCF-7
cells demonstrated very little CD44 or EGFR surface staining, and sUb-population
analysis for differential CD147 expression revealed no significant differences (Fig. 3-8C;
right panel). We also measured levels of various proteins in the two sub-populations by
immuno-blotting and found that CD 147Hi cells demonstrated increased p-ERK and pEGFR compared to CD147 Lo cells, whereas the total levels of CD44 and EGFR were

104

similar (Fig. 3-8D). Finally, we evaluated the invasive characteristics of the CD 147Hi vs.
CD147 Lo cells and similar to our above results in CD 147-depleted 10A-K-Ras Vl2 cells
(Fig. 3-5F), we found that CD 147Hi cells had a much greater percentage of cells with
actively degrading invadopodia than CD147 Lo cells, whereas no significant difference
was observed between CD147 Hi vs. CD147 Lo cells in regards to invadopodia formation
(Fig. 3-8E).

Discussion
Breast cancer is a heterogeneous disease and, as with other cancers, metastases to distant
organs remains the primary cause of mortality,{S~ffer and Weinberg, 2011). Currently
the evaluation of hormone receptor expression, ErbB2 amplification and the presence of
cytokeratin forms represent the mainstay utilized clinically for treatment stratification,
though much effort has also been placed on characterizing distinct sub-populations
isolated from the tumor bulk with differing cell surface expression profiles. One of the
main surface markers that has emerged in identifying invasive and therapy-resistant
cancer cells is CD44 (Alexander and Friedl, 2012). Hyaluronan (HA), a primary CD44
ligand, facilitates construction of pericellular matrix scaffolds which stabilize signaling
and transporter complexes (Slomiany et aI., 2009a; Slomianyet aI., 2009b). Multiple
studies have shown that HA-CD44 interactions are intimately involved in the integration
of signaling pathways leading to RTK activation, therapy resistance and invasion (Toole,
2009).
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Accumulating evidence suggests that the IgSF glycoprotein CD147 regulates HA
synthesis in various cell types (Edward et aI., 2011; Ghatak et aI., 2005; Kato et aI., 2011;
Marieb et aI., 2004; Qin et aI., 2011), though the mechanism of this regulation is not fully
understood. In addition, CD 147 has an essential role in regulating MMP production, and
our recent study found that CD147 plays a role in invadopodia activity (Grass et aI.,
2012). In this study we have begun to evaluate the functional relationship between
CD147, HA, CD44 and MMP production in regards to breast cancer invasion.
We and others have previously demonstrated that CD147 influences migration
and invasion via protease induction and cytoskeletal remodeling (Grass et aI., 2012;
Weidle et aI., 2010; Zhao et aI., 2011), though the exact signaling mechanisms regulating
these processes have not been fully elucidated~'~JI¥te we have shown that up-regulation
of CD147 in non-transformed breast epithelial cells leads to increased EGFR, Ras and
ERK activation. Moreover, we show that the activation of EGFR and ERK by CD147 is
mediated in large part by increased HA-CD44 signaling an~ is accompanied by enhanced
interactions between CD147, CD44 and EGFR. These interactions most likely take place
within lipid raft-like regions of the plasma membrane, which are known to participate in
cell signaling complex formation (Staubach and Hanisch, 2011). Of interest, our
microscopic evaluation of CD147 and lipid rafts revealed that CD147 co-localizes with
Ctx -B at the leading edge of the cells and appears to arrange in a single-file fashion along
Ctx-B-enriched filopodial projections (Fig. 3-3A). Our evidence suggests that
enrichment of CD44 and EGFR in lipid rafts is not due to increased trafficking to the cell
surface, since our cell surface analysis revealed no significant differences in either CD44
or EGFR expression (Fig. 3-3C). Rather, we hypothesize that this may be due to
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increased assembly of signaling complexes in lipid rafts on the cell surface, which are
vital for invadopodia formation and activity (Caldieri et aI., 2009; Yamaguchi et aI.,
2009).
Oncogenic Ras signaling has a less appreciated role in breast cancer pathology
since Ras mutations are infrequent (Pylayeva-Gupta et aI., 2011). However, chronic Ras
activity has been found in multiple breast cancer cell lines and patient tumor tissues
without any apparent Ras mutations (Eckert et aI., 2004; Lintig et aI., 2000). A recent
study suggests that increased activity of wild type Ras can result in a similar phenotype
induced by oncogenic Ras (Zhang et aI., 2009). The present study suggests that CD 147
can stimulate wild type Ras activity, as MCF-10A cells have not been found to contain
any mutant Ras forms (Soule et aI., 1990). TO~~V~1iate this relationship between CD147
and Ras further, we utilized 10A-K-RasV12 cells, as K-Ras mutations are the most
frequent of those that do occur in breast cancer (Karnoub and Weinberg, 2008). We
found that oncogenic Ras increases HA synthesis (Fig. 3-4A), as found previously
(Hamilton et aI., 2007), and also stimulates expression ofCD147 and MT1-MMP protein
(Fig. 3-4B). Interestingly, qPCR analysis revealed only minor differences in CD147
message between empty vector and 10A-K-RasV12 cells (Fig. 3-4C), suggesting that Ras
may influence CD147 expression predominantly at the post-transcriptional level.
We also showed that 10A-K-RasV12 cells are highly invasive in matrigel and
formed highly active invadopodia (Fig. 3-4D,E,F), which is similar to earlier studies in
pancreatic cancer cells (Neel et aI., 2012). The invasiveness of these cells was found to
be dependent on MEK-ERK signaling. Also, in agreement with our previous study
demonstrating that CD147 is involved in invadopodia activity (Grass et aI., 2012), we
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showed that CD147, at least in part, mediates the invasive phenotype seen in 10A-KRas v 12 cells. We found that CD 147 expression in these cells is also dependent on MEKERK signaling and that endogenous CD44, EGFR, and CD147 associate and co-localize
in lipid raft fractions in these cells in similar fashion to cells with upregulated CD147.
Again, CD147 message levels were not significantly affected by the MEK-ERK signaling
pathway, suggesting that regulation of CD147 expression by this pathway is also
predominantly post-transcriptional. A striking finding was that, although HA-CD44
interactions clearly mediate most CDl47-induced EGFR and ERK activation, disruption
of HA-CD44 interactions with oHA or CD44 siRNA did not significantly affect CD147induced MTI-MMP protein levels, as shown herein, or invasiveness (data not shown).
This may be due to a divergence in

CD147-induc~q"signaling,

where one effect of CD147

'/"."'/'
is mediated by HA extrusion and subsequent CD44 binding, and the other is mediated by
other CD 147-binding interactions independent of CD44.
We also found that CD147 Hi and CD147 Lo cell sub-populations isolated from
10A-K-RasV12 cells, and from the metastatic breast cancer cell line MDA-MB-231, have
distinct properties. The CD147 Hi cells have significantly more CD44 and EGFR on the
cell surface than their CD 147 Lo counterparts. Additionally, CD147 Hi lOA-K-Ras V12 cells
had increased pEGFR and pERK levels as well as more active invadopodia compared to
CD147 Lo cells. Interestingly, densitometric analysis of CD147 in the CD147 Hi and
CD 147Lo western blots demonstrated small changes in total CD147 protein (data not
shown). This suggests that increased CD147 on the cell surface may be due to increased
retention at the cell surface and/or rapid recycling rather than increased protein synthesis.
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Finally, our data shows that up-regulation of CD147 in non-transformed and noninvasive breast epithelial cells leads to activation of the EGFR-Ras-MEK-ERK signaling
cascade. Ras mutations in breast cancer are a rare event (Pylayeva-Gupta et aI., 2011),
though chronic Ras activation is evident in patient-derived breast cancer tissue and cell
lines without Ras mutations (Eckert et aI., 2004; Lintig et aI., 2000). Our data suggests
that wild-type Ras activity is increased in CD 147-upregulated MCF-10A cells and this
may be a potential mechanism that CD147 employs to elicit the previous invasive
phenotype we identified in CD147-upregulated MCF-IOA cells (Grass et aI., 2012). To
our knowledge, no mutations or intrinsic signaling motifs have been identified in CD 147,
thus it is probable that CD147 mediates breast cancer progression by facilitating the
assembly of pro-tumorigenic multi-protein compll'~f{es< on the cell surface. Also, though
'J'~'~/'~/"

we saw differences in protein levels of CD147 with MEK inhibition or comparison of
10A-EV to 10A-K-RasV12 cells, negligible changes in the mRNA level of CD147 were
observed in both cases. This may suggest that the influenct1 of Ras-MAPK signaling on
CD147 expression occurs more at a post-transcriptional level; similar post-transcriptional
regulation of CD147 has been observed in previous studies (Chen et aI., 2010; Deora et
aI., 2005; Fanelli et aI., 2003; Gallagher et aI., 2007; Noguchi et aI., 2003). Thus, even
though CD147 expression is clearly increased in most aggressive cancers, identification
of CD147 as a differentially expressed message in microarray analyses may not always
be apparent. CD147 may act as an independent prognostic factor in some breast cancer
types (Liu et aI., 2010; Reimers et aI., 2004) and further studies should evaluate the utility
of CD147 surface expression in stratifying sub-populations in breast cancer.
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Figure 3-1. Up-regulation of CD147 induces activation of EGFR-Ras-ERK
signaling. (A) Western blot depicting surface biotinylation of MCF-l OA cells, treated
with an Mal of 2 of ~-gal or CD147 adenovirus, and parental MDA-MB-231 cells.
An Mal of 2 was used in all subsequent adenovirus experiments. A lane with beads
only was used as a negative control; n=3. (B) Evaluation ofRas activity in MCF-I0A
cells treated with ~-gal or CD147 adenovirus. Lanes with GDP and GTP were used as
negative and positive controls, respectively. Activated Ras was identified by probing
with a pan-Ras antibody. ~-actin was used as a loading control; n=4. (C) MCF-10A
cells were treated with ~-gal or CD147 adenovirus, starved and subsequently treated
with vehicle (DMSO) or 0.5 ~M and 5.0 ~M tyrphostin (AG 1478) overnight. ~-actin
was used as a loading control; n=3. (D) MCF-10A cells were treated with ~-gal or
CD 147 adenovirus, starved and evaluated for EGFR activation by probing for
phosphorylation at the Tyrosine 1173 or 1068 residues in the presence or absence of
EGF in the medium. For controls, MCF-I0A cells were starved or starved and treated
with EGF (10 ng/ml). ~-actin was used as a loading control; n=3.
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Figure 3-2. Hyaluronan-CD44 interaction mediates CD147-induced
activation of EGFR signaling. (A) MCF-l OA cells treated with ~-gal or
CD147 adenovirus were seeded into 24 well plates. The media was
replaced with fresh media and after 24 hours it was collected and analyzed
for hyaluronan concentration using an ELISA-like assay. Hyaluronan in
the media was normalized to cell number and depicted as mean fold
change; each column represents triplicate wells in three independent
experiments. (B) MCF-IOA cells treated with ~-gal or CD147 adenovirus
were subsequently treated with 100 ~g/ml of o-HA for 1, 12 and 24 hours
and probed for p-EGFR (Tyr I068 ) and p-ERK. ~ -actin was used as a
loading control; n=3. (C) MCF-10A cells treated with CD147 adenovirus
were treated with non-specific control siRNA or pooled CD44-specific
siRNA as described in Materials and Methods and probed for indicated
proteins. ~-actin was used as a loading control; n=3.
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Figure 3-2 (continued). Hyaluronan-CD44 interaction mediates CD147-induced
activation of EGFR signaling. CD) Representative images demonstrating proteinprotein interactions « 40 nm) using a proximity ligation assay (see Materials and
Methods for details). CD 147-treated MCF-IOA cells were probed with primary
antibodies in the following combinations: CD44 (mouse) and EGFR (rabbit) (top
row); CD147 (mouse) and EGFR (rabbit) (middle row); and CD147 (mouse) and
CD44 (rabbit) (bottom row) to detect protein-protein interactions in the cell
population. Protein-protein interactions appear as small punctate green signals (i.e.
dots) and cell nuclei were identified by co-staining with DAPI. Treatment of cells
with a single primary antibody only was used as a negative control and indicates the
specificity of the reaction (right panels in each row). (D) Quantification of indicated
protein-protein interactions in the cell population over 5 random fields with at least 50
cells per field; column values are means ± s.e.m. over three independent experiments.
**P<O.Ol; ***P<O.OOI.
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Figure 3- 4. Activated Ras and ERK regiil3't~4i'yaluronan synthesis, CD147 and
MTI-MMP expression and cancer invasiveness. (A) Hyaluronan synthesis was
quantified from 10A-EV and 10A-K-RasVl 2 cells using an ELISA-like assay.
Hyaluronan in the media was normalized to cell number and depicted as mean fold
change ± s.e.m.; each column represents triplicate wells in three independent
experiments. (B) Representative western blot depicting CDl47 and MTI-MMP
expression in 10A-EV and 10A-K-Ras Vl 2 cells. ~-actin was used a loading control;
n=4. (C) Comparison of CDl47 mRNA levels in 10A-EV and 10A-K-RasVl 2 cells, as
measured by qPCR; normalized to ~-actin; n=3. (D) Quantification of invasion through
Matrigel by 10A-EV and 10A-K-RasV1 2 cells. Columns represent the mean number of
cells invaded (± s.e.m.) per field; n=3. (E) Representative micrograph demonstrating
10A-EV and 10A-K-Ras V1 2 cells cultured on fluorescent matrix. After fixation, cells
were immunolabeled for cortactin followed by secondary Alexa-Fluor-488 antibody and
Alexa-Fluor-647 phalloidin. Actin and gelatin matrix were pseudo-colored red and
blue, respectively to allow easier visualization of colocalization (yellow) of actin (red)
and cortactin (green). Invadopodia-mediated matrix degradation appears as dark black
foci in the bright fluorescent matrix field. The boxed regions with red arrow heads
depict actively degrading invadopodia. Scale bar: 10 ~m. (F) Percentage of cells
degrading the matrix; defined as a cell with at least one degradation spot underneath the
cell or near the cell edge. (G) Quantification of invadopodia/cell; defined as actincortactin aggregate over degraded matrix. Each invadopodia parameter was calculated
by evaluating random fields containing at least 15 cells per field over three independent
exneriments. Column values are means ± s.e.m. ** P<O.Ol: ***P<O.OOl.
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Figure 3-5. Knockdown of CD147 in MCF-I0 J$:.~RasV12 cells results in decreased
hyaluronan synthesis, MTI-MMP expressio.n ;~hd invasiveness. (A) Western blot
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number of cells invaded (± s.e.m.) per field; n=3 . (D) Representative micrograph
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Figure 3-7. Identification and localizatioft"pf<~dogenous proten-protein
interactions in MCF-IOA-K-Rasv12 cells. (A) Representative DIC-fluorescent merge
images demonstrating endogenous protein-protein interactions « 40 nm) using a
proximity ligation assay (see Materials and Methods for details). 10A-K-RasV12 cells
were probed with primary antibodies in the following combinations: CD44 (mouse)
and EGFR (rabbit) (left column); CD147 (mouse) and EGFR (rabbit) (middle column);
and CD147 (mouse) and CD44 (rabbit) (right column) to detect protein-protein
interactions in the cell population. Protein-protein interactions appear as punctate
green signals (i.e. dots) and cell nuclei were identified by co-staining with DAPI
(bottom row). The boxed regions are shown as higher magnification insets. Examples
of protein-protein interactions are highlighted by arrow heads. Top row depicts
automatic threshold images of the protein-protein interaction channel for easier
visualization. Scale Bar: 25 ~m. (B) Quantification of indicated protein-protein
interactions per cell; Scatter plot with mean ± s.e.m.; n=3. (C) Representative image
demonstrating colocalization (yellow) of endogenous CD147 (red) and cholera toxin-B
(green) in 10A-K-Ras VI2 cells. Scale bar: 10 ~m. (D) Western blot comparing
endogenous protein distribution between 10A-EV and 10A-K-Ras V12 cells subjected to
detergent -resistant membrane isolation and probed for indicated proteins. Light
fractions are from the gradient interface (0-20%) where detergent-resistant membrane
domains such as lipid rafts localize; n=2. ***P<O.OOl.
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Figure 3-8. MCF -lOA-K-Ras VI2 cells with high constitutive surface levels of
CD147 have elevated activation of EGFR-ERK signaling and are more invasive.
(A) Representative micrograph demonstrating heterogeneity in CD147 and CD44
staining intensity across the 10A-K-RasV12 cell populatioh. Scale bar: 25 ~m. (B)
FACS scatter distribution of total 10A-K-Ras V12 cell population (left panel).
Identification of CD147 Lo and CD147 Hi cells, bottom and top 20%, respectively, in the
distribution of CD 147 -expressing cells (right top panel) with corresponding scatter
characteristics (bottom right panels). Note that this cell sorting scheme identifies two
distinct cell populations. (C) FACS analysis of cell surface expression of CD44 and
EGFR in CD147 Lo and CD147 Hi cells in 10A-K-RasV12 (left column; n=3), MDA-MB231 (middle column; n=3), and MCF-7 (right column; n=2) cells. Distributions with
dark gray shading, solid black lines with no shading and dotted black lines with light
gray shading represent IgG-isotype control, CD147 Lo and CD147 Hi cell, respectively.
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Figure 3-8 (continued). MCF-IOA-K-RasV12 cells with high constitutive surface
levels of CD147 have elevated activation of EGFR-ERK signaling and are more
invasive. (D) Left panel: Immunoblot comparing protein expression of indicated
proteins in CD 147Lo and CD147 Hi 10A-K-Ras V1 2 cells. ~-actin was used as a
loading control; n=2. Right panel: Histogram demonstrates fold change between
CD147 Hi and CD147 Lo cells for pEGFR (Tyr 1068), pERKl and pERK2 protein
levels; densitometric intensities were normalizeq tq,.total EGFR and ERKl/2 protein.
(E) Quantification of percentage of cells with-a¢ti.?ktortactin aggregates with or
without underlying degraded matrix in CD147 Lo and CD147 Hi 10A-K-Ras V1 2 cells
was calculated by evaluating random fields containing at least 15 cells per field over
three independent experiments. Column values are means ± s.e.m. *P<O.05;
**P<O.Ol; ****P<O.OOI.
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Chapter 4: Overview, Novel Contributions and Future Work
As described above, CD 147 participates in a variety of biological functions.
CD147 expression is associated with an invasive phenotype in a wide array of cancer
types, including breast cancer. One of the most significant findings supporting a role for
CD147 in breast cancer invasion was a study discovering that weakly malignant breast
cancer cells overexpressing CD147, which were injected into mouse mammary fat pads,
demonstrated increased local invasion and extensive metastases to the liver, mediastinum,
pleura, spleen, lymph nodes and mesentery

(Zuck~~<,et"al.,

2001). CD147 is a
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predominant marker (..... 90%) in bone micrometastases (Klein et al., 2002; Reimers et aI.,
2004) isolated from breast cancer patients, is enriched in malignant pleural effusions
(Davidson et aI., 2004) and is expressed on circulating tumqr cells (Pituch-Noworolska et
aI., 2007), suggesting a prominent role for CD147 in cancer progression. CD147
expression may also be an independent prognostic factor in some breast cancer types (Liu
et aI., 2010; Reimers et aI., 2004).

CD 147-induced MTl-MMP Induction Mechanism
The mechanism mostly attributed to CD 147-induced invasion is the induction of
proteases, including soluble and membrane-type MMPs (Yan et aI., 2005). In support of
this, CD147 has been identified at the invasive edge of breast carcinomas
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(Polette et aI., 1997) and in some invasive breast and lung cancers it colocalizes on the
cell surface with MT1-MMP and MMP-1, respectively (Dalberg et ai., 2000; Guo et ai.,
2000). CD147 regulates MT1-MMP synthesis and cell surface expression in various cell
models (Sameshima et aI., 2000; Schmidt et ai., 2006; Seizer et aI., 2010). MT1-MMP
regulation is very stringent, as the increased presence of a highly proteolytic enzyme on
the cell surface could be detrimental to cells not needing to cleave matrix substrates or
cell surface factors that facilitate invasion. Similar to other MMPs, MT 1-MMP is
synthesized as a zymogen that needs processing to the active form. In the case ofMT1MMP, processing occurs via a furin-mediated cleavage event in the Trans-Golgi network
during protein trafficking to the cell surface. MT1-MMP is then endocytosed and
recycled back to the cell surface or sent for degrapation, thus active MTl-MMP is the
r
·/-,'·I*'J
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predominant form localized on the cell surface (Frittoli et aI., 2011). Our recent
publication suggests that CD147 may regulate the trafficking of MTl-MMP into cell
surface localized lipid rafts within invadopodia (Grass et alh 2012). Support for CD147
having a role in MTl-MMP trafficking is found in a study identifying that CD147
associates with both pro and active forms of MTl-MMP (Niiya et aI., 2009), though
further work with live-cell imaging will be needed to fully prove this hypothesis.
Alternatively, CD147 may be associated in a complex that regulates pro-MT1-MMP
processing in the golgi.
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CD147-induced EGFR-Ras-ERK Signaling
It has been recognized that xenografts of CD 147 -overexpressing breast cancer
cells contain increased ERK activation at the advancing margin of the tumor (Tang et aI.,
2006). The current mechanisms explaining CD 147-mediated ERK activation are cis
homodimerization of CD147 (Cui et aI., 2012), cooperation with cyclophilins
(Yurchenko et aI., 2010), syndecan-1 (Pakula et aI., 2007) or HA-CD44 interactions
(Marieb et aI., 2004). Our studies provide further evidence of an involvement of CD147
cooperating with HA-CD44 signaling. In this respect, we found that up-regulation of
CD147 increases HA synthesis, which in turn led to EGFR activation and subsequent
activation of ERK. Abrogation of HA-receptor interactions with oHAs attenuated
CD147-induced EGFR and ERK phosphorYlat-i~~kD44 depletion also reduced EGFR
and ERK activation, but to a lesser extent. Our earlier findings identified that upregulation of CD147 in MCF-10A cells led to increased MT1-MMP protein levels (Grass
et aI., 2012), though when CD44 was knocked down in CD\47-overexpressing MCF-10A
cells no difference in MT 1-MMP protein was noticed. Similar results were obtained in a
previous study where it was shown that increased HA stimulates invasiveness and MMP
expression, but subsequent treatment with oHAs had no effect on MMP expression and
only moderate inhibitory effect on invasion (Zoltan-Jones et aI., 2003). Thus, there may
be diverging pathways elicited by CD147: one that is mediated via HA-CD44
interactions and others that may utilize other molecular partners. In conjunction with our
earlier findings, this data suggests that up-regulation of CD 147 may lead to an invasive
phenotype by facilitating assembly of CD44-EGFR-CD147 signaling complexes that
activate ERK and result in increased MT1-MMP protein levels.
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When initially evaluating upstream regulators of CD 147-induced Ras activation,
we found that the specific EGFR inhibitor AG 1478 attenuated CD 147 -mediated ERK
activation.

The cytoplasmic tail of EGFR contains six tyrosine residues, which can be

trans-autophosphorylated via the intrinsic tyrosine kinase activity of EGFR (Eccles,
2011). Earlier studies have identified that the Tyrosine 1173 (Sakaguchi et aI., 1998) and
1068 (Rojas et aI., 1996) residues are important for EGFR-mediated Ras-MAPK
signaling by acting as docking sites for the scaffold proteins Shc and Grb2, respectively.
Further evaluation of CD 147-induced EGFR activation revealed that EGFR was
specifically phosphorylated on the Tyrosine 1068 residue. Why CD147 induced only
Tyrosine 1068 phosphorylation and not 1173 is currently not known, but may depend on
the spatio-temporal interactions between the

pho~phbrylated

tyrosine residues and

"~~;1/'~

associated scaffold proteins. Such a relationship was identified between Tyrosine 1173
and SHP-l, a protein-tyrosine phosphatase, where binding attenuated EGFR-mediated
signaling (Keilhack et aI., 1998) and later studies

suggeste~ that

the main role of Tyrosine

1173 phosphorylation was to recruit SHP-l and inactivate ERK signaling (Hsu et aI.,
2011). Individual phospho site activation may correlate with bias toward specific cellular
phenotypes. For instance, a recent study identified that specific EGFR tyrosine residue
activation resulted in differential abilities of cells to undergo chemotaxis and wound
healing (Yamaoka et aI., 2011). Furthermore, a study evaluating non-small cell lung
cancer tissues identified that specific EGFR tyrosine residues are biased in their
activation state (VanMeter et aI., 2008). Even though CD147 increases Tyrosine 1068
phosphorylation, the specific function of this phosphosite activation is not known.
Additionally, this may be due to a cell- or tissue-specific context, since EGFR is known
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to promiscuously dimerize with other ErbB family members; thus EGFR activation bias
may depend on which isoforms of Erb receptors a cell expresses (Eccles, 2011). In line
with this, we found that treatment of MCF-l OA cells with EGF resulted in a greater
activation of Tyrosine 1068 than 1173; as mentioned above this may be due to certain
cellular contexts, as MCF-I0A cells express very low levels of ErbB2, a potential
heterodimeric binding partner for EGFR.

CD147 and Ras in Breast Cancer
Oncogenic Ras forms are rarely identified in breast cancer (Pylayeva-Gupta et aI.,
2011), yet chronic Ras activation has been o~~~:r~,d in several breast cancer cell lines and
,

-,l

patient-derived tumor tissues with no evident Ras mutations (Eckert et aI., 2004; Lintig et
aI., 2000). A recent study identified that up-regulation of wild type Ras resulted in an
oncogenic phenotype in non-transformed breast epithelial reUs (Zhang et aI., 2009).
CD147 expression intensity seems to progressively increase as breast cancer transitions
from a benign proliferation to an invasive carcinoma (Liu et aI., 2010), but whether
CD147 alone is a driver or just a passenger oncogene is not known. We have identified
that up-regulation of CD 147 alone in non-transformed breast epithelial cells initiates an
invasive program, increases HA synthesis and activates an EGFR-Ras-MEK-ERK
signaling cascade, supporting its possible role as a driver of oncogenesis, especially with
respect to invasiveness.
Complex signaling networks have been suggested between HA and Ras and
descriptions of these relationships follow. Some of the strongest evidence comes from
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studies employing HA synthase 2 (Has2) null mice, which are embryonic lethal, are
defective in EGFR family signaling, and demonstrate Ras dependence in cellular invasion
and the ability to undergo an EMT (Camenisch et aI., 2002; Camenisch et aI., 2000).
Additionally, HA has been shown to increase Ras activity in vitro (Fitzgerald et aI., 2000;
Serbulea et aI., 1999) and oncogenic Ras has been shown to increase HA synthesis
(Hamilton et aI., 2007), thus forming a potential positive feedback loop. CD44, the main
HA receptor, also cooperates with Ras activation (Sohara et aI., 2001) and HA-CD44
interactions have been demonstrated to activate various RTKs upstream of Ras
(Bourguignon et aI., 2006; Misra et aI., 2006; Wang and Bourguignon, 2006) as well as
downstream effectors of Ras (Bourguignon et aI., 2005; Hamilton et ai., 2007). An
additional feedback loop was identified between ,Ras and CD44, where Ras induced
,/J"J '~/'I
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CD44 alternative splicing, which in turn facilitated further Ras activation (Cheng et aI.,
2006). Later studies found that CD44 splice isoform switching was important in
initiating an EMT program in breast epithelial cells (Browq et aI., 2011) and different
CD44 splice isoforms may correlate with different breast cancer subtypes (Olsson et aI.,
2011). Our finding that CD147 increases HA synthesis and EGFR-Ras-ERK activation
suggests that CD147 integrates into this HA-CD44-Ras signaling module. Previous
evidence indicates that HA is involved in assembling signaling complexes in lipid rafts
(Ghatak et aI., 2005), thus CD 147-induced HA signaling may also lead to a similar
phenomenon. We have found that increased CD147 expression leads to enrichment of
MT1-MMP, CD44 and EGFR in lipid raft domains, suggesting that CD 147-induced HACD44 interactions, higher order oligomerization of CD 147 or heterophilic protein
interactions between CD147 and other binding partners results in multi-protein complex
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assembly. It will be interesting to see if the integration of CD147 with HA-CD44-RasERK signaling plays a role in different aspects of tumor progression. A previous study
suggested that initiation of tumor growth is dependent on Ras-mediated effector
pathways, but a reduction in the requirement of Ras occurs during tumor maintenance,
even though Ras effector pathways still remain active (Lim and Counter, 2005). It is clear
that the tumor microenvironment changes during cancer progression, hence it will be
important to evaluate whether CD 147-induced signaling pathways can potentiate Ras
effector pathways independent of Ras. This may be the case because increases in HA
synthesis confer an anchorage-independent growth advantage to cells (Zoltan-Jones et aI.,
2003). Since CD147 induces HA-CD44-dependent anchorage-independent growth
(Marieb et aI., 2004), it is likely that CD147-med!~ted resistance to anoikis (Yang et aI.,
"'"'7 J
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2006) is dependent on HA-CD44 interactions, which supply the cell with supplemental
pro-survival ECM signals in the absence of integrin-based adhesion.

Glycosylation and CD147 Function and Stability

As mentioned previously, the core protein of CD147 may contain diverse
combinations of carbohydrate attachments. Several authors have observed that CD 147
migrates on SDS-P AGE between 31-65 kDa, a characteristic attributed to heterogeneous
glycosylations, composed of branched polylactosamine, fucosylation, sialylation and
Lewis X glycan attachments. CD147 glycoforms were previously characterized as
mannose-rich LG-CD147 and branched polylactosamine HG-CD147 (Tang et aI., 2004a).
Currently, HG-CD147 is the only glycoform that has been attributed with a specific
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function; in this case HG-CD 147 is associated with MMP induction. In contrast,
accumulating evidence suggests that the high-glycosylated form is not necessary to
induce MMPs (Attia et aI., 2011; Belton et aI., 2008; Kawakami et aI., 2011).
Protein N-glycosylation begins in the endoplasmic reticulum and is followed by
sequential addition or removal of sugar residues by various enzymes as the protein
transits through the golgi apparatus (Lau and Dennis, 2009). An elegant study
demonstrated that the protein gl ycoform synthesized by the cell is highly dependent upon
cooperation between the expression profile of golgi transferases and metabolic flux
through the hexosamine pathway (Lau et aI., 2007). This cooperativity between cell
environment (e.g. metabolic substrates) and cell-type specific expression of tranferases
may explain the variation in CDI47 glycoform~/i#ntified from cell lines derived from
the same tissue of origin (Riethdorf et aI., 2006).
The HG-CDI47 form contains

~1,6-branched,

polylactosamine-type sugars
1

attachments initiated by the activity of N-acetlyglucosaminyltransferase V, which is
encoded by the gene Mgat5 (Lau and Dennis, 2009). Interestingly, Mgat5 transcription is
increased by Ras signaling (Chen et aI., 1998) and Ras has been shown to lead to
differential sialylation of integrins (Seales et aI., 2003). Whether Ras regulates CD147
glycosylation by initiating branching of polylactosamines or addition of sialic acid
residues is unknown, but our current evidence suggests that this may be plausible as Ras
does not appear to increase CDI47 transcription dramatically and our immunoblots
demonstrate differential CD 147 gl ycoforms between cells with or without oncogenic Ras.
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The LG-CDI47 form was characterized to contain high-mannose type
carbohydrates, possibly via caveolin-1-mediated inhibition of further branching by Mgat5
in the golgi (Tang et aI., 2004a). Earlier studies proposed that the LG-CDI47 form is
immature and remains confined to the endoplasmic reticulum (Gallagher et aI., 2007), yet
our surface biotinylation results as well as others demonstrate that the LG-CD 147 form is
present on the cell surface (Tang et aI., 2004a; Tang and Hemler, 2004). As discussed
previously, LG-CDI47 preferentially associates with caveolin-l, but may also associate
with a3~1 or a6~1 integrins (Berditchevski et aI., 1997). Pulse-chase analysis discovered
that LG-CDI47 was converted to HG-CDI47 or degraded in less than two hours (Tang
and Hemler, 2004), suggesting that the kinetics of LG-CDI47 may be different than HGCD147.
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Whether LG-CDI47 participates in different functions than HG-CD147 is
unknown. It is possible that LG-CD 147 preferentially localizes in the rapid recycling
compartments previously identified (Eyster et aI., 2009) and takes part in dynamic
cellular processes such as matrix remodeling and metabolic substrate transport, whereas
HG-CD 147 is more confined to the cell surface and aids in cell adhesion events (Sun and
Hemler, 2001). Possibilities for the differences in membrane retention may be depend
upon HG-CDI47 N-glycan interactions with extracellular matrix protein scaffolds such
as galectins (Liu and Rabinovich, 2005). For instance, branched glycans in HG-CD147
would be expected to have stronger avidity for galectins compared to high-mannose LGCD147 forms (Lau et aI., 2007), which could lead to retention of HG-CDI47 on the cell
surface and allow dynamic trafficking of the LG-CD 147 form. Additionally, decreased
glycosylation has been shown to promote ubiquitination and subsequent degradation of
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CD147 (Wang et aI., 2008), yet further work is needed to elucidate how recycling and
protein turnover cooperate in regulating CD 147 function. Whether specific
glycosylations on CD147 dictate function is unknown and future studies should
,determine localization patterns of different glycoforms using various lectin approaches
coupled with subcellular organelle characterization techniques.

Utility of CD147 as a Cell Surface Marker for Breast Cancer Cell Sub-population
Analysis

Breast cancer is a heterogeneous disease that has been separated into several
clinical subsets (Voduc et aI., 2010). Profilingqthreast cancer specimens using genetic
'-'~~I
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profiling and immunohistochemistry demonstrates that breast cancer is divided into
distinct subtypes: Luminal A, Luminal B, Luminal-ErbB2 positive, ErbB2-amplified,
basal-like and triple negative. The latter two are considered similar by some
investigators, though much debate currently exists with respect to this classification
(Foulkes et aI., 2010). A recent study found that six additional subtypes can be clustered
into triple negative breast cancer, making the classification scheme even more complex
(Lehmann et aI., 2011). Currently, evaluation of hormone receptor status, cytokeratin
expression and ErbB2 amplification represent the mainstay utilized clinically for
treatment stratification, but higher resolution characterization of breast cancers is needed
to identify responders and non-responders to our current treatment modalities.
Complementary to these analytical approaches, evaluation of cell surface
expression profiles on individual cancer cells has also demonstrated utility (Ricardo et aI.,
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2011). In this respect, differential surface expression of CD44, CD24 and others markers
have aided in identifying cells with stem-like properties that are invasive and resistant to
current therapies (Visvader and Lindeman, 2008). CD147 associates with CD44
(Slomiany et aI., 2009b) and EpCAM (Xu and Hemler, 2005), two proteins that were
employed in the initial isolation of highly tumorigenic breast cancer cells (AI-Hajj et aI.,
2003) and cells from breast cancer cell lines with stem-like qualities and intrinsic
resistance to chemotherapy (Fillmore and Kuperwasser, 2008). We have shown that
enrichment of cells with differing CD 147 surface expression patterns affords us the
ability to isolate cells with different capacities to invade and activate EGFR-ERK
signaling pathways. Additionally, cells with high constitutive surface expression of
CD 147 have increased CD44 and EGFR surface lelvers. Future studies should address
'~'-"~I '(,'

whether enriching for cells with differential surface levels of CD147 may be an
alternative approach to isolate cells with diverse functional phenotypes in breast cancer or
aid in classifying certain breast cancer subtypes.

Translating CD 147 to the Clinic
The presence of CD147 on the cell surface makes it a plausible molecular target for
various targeted therapies, including monoclonal antibody therapy. In this regard, a doseescalation study with a murine IgM monoclonal antibody targeting CD 147 was evaluated
in the context of steroid-refractory acute graft-versus-host disease. In this study, the
dose-limiting factor was severe myalgias at 0.3 mg/kg, which could be controlled by
narcotics. Additionally, no significant differences were seen in T cell or B cell numbers,
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though the treatment demonstrated efficacy in this setting (Deeg et aI., 2001). Neutrophil
or erythrocyte counts were not evaluated in this study.
The first cancer-related study targeting CD147 in patients was performed in Phase
IIII trials in China using a CD 147-specific F(ab')2 fragment conjugated to iodine l3l ,
which is called metuximab (Licartin). In this study metuximab was infused into the
hepatic artery and the safety and efficacy of this therapy was evaluated in hepatocellular
carcinoma (HCC) patients. No life-threatening toxic side effects were identified, though
Grade 3 hematologic and hepatic toxicity was identified in some patients. The CD 147targeting antibody fragment was found to concentrate primarily in the tumor tissue and
resulted in an improved survival rate, with a median survival time of 19 months;
normally patients with HCC progress rapidly--a:r&Jiave a survival time of 3.2 months.
"

Interestingly, unconjugated metuximab demonstrated low clinical efficacy alone and was
not tested in these trials (Chen et aI., 2006b).
Preclinical studies in HNSCC are also underway. In tumor xenografts in mice,
administration of CNT03899, a chimerized monoclonal human IgG 1 antibody targeting
CD 147, resulted in decreased cell proliferation and in combination with irradiation
resulted in additive toxic effects to the tumor (Dean et aI., 2009). Additional studies
found that this antibody also induced apoptosis (Dean et ai., 2010) and partially slowed
down glucose uptake in pancreatic cancer xenografts (Shah et ai., 2011).
Though CD 147 -targeting monoclonal antibody therapy appears to have clinical
benefit, the epitope targeted by the antibody should be closely examined. Antibodies
directed against different epitopes of the extracellular domain of CD 147 have resulted in
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opposing effects. For example, a study characterizing antibodies generated toward
CD147 found that some inhibited invasion and MMP synthesis, whereas others increased
both invasion and MMP synthesis (Wang et aI., 2006). Furthermore, studies in immune
cells identified that CD147 may contain two separate bioactive domains, one involved in
cell aggregation and the other in T cell activation (Chiampanichayakul et aI., 2006), thus
binding of natural ligands or targeted antibodies may elicit differing cellular responses.
Alternatively, antibodies targeting CD147 may alter CD147 homo- or hetero-philic
protein interactions leading to reorganization of lipid raft domains (Staftler et aI., 2003).
Thus before CDl47-targeted antibody therapy makes a stride towards the clinic, stringent
evaluation of epitope-associated CD147 function needs to be clarified. A better suited
use of CD 147-targeted antibodies may be in thetutHity of in vivo detection of tumor cells
'-"~'~,
by employing fluorescently-conjugated CD147 antibodies (Newman et aI., 2008b).

0/'

Due to the pleiotropic nature of CD 147 function, consideration should be taken
into account when evaluating therapies to down-regulate CD 147. Various physiological
processes, such as fertilization, immune cell differentiation, transport of metabolic
intermediates, wound healing and blood-brain barrier maintenance have all been
attributed to CD 147 function. It is of interest, that in the above clinical studies, no
mention of deleterious side effects was noted. This may be due to the highly targeted
administration of metuximab through the hepatic artery and subsequent concentration
primarily in liver tissue or the masking of side effects seen in the graft-versus-host
disease cohort, which had poor baseline function of various organs. Further prospective
randomized controlled studies are needed for evaluating CD 147 efficacy in patients, since
the CD 147 -targeting cancer trial did not compare results to any standard of care.
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Various studies have evaluated tumor biology by examining patient tumor
samples before, during or after therapy regimens. Many of these studies focus primarily
on the mRNA levels of proteins and rate whether differences are significant by setting a
threshold ratio. Our data presented in this thesis, as well as data from other groups, have
found that CD 147 expression may be regulated more at a post-transcriptional level (Chen
et aI., 2010; Deora et aI., 2005; Fanelli et aI., 2003; Gallagher et aI., 2007; Noguchi et aI.,
2003). Thus, in some experimental contexts underestimation of differences in CD 147
expression may occur when evaluating tumor samples. Additionally, CD147 is
extensively modified by post-translational carbohydrate additions and interacts in diverse
cellular compartments with various binding partners, all features that are missed in broad
microarrayanalyses. Future studies should be

dire~ted

'>'~~/?j

to elucidating the mechanisms

that regulate CD147 post-transcriptionally, including: message stability, translation
regulators, and glycosylation modulators.

Closing Remarks
It is becoming evident that the name Extracellular Matrix MetalloPRoteinase

INducer (EMMPRIN) does not suffice to describe the role ofCD147 in cell biology.
Though CD 147 has a prominent role in MMP induction in various cell models, it also
appears to have a distinct role in organizing multi-protein complexes consisting of RTKs,
metabolic transporters, drug efflux pumps and cell adhesion molecules. Additionally,
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CD 147 is emerging as a regulator of the cytoskeleton and participates in the
migration/invasion phenotype of various cancer cells, both in vitro and in vivo.
In this thesis, we have identified several novel roles of CD 147 in breast cancer
invasion. We have demonstrated that CD147 can regulate invadopodial dynamics,
membrane reorganization events and the assembly of signaling complexes. Specifically,
we found that interweaved relationships are present between MT1-MMP, HA-CD44
interactions and EGFR-Ras-ERK signaling in breast cancer biology (Figure 4-1). Further
studies should investigate whether similar relationships exist in other cancer types,
especially those that have been identified to rely strongly on EGFR and Ras signaling for
their progression.
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Figure 4-1. Working model: CD147 regulates invadoppdia dynamics by
facilitating the assembly of multi-protein signaling complexes in lipid rafts. A)
Distribution of endogenous CD147, EGFR, MTI-MMP and CD44 in the absence of
CDl47 up-regulation. Thin yellow membrane indicates non-raft membrane. See
Figures 2-5C and 3-3B for supporting data. B,D) Up-regulation of CDl47 leads to
MTI-MMP accumulation in lipid raft domains (dark brown membrane) possibly
enriched in invadopodia. C) Up-regulation of CDl47 leads to assembly of multiprotein complexes containing CD147, MTI-MMP, EGFR and CD44, which
facilitate invasion. Also, these complexes activate EGFR-Ras-MEK-ERK signaling
cascades that are dependent on HA-CD44 interactions. Of note, the Ras-MEK-ERK
pathway may regulate CD147 via post-transcriptional modulation.
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